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The ASCOT randomised factorial trial compared calcium channel blocker (CCB) 
based-therapy versus beta blocker (BB) based-therapy and statin versus placebo. 
19,342 hypertensive patients were recruited between 1998 and 2001 and followed 
for a median of 5.5 years. Primary results were published in 2003 and 2005. A total 
of 8,580 British ASCOT patients were followed-up for a median of 17.4 years to the 
end of January 2018, by which time 4040 deaths had occurred, 1,402 from 
cardiovascular (CV) causes. This thesis analysed the impact of randomised 
treatment and blood pressure on long-term mortality in this subset of patients and 
consists of three main sections.  
The effect of randomised treatment on long-term survival was assessed, taking into 
consideration potentially non-proportional treatment effects over time and 
competing risks from different causes of death. Results showed that statin-therapy 
reduced coronary heart disease (CHD) mortality compared to placebo (hazard ratio 
[HR]=0.76, p=0.018) and CCB-based treatment reduced stroke mortality compared 
to BB-based treatment (HR=0.73, p=0.011).   
Several alternative components of blood pressure recorded at baseline were 
compared for their ability to predict long-term CV mortality.  Each was strongly 
associated with CV mortality and their relative association attenuated with age.  
While systolic and pulse pressure (PP) were the strongest single predictors, PP had 
the clearest continuous monotonic relationship with risk, and was the stronger 
predictor in older subjects.   
Repeated blood pressure measurements collected during the trial were used to 
investigate how features of blood pressure profiles relate to and predict CV-related 
mortality, e.g. within-subject mean blood pressure, variability and rate of change 
over time.  Factors influencing blood pressure level and variation were investigated.  
Landmark survival analyses showed again that PP was the most useful summary 
measure, and both its mean and its variability were independently associated with 
risk of CV mortality.  A clinically useful risk score model was developed containing 
mean PP and the coefficient of variation (COV) for PP, along with key risk factors. 
Overall, this thesis provides useful insights into the impact of treatments on CV 
mortality risk in the long-term and how blood pressure relates to CV mortality risk 
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 Background  
1.1.1 Introduction 
The collective group of disorders relating to the heart and vascular system is known 
as cardiovascular disease (CVD).   CVD is responsible for the largest global mortality 
burden.  The World Health Organisation (WHO) estimates that currently around 17.9 
million people lose their lives to CV-related causes each year 1. 
This research degree centres around blood pressure (BP) and treatment for 
hypertension and hyperlipidaemia, two of the most well-established risk factors for 
CVD.  This thesis presents analyses which utilise long-term mortality follow-up 
data relating to a hypertensive UK cohort of subjects at high risk of CVD who took 
part in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), to address 
meaningful scientific questions with practical applications.   
Subjects were eligible to be enrolled and randomised into the ASCOT trial if they 
presented with hypertension and had an additional three risk factors for CV disease.  
The factorial trial randomised all patients to one of two blood pressure lowering 
treatment regimens.  This factor of the trial is referred to as the blood pressure-
lowering arm (BPLA).  The trial further randomised a subset of those patients who 
were eligible to either lipid-lowering statin-therapy or placebo.  This factor of the 
trial, made up of a subset of the BPLA is referred to as the lipid-lowering arm (LLA).  
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A cohort of subjects from England, Wales, and Scotland were targeted for long-term 
post-trial follow-up for mortality outcomes.   
This thesis presents research which focuses on three main topics that are covered 
across the next three chapters.  The first investigates the long-term legacy effect 
on survival of originally allocated trial treatments.  The second compares the 
predictive ability of different components of blood pressure as measured at 
baseline in relation to long-term CV-related mortality, with a particular focus on 
comparing systolic blood pressure (SBP) and pulse pressure (PP).  The final topic 
focuses on assessing the impact of blood pressure level and variability on long-
term CV-related mortality. 
1.1.2 Blood pressure 
Blood pressure is a well-established important risk factor for CV morbidity and 
mortality 2–4.  When blood pressure levels are too high (hypertension), excess strain 
is exerted in the arteries which can cause damage, leading to increased risk of CV 
disease.  Hypertension is highly prevalent and recognised to be a leading 
preventable risk factor for cardiovascular disease and mortality. 
Examination of the pulse goes back centuries, but it was not until the beginning of 
the 20th century that a non-invasive, clinically applicable way of measuring blood 
pressure was developed.  After that time, a greater understanding of the link 
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between blood pressure was developed and CVD was developed.  The first study to 
provide real evidence of the connection was the Framingham Heart Study 2.   
Blood pressure is measured at two points: the maximum arterial pressure reached 
during the contraction of the left ventricle (SBP); and the lowest arterial pressure 
reached during cardiac relaxation (DBP).  Other aspects of these measurements are 
often also of interest, such as pulse pressure (PP) which is the magnitude in change 
in blood pressure between systolic and diastolic states.  
Only since the 1940s has hypertension been considered a treatable condition.  The 
introduction of thiazide diuretics in the late 1950s were among the first to gain 
evidence of hypotensive effects. The Veterans Administration Medical Centres in the 
US conducted large multi-centre studies which led to the first multi-centre 
randomised placebo-controlled antihypertensive treatment trial, providing evidence 
that antihypertensive treatment exerted a beneficial effect in reducing CVD risk in 
high-risk patients 5. 
Researchers have studied many new anti-hypertensive treatments over the years.  
The beta blocker (BB) were considered the leading anti-hypertensive treatment in 
the 1960s.  Thereafter the converting-enzyme blockers and Calcium channel 
blocker (CCB) rose up as important treatments. Many studies have demonstrated 
the effectiveness of anti-hypertensive treatments 6.  The ASCOT trial is among a 
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number of studies that have compared active treatments and helped provide 
evidence that can help improve treatment strategies.  
1.1.3 Lipids 
Lipids play a variety of important roles in the body, such as acting as energy stores 
and contributing to tissue structures.  Triglycerides and cholesterol are two types of 
lipids that circulate in the bloodstream.   
Lipoproteins are compounds that serve to transport cholesterol around the body via 
the bloodstream.  They are mainly differentiated by their density: low- and high-
density lipoproteins (LDL and HDL, respectively).  LDL transports cholesterol to 
bodily cells while HDL is involved in excess cholesterol removal and transportation 
to be broken down in the liver.  High levels of LDL cholesterol greatly increase the 
risk of atherosclerosis in blood vessels because LDL molecules contribute to 
atherosclerotic plaque formation 7.  Conversely, low levels of HDL increase the risk 
of atherosclerosis because HDL molecules work to prevent plaque formation, and 
can even cause existing build-ups to reduce 8,9.  
Atherosclerotic plaque is one of the main causes of CV dysfunction.  As plaque 
builds up, walls of blood vessels thicken and vessel aperture narrows at the build-
up sites.  This can lead to restricted blood flow, vascular inflammation, remodelling, 
and vessel dysfunction, all of which can eventually lead to reduced blood flow to 
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target organs.  In addition, the formation of blood clots (thrombosis) could occur at 
the plaque build-up sites which could break loose and cause blockages elsewhere.   
High levels of triglycerides can also increase the risk of atherosclerosis, although 
the mechanism behind this is not exactly known.  
The Framingham Heart Study was the first major study to link cholesterol to risk of 
CVD in the 1960s.  The study identified the positive relationship between LDL level 
and risk and the negative relationship between HDL level and risk 2,9. 
There are a variety of differently functioning lipid-lowering treatments available, 
but the most commonly prescribed are drugs from the statin family.  Statins work 
by inhibiting the rate of cholesterol synthesis resulting in blood LDL cholesterol 
decline.   
There is now a wealth of evidence for the efficacy of statins in reducing CVD 
morbidity and mortality.  The West of Scotland Coronary Prevention 
Study (WOSCOPS) was the first primary prevention study to show that statins were 
associated with reducing coronary heart disease (CHD) events and CV mortality, 
compared to placebo 10.  
Many other studies followed, such as the MRC/BHF Heart Protection Study (HPS) of 
simvastatin which showed a significant reduction in all-cause mortality associated 
with statin use compared to placebo 11.  More recently the Justification for the Use 
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of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) 
showed statin benefit in a population with elevated C-reactive protein levels 12.  The 
ASCOT trial is among those influential studies that demonstrated the cardio-
protective effects of statin-use, contributing to their well-established efficacy and 
safety profile 13. 
 The ASCOT Trial 
The ASCOT trial enrolled 19,342 hypertensive subjects between 1998 and 2001 
who were over 40 years of age, had no history of CHD, but with at least three 
additional risk factors for CV disease.  The trial had a two-by-two factorial design, 
with a blood pressure-lowering arm (BPLA) and a lipid lowering arm (LLA). 
All eligible, consenting participants were randomised with a ratio of 1:1 to one of 
two blood pressure-lowering treatment regimen in the BPLA: either BB-based or 
CCB-based treatment.  The BB-based regimen consisted of atenolol with additional 
thiazide diuretic, bendroflumethiazide (BFZ), if necessary, and the “newer” CCB-
based regimen consisted of amlodipine with additional angiotensin-converting 
enzyme inhibitor (ACEi), perindopril, if necessary.   
A subset of 10,305 patients with non-fasting total cholesterol concentrations of 6.5 
mmol/L or less and no history of statin use were further randomised with a ratio of 
1:1 to either anti-hyperlipidaemia statin therapy with atorvastatin or placebo.   
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The BPLA was stopped early, after a median of 5.5 years following the 
recommendation from the data safety and monitoring board (DSMB) in October 
2004, on grounds of excess mortality and other secondary outcomes in the 
atenolol-based group.  Results, published in the Lancet in 2005, provided evidence 
that amlodipine-based treatment is associated with reduced risk of CV-related and 
all-cause mortality, stroke, and heart failure, compared to atenolol-based treatment 
14.   The primary endpoint of non-fatal MI plus fatal CHD did not quite reach 
statistical significance at the 5% level (HR=0.90, p=0.105), likely a consequence of 
reduced power from early trial termination.   
Prior to the early termination of the BPLA, the LLA was also stopped early after a 
median of 3.3 years following the recommendation from the DSMB in September 
2002, on grounds of reduced CHD and stroke events associated with the 
atorvastatin arm.  Results, published in the Lancet in 2003, provided evidence that 
atorvastatin is associated with a reduction in the primary endpoint (HR=0.64, 
p=0.001), and also with reductions in CV events and procedures, and coronary 
events, compared to placebo 13. 
 The ASCOT Legacy Cohort 
A subset of ASCOT patients from England and Scotland were targeted for long-term 
follow-up at the end of the trial.  718 (8.4%) of these patients had died within the 
trial period, and out of the remaining 7862 patients who were alive at the end of the 
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trial, 7300 (92.9%) consented to long-term follow-up for morbidity and mortality 
outcomes. The complete subset of 8580 patients are referred to as the ASCOT 
legacy cohort.  Those who were alive at the end of the trial but did not give consent 
for further follow-up were included in relevant analyses but were censored at the 
trial end.   
Mortality data has been acquired from NHS Digital for the consenting ASCOT legacy 
patients up to the end of 2015, a median follow-up time of 15.7 years (maximum 
17.9 years).  We used this data to analyse the long-term effects of the originally 
randomised trial treatment, results published in the Lancet in 2018 15.  
Subsequently, additional data has been received from NHS Digital containing 
mortality data up to the end of January 2019, a median follow-up time of 17.4 
years (maximum 20.9 years).  Hence, the analysis conducted in Chapter 2 of this 
thesis, which reflects the work done for the 2018 Lancet paper, has been updated 
to utilise the more recently updated follow-up data.     
The mortality data includes date of death as well as detailed causes of death.  Two 
clinicians independently adjudicated the causes of deaths, and classified them as 
being either CV-related or not CV-related.  The CV-related deaths were further 
categorised as being related to either stroke, CHD, or “other” CV causes.  Deaths 
that were classified as not being related to CVD were further categorised as being 
related to either cancer, infection or respiratory, or “other”.  
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Over long-term follow-up after trial end, a further 3322 subjects had died, a total 
of 4040 subjects, 47.1% of the total 8580 ASCOT legacy cohort.  This overall 
number of deaths is, of course, likely to be slightly less than the true number, due 
to the number of censored subjects for whom we have no post-trial follow-up data.      
 Aims and objectives of this research degree 
This research degree uses long-term follow-up mortality data relating to 
participants who took part in the ASCOT trial, and who form the ASCOT legacy 
Cohort, to address three main aims.  
1.4.1 Aim 1: Measure the impact of trial treatments on mortality over long-term 
follow-up 
The first aim was to assess the impact of randomised trial treatments on long-term 
survival.  This aim is addressed in Chapter 2, where the objective was to use 
survival analysis to measure the relationship between the trial treatment groups 
that subjects were randomised to on an intention to treat (ITT) basis, and mortality.  
Specifically, the objectives included assessing the effect of statin use as compared 
to placebo, and the effect of amlodipine-based treatment use as compared to 
atenolol-based, on long-term mortality.  In addition to effects on all-cause 
mortality, effects on cause-specific mortality was also analysed.   
1.4.2 Aim 2: Assess and compare the relationship that different components of 
blood pressure have with long-term mortality 
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The second aim was to assess how different components of blood pressure relate to 
mortality, and to compare their predictive ability.  This aim is addressed in Chapter 
3, with the objective to relate different components of blood pressure, using blood 
pressure recorded at baseline, to mortality using survival analysis, and to make 
direct comparisons between components’ predictive ability.   The influence of 
subject age on such relationships and strength of predictive ability was also 
considered.  The focus for this aim was on CV-mortality, but in addition all-cause 
mortality, as well as the more specific stroke- and CHD-related causes of death 
were analysed.     
1.4.3 Aim 3: Evaluate the relationship between blood pressure level and long-
term CV-related mortality, and the independent importance of variability 
in blood pressure over time  
The third aim was to evaluate how blood pressure level and variability predict CV-
related mortality, and in the process identify the best representations of these 
characteristics of blood pressure profiles.  This aim is addressed in Chapter 4, with 
the objective to use repeated measurements of blood pressure collected during the 
ASCOT trial period, to estimate blood pressure level and the amount of variability in 
blood pressure for each subject, to investigate factors that influence these 
characteristics of BP profile, and describe and quantify the relationship of these 
blood pressure characteristics with CV-related mortality. 
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Building upon the work in Chapter 3, those components of blood pressure: SBP and 
PP, that demonstrated the strongest predictive ability (both in this research and in 
wider research), became the focus to address this aim.  
The final objective to conclude this thesis was to build a clinically useful and 
appropriate predictive survival model for CV-related mortality containing both a 
representation of blood pressure level and blood pressure variability, modelled 
appropriately together with other important risk factors.  This model contained the 
single representation of both blood pressure level and blood pressure variability 
that demonstrated the strongest predictive ability in this dataset.  The purpose of 
the model was to investigate and illustrate how both the level and viability of blood 
pressure can fit together appropriately within a useful clinical risk prediction model 
alongside other key risk factors.              
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 Background  
2.1.1 Legacy studies in cardiovascular medicine 
The term “legacy study” is often used to describe a study which is birthed out of an 
existing interventional study.  A legacy study uses longer-term follow-up of 
subjects beyond the original designed study period to assess potential treatment 
effects beyond that seen during the trial.  “Legacy effect” refers to interventional 
effect that are sustained or even emerge beyond the original study period.  Legacy 
effects have been described as “a memory of a treatment which produces benefits 
long after the cessation of the intervention” 16.   In many legacy studies, the 
assumption behind legacy effects is that the intervention was responsible for 
making pathological changes that have some permanency and in turn impact on 
disease in the long-term. However, in these settings, causal effects, whether direct 
or indirect, are often hard or impossible to prove.   
There have been a number of legacy studies that have been born out of clinical 
trials in cardiovascular medicine, including placebo controlled statin and blood 
pressure-lowering trials that have shown long-term survival benefits to those 
originally randomised to active treatments 17–19. 
2.1.2 Blood pressure lowering legacy studies 
Evidence for long-term, post-trial, persistent effects of decreased all-cause 
mortality associated with randomisation to active antihypertensive medication has 
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been presented from placebo-controlled trials.  A meta-analysis involving 18 anti-
hypertensive studies was conducted by Kostis et al. which produced evidence of a 
reduction in all-cause mortality both within the trial periods as well as in the post-
trial periods, and was observed in all drug classes included in the analysis (ACEis, 
BBs, diuretics) 20.  Overall reduction in mortality was similar out of trial (open-label 
period) as it was within the trial period, despite subjects in both active and placebo 
randomised arms being advised to go on to the same active treatments post-trial.  
Many individual studies have reported a “carry-over” of effect on mortality reduction 
associated with active anti-hypertensive interventions in post-trial periods 21.  
However, there is sparse long-term data available from studies comparing active 
treatments 22.  
Evidence for sustained benefits of CCB therapy coupled with an ACEi as compared 
to placebo over longer post-trial follow-up have been presented 23.  Although there 
is good evidence of the benefits of randomisation to a CCB-based regimen 
compared to another active treatment within trial periods, there are few long-term 
follow-up studies that have investigated whether randomisation to a CCB-based 
therapy boasts longer-term benefits on survival beyond the end of a trial 24.   
Another study to randomise subjects both to lipid-lowering and blood pressure-
lowering treatment arms was the Antihypertensive Lipid-Lowering to prevent Heart 
Attack Trial (ALLHAT).  They randomised hypertensive patients to one of four anti-
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hypertensive treatments, either the diuretic: chlorthalidone, the ACEi: lisinopril, the 
CCB: amlodipine, or the alpha blocker: doxazosin (although the doxazosin arm was 
discontinued due to safety concerns).  The trial duration varied from four to eight 
years, after which patients were followed-up up through electronic health records 
for morbidity and mortality outcomes for a total follow-up varying from eight to 13 
years.  At the end of follow-up results were varied, but the in-trial benefits 
associated with the diuretic chlorthalidone over Lisinopril and amlodipine were no 
longer evident over longer follow-up 25–27. 
2.1.3 Lipid lowering legacy studies 
There has been a lot of interest in the long-term benefits of statins and there has 
been evidence from a number of large placebo controlled trials for the longer-term 
benefits of statin use 18,28.  Such studies have presented evidence of sustained 
survival advantages beyond the trial period to subjects randomised to statins.   
It has been suggested that legacy effects from statins could be due to plaque 
stabilisation, that statin treatment can slow down the development of 
atherosclerotic plaque build-ups in arteries which alters the progression of the 
disease even after cessation of treatment 29,30.   As a result it has been argued that 
treatment of high cholesterol in younger people with statins early on should be 
considered, and further, some have even argued that statins should be offered to all 
young people regardless of their cholesterol level 31–34.  
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The results from the 20-year follow-up of the West of Scotland Coronary Prevention 
Study (WOSCOPS) in high-risk men with elevated LDL cholesterol but no history of 
myocardial infarction (MI), concluded that a 5-year period of statin treatment was 
associated with a legacy benefit of statin use compared to placebo over the 20-year 
follow-up period 35. They reported lower mortality from any cause in the statin arm 
over the whole of follow-up with a hazard ratio (HR) of 0.87 (95% CI: 0.80-0.94, 
p=0.0007), a larger reduction in CV-related mortality with a HR of 0.79 (95% CI: 
0.69-0.90, p=0.0004), and an even stronger effect for mortality attributed to CHD 
with a HR of 0.73 (95% CI: 0.62-0.86, p=0.0002), estimated from adjusted Cox 
proportional hazards (PHs) models.   They commented that although the greatest 
relative risk reduction was seen during the trial-treatment period, the continued 
long-lasting effect that was observed, questioned the need for life-long treatment.  
They concluded that life-long exposure to the drug may not be required if such 
legacy effects from shorter therapy duration yield clinically acceptable benefit, and 
that a study comparing outcomes from varying durations of statin-use could add 
value to this question.    
The long-term follow-up of ASCOT legacy patients provided a great opportunity to 
investigate the long-term impact of being randomised to CCB-based treatment 
compared to BB-based treatment, as well as to potentially strengthen existing 
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evidence of the long-term benefits associated with statin therapy compared to 
placebo 36,37. 
 Aims 
The aim of this chapter was to evaluate the impact of having been randomised to a 
particular blood-pressure lowering treatment regimen, and the impact of being 
randomised to statin-therapy compared with placebo, on long-term survival using 
post-trial follow-up data from the ASCOT legacy cohort.  The focus was to assess 
the legacy impact of treatment on CV-related mortality, and more specifically from 
stroke-related and CHD-related mortality.   
Furthermore, the aim was to assess whether treatment effects change over time, 
and describe such patterns of change should they exist.  Paying particular focus to 
the comparison of within-trial and post-trial periods, the aim was to assess the 
extent to which effects are sustained and whether some effects are later to emerge 
over time. 
Lastly, the aim was to assess the impact of competing causes of mortality 
(competing risks) when estimating effects on specific causes of death.  
 Measuring the effects of treatments on survival over time 
The statistical analysis of time-to-event data is often referred to as survival 
analysis, although the event need not be mortality.  
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Survival analysis is distinct from other types of statistical analysis due to the 
presence of right or left censoring of observation time.  Censoring refers to periods 
in time during which we are unable to observe subject outcomes.  One of the most 
common types of censoring, and relevant in this context, is right censoring which 
occurs from the point when a subject is no longer being observed at a certain time-
point.  This could be due to the death of the subject, when a subject is lost-to-
follow-up, or when a subject experiences an alternative event (also known as a 
competing event) which subsequently precludes the subject from experiencing the 
event of interest. 
Censoring can be seen as either informative (i.e. the reason behind censoring is 
related to risk in some way) or non-informative (i.e. given observed co-variates, 
censoring can be considered to occur at random, unrelated to risk).  Common 
approaches to survival analysis assume that censoring (not due to the event of 
interest) is not informative.  This can lead to biased estimates if untrue.  
There are many approaches to analysing survival data.  There are non-parametric 
approaches such as life tables, Kaplan Meier or Nelson-Aalen methods 38.  There are 
parametric approaches relating a set of covariates to survival time assuming an 
appropriate distributional form of the underlying risk over time, for example 
Poisson, exponential, or Weibull models.  There are also alternative parametric 
approaches, for example, the flexible parametric model proposed by Royston & 
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Parmar which involves the use of restricted cubic splines to model the underlying 
hazard rate over time rather than assuming a more specific distribution 39.   
An alternative to a fully parametric approach was proposed by Sir David Cox in 
1972, known as the Cox Proportional-Hazards (PH) model.  While this semi-
parametric model assumes that relative hazards (for unit increases in covariates 
present in a model) are proportional over time, it makes no parametric assumptions 
about the underlying “baseline” hazard, which is data-driven and free to vary over 
time.  This approach has become the most commonly used model for analysing 
survival data, possibly due to its robust nature making it simple to use as one does 
not have to consider the distributional shape of the underlying risk over time.  Still, 
as with other parametric approaches, care must be taken in assessing whether the 
assumption of proportional hazards is appropriate, otherwise estimates of hazard 
ratios can be misleading 40.    
 Challenges in estimating long-term impact of randomisation to 
trial treatment 
There are many factors that make any long-term differences between randomised 
treatment groups difficult to interpret and form direct causal inferences.  Any long-
term differences in mortality observed between originally randomised groups must 
be interpreted within the context they are in, acknowledging existing limitations.   
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One of the main challenges in interpreting long-term effects beyond the end of the 
trial was that information about post-trial treatment was not available.  It may be 
the case that treatment choices beyond the end of the trial were completely 
independent of which trial arms subjects were randomised to.  However, there may 
be some association between post-trial treatment and randomised trial treatment.  
If post-trial treatment choices were independent of the original treatment 
randomised to, then we might expect that any within-trial survival effect seen 
between groups would diminish post-trial over time as groups become more similar 
with regard to treatment received.  It might be that some treatment effects could be 
sustained beyond the end of the trial if the effect of a treatment during the trial 
period actually was to have a fundamental impact that was able to continue to 
outwork, or possibly even emerge later.   
However, it might be that post-trial treatment choices were impacted by which 
randomised treatment group a subject was assigned to, at least in some way.  For 
example, subjects may be more likely to remain on the same treatment they were 
allocated to during the trial due to familiarity.  Conversely, perhaps subjects in a 
treatment arm associated with worse outcomes would be more likely to go on to a 
more favourable therapy after the trial than those in the comparator group.   
Depending on the mechanisms at play, differences in ongoing treatment choices 
between the originally allocated groups could have an effect on survival, but as 
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post-trial treatment choices were unknown, strong causal interpretations of effect 
that link directly to the randomised treatments are hard to make.  
In addition to the problem of unknown confounding due to unknown post-trial 
treatment choices, the emergence of other confounders over time is an additional 
problem when analysing long-term survival differences between originally 
randomised groups.  While treatment groups were similar at baseline as a result of 
the randomisation process, over time fundamental differences between groups 
could have emerged as a direct result of differences associated with allocation to 
specific trial group.  When we analyse survival over time, at each time-point survival 
is conditional on subjects having survived at least up to that time-point.  If 
differences between groups emerge over time, including in survival, prior to a 
certain time-point then the surviving populations in each group will no longer be 
completely random as a direct result of differences in interventions.  Hence, 
randomised comparisons may become increasingly less similar over time.   
While faced with such limitations, this research opportunity was rare and powerful, 
giving the opportunity to investigate treatment effects in a large cohort of subjects 
over an extensive time-span.  Evidence for the benefits of statins over longer time-
frames, and whether usage over a period can have long-lasting favourable effects 
on cardiovascular health is needed.  The optimal therapy for hypertension is still 
uncertain, and while there are recommended strategies, evidence for the long-term 
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impacts of strategies is lacking.  This research, while needing to be interpreted in 
the context of existing limitations, can contribute greatly and provide substantial 
insight into long-term benefit of these treatments.   
 Changes in effect over time 
In the context of clinical trials and observational studies, a common approach to 
survival analysis is to estimate a measure of effect comparing different 
interventions that assumes that the effect is constant over time.  For example, a 
common approach is to use the Cox PH model to estimate a hazard ratio, under the 
assumption that the relative hazards are the same across all of time.  A single HR 
will represent an average effect over the whole of follow-up time, and the validity of 
this single measure depends on the assumption that the relative hazard has truly 
remained constant over time.   
However, the assumption of proportional hazards over time may not always be 
valid.  Treatment effects may change over time, even when use of treatment is 
consistent.  For example, there may be delayed effects or early effects that reduce 
over time.  In settings where the hazard ratio is not truly constant over follow-up 
time, estimating a single hazard ratio for the duration may no longer be meaningful 
or appropriate.  In such settings there are many alternative approaches to 
describing and comparing treatment effects over time that have been proposed.  
Alternative approaches include the treatment effect expressed as a ratio of failure 
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time (accelerated failure time model), comparing mean survival times between 
interventions (restricted mean survival times), and milestone analyses whereby one 
compares the proportion of events that have occurred by a specified “milestone” 
time-point.  
In settings where relative hazards do change with time, the choice of alternative 
approach should be appropriate to the scenario, e.g. early effect or delayed effect.  
The approach should be considered in the context of the research questions being 
asked, making sure that it is appropriate and ultimately meaningful.  
2.5.1 Milestone analysis 
Milestone analysis refers to the comparison of the difference in proportion of events 
between study groups that have occurred by a certain fixed milestone time-point. 
In this approach there is no assumption placed on whether the effect is constant 
over time, but purely the overall effect by the fixed time-point.  Therefore, this 
approach is dependent on the choice of milestone time, and hence the choice of 
milestone time is important and should be meaningful.    
2.5.2 Restricted mean survival time analysis 
Restricted mean survival time (RMST) refers to the mean time spent free of an event 
of interest up to a defined time-point (milestone time).  It is the integral of the 
survival function up to a specified time, i.e. area under the survival curve from time 
of origin to the defined time-point.  This analysis is concerned with the comparison 
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of RMSTs between study groups.  As with milestone analysis, this approach makes 
no assumption about the consistency of effect over time, but is dependent on the 
choice of milestone time.  
2.5.3 Accelerated failure time analysis  
Rather than considering the hazard of failure at a given time, the accelerated failure 
time approach considers the time until failure, and assumes that the effect of study 
group on failure time can be represented by a fixed constant.  The accelerated 
failure time models used are predominantly fully parametric, with a distributional 
assumption placed on the underlying failure time, most commonly a log-logistic or 
Weibull distribution.   
 Competing risks 
In time to event analysis, competing risk refers to the risk of the occurrence of an 
alternative event to that of interest, and the occurrence of such would preclude the 
event of interest from occurring.  For example, a subject may be at risk of both 
CHD-related and stroke-related mortality, if they should die from one cause, they 
can no longer die from the other, and hence risk of either of these causes of death 
are competing risks for the other.       
Standard approaches to survival analysis often ignore the issue of competing risk, 
and censor exposure time from the time a competing event occurs under the 
assumption that the competing event was not informative.  However, if this 
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assumption was not true and the occurrence of a competing event was informative 
about subjects’ risk for the event of interest, then to ignore this in the analysis 
could lead to biased estimation of underlying risk, and also relative risks between 
covariate levels 41.  
In this context where we are studying specific causes of death, it is possible and 
indeed likely that to some extent certain classifications of death may be informative 
of the risk subjects were also at for death from an alternative cause.    
If we censor time at the point of a death from a competing cause, then we may end 
up with an over-estimate of the overall risk of death from the cause of interest if 
both causes of death are in some way correlated.  For example, if we study the time 
to stroke-related death but ignore the possibility of dying from something other 
than stroke and censor subjects at the time of death from an alternative cause, then 
eventually all cumulative incidence curves for stroke-related mortality would be 
one, i.e. everyone either leaves the study (censored prior to stroke event) or goes on 
to die from stroke.  Hence this approach may increasingly overestimate the risk of 
stroke as time goes on and as an increasing number of subjects are censored from 
competing events.  As mentioned above, this approach can also lead to biased 
estimates for relative effects between levels of covariates, if there are differences in 
risk of alternative events between groups, and correlation between the risk of 
alternative events and the risk of the event of interest.  For example, consider 
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comparing the effect on stroke-related death of one treatment (treatment group A) 
to another (treatment group B).  If there was an excess of CHD-related deaths in 
treatment group A, and if those who are at higher risk of CHD-related death are 
also at higher risk of stroke-related death, this would result in a higher number of 
subjects at high risk from stroke-related death being censored in treatment group 
A compared to treatment group B.  Hence, a bias would be emerging over time as 
risk of mortality from stroke is being reduced in treatment group A at a higher rate 
than in treatment group B, and would falsely give the impression that there was 
lower risk of stroke-related death in relation to treatment B group.  In such a 
scenario, it would be important to consider the effect on the event of interest in the 
context of the effect on correlated completing events.  
There are a number of approaches to survival analysis which consider the issue of 
competing risks in some form.  Each method carries some value along with its own 
limitations.  While there is no single universally correct approach, it is important 
that competing risks are not simply ignored but should be taken into consideration 
as part of the analysis.    
There are two main approaches in the literature, each describing the hazard 
function differently.  The first approach is concerned with estimating cause-specific 
relative hazard, and the second with estimating sub-distribution relative hazard.  
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Each type of relative hazard has value but represents something different, and 
hence should be interpreted appropriately.   
2.6.1 Cause-specific hazard model 
The cause-specific approach refers to the most commonly used Cox PH model 
approach, and considers the hazard function for the cause of interest in the 
presence of competing causes of failure.  The probability of each type of event is 
estimated, while treating other competing events as censored in addition to those 
who are censored from loss-to-follow-up or withdrawal etc. 
The cause-specific hazard function ℎ𝑘(𝑡) is defined as the probability, at a given 
time 𝑡, of a subject experiencing the event of interest 𝑘 in the next infinitesimal 
space of time, given that the subject has survived until time t.  The cause-specific 
hazard function for cause 𝑘 is expressed below: 
ℎ𝑘(𝑡) = 𝑙𝑖𝑚𝑑𝑡→0
𝑃(𝑡 ≤ 𝑇 < 𝑡 + 𝑑𝑡, 𝐾 = 𝑘|𝑇 ≥ 𝑡)
𝑑𝑡
 
A proportional cause-specific hazards model is as follows: 
ℎ𝑘(𝑡|𝑋) = ℎ0𝑘(𝑡) exp (∑ 𝛽𝑖𝑘𝑋𝑖
𝑃
𝑖=1
)          𝑘 = 1, … , 𝑁 
Where ℎ0𝑘 is the baseline hazard and 𝛽𝑖𝑘 are the corresponding regression 
coefficients (log HRs) for cause k, for parameters i=1 to P.   
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The cause-specific modelling approach can be carried out by modelling a single 
cause of interest, or by jointly modelling all types of events together, using a 
stacked data approach 42,43.  
In the cause-specific setting, one can only assume that the relative hazard is an 
actual true measure of effect if the assumption of independence of alternative risks 
is valid, otherwise the hazard ratio would represent an apparent effect given that 
individuals have survived all competing events up to time t.   Obviously, there is no 
way to formally test this assumption directly from a dataset because subjects will 
never experience more than one such competing event.    
As discussed above, the cause-specific hazard model might overestimate true 
cumulative hazard of an event over time when competing risks are present.  
If the assumption of independence of competing risks was valid then this approach 
would lead to the interpretation of a relative hazard that represents a more 
conceptual difference, in a world where subjects can only experience the event of 
interest.   
2.6.2 Sub-distribution hazard model 
Due to the strong assumption of independence in the censoring of time following a 
competing risk in the cause specific approach, competing risk literature has also 
focused on alternative approaches, the most popular being based on the sub-
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distribution of the cumulative incidence function (CIF) for each competing event.  In 
this approach, the CIF for the event of interest would be equivalent to the 1- 
[Kaplan-Meier (KM)] estimator in the cause-specific setting when there are no 
competing events.  When there are competing events, the CIF differs in that it 
represents an overall survival function that includes failures from all competing 
events in addition to the event of interest.  Therefore, there is no assumption being 
made about independent censoring in relation to competing events, because 
subjects are not being censored upon the occurrence of a competing event, rather, 
they remain in the risk set thereafter.   
Unlike in the cause-specific approach, with this approach, the cumulative incidence 
will have an interpretation that represents the proportion of subjects that 
experience the event of interest, recognising that those who have a competing 
event will never have that event of interest.   Retaining subjects in the risk set 
following a competing event places a constraint on this hazard function definition.   
Under this structure, the hazard function is defined as the probability of the event 
of interest given a subject has survived up to time t either event-free or having 
experienced a competing event prior to time t.   
Fine & Gray proposed a proportional hazards model, similar to the Cox PH model, 
except that it models the sub-distribution hazard which is derived from the CIF, 
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and uses inverse probability of censoring weighting with a time-dependent weight 
function 44.  
The sub-distribution hazard function for cause 𝑘 is expressed below: 
ℎ𝑘(𝑡) = 𝑙𝑖𝑚𝑑𝑡→0
𝑃(𝑡 < 𝑇 ≤ 𝑡 + 𝑑𝑡, 𝐾 = 𝑘|𝑇 < 𝑡 ∪ (𝑇 < 𝑡 ∩ 𝐾 ≠ 𝑘))
𝑑𝑡
 
A proportional sub-distribution hazard model is as follows: 
ℎ𝑘(𝑡|𝑋) = ℎ0𝑘(𝑡) exp (∑ 𝛾𝑖𝑘𝑋𝑖
𝑃
𝑖=1
)          𝑘 = 1, … , 𝑁 
Where ℎ0𝑘 is the baseline sub-distribution hazard for cause k, and 𝛾𝑖𝑘 are the 
corresponding regression coefficients (log sub-distribution hazard ratios [log 
sHRs]) for cause k, for parameters i=1 to P.   As with the Cox PH model, this model 
also carries the assumption of proportional hazards.  
The estimated coefficients from the sub-distribution hazard model can be 
interpreted in a similar way to those from a Cox PH model, except that these 
coefficients are estimated in the presence of competing events.   Therefore, this 
approach leads to more pragmatic, less theoretical estimates of underlying hazard 
and covariate effect.  This approach may be more of interest when wanting to 
estimate the actual incidence, or predicting an individual’s risk of an event truly 
occurring.  This would be helpful in a clinical setting, or for the allocation of 
medical resources, for example.  




Cumulative incidence curves were plotted for death from any cause, as well as from 
overall CV-related causes, and more specifically mortality from stroke and from 
CHD, showing the cumulative proportions of death for each randomised trial arm.  
Subjects who did not give consent for follow-up beyond the end of the trial period 
will be included in analyses, censored at their end of trial date if they were still 
alive.  Those consenting to long-term post-trial follow-up will be censored at the 
time of a competing event, at the time when they are lost-to-follow-up or at the 
end of the follow-up period.  
The impact of both the BPLA and the LLA randomised group allocations on long-
term mortality were analysed using Cox PH models.  The outcome of death from all 
causes was assessed, as well as death from a more specific cause, with a focus on 
overall CV-related mortality, and more specifically mortality from CHD and from 
stroke.  Cause-specific HRs were estimated for each cause of death.   
For each cause-specific Cox PH model, the proportional hazards assumption was 
tested for the randomised treatment effect for each treatment comparison using 
scaled Schoenfeld residuals (on the Cox models).  The residuals when plotted 
against [functions of] time should have a zero gradient if hazards are proportional.  
The null hypothesis that the gradient is equal to zero for each model was be tested 
using a global test proposed by Grambsch and Therneau (1994) 45.  
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An alternative approach was also undertaken where sub-distribution hazard ratios 
were estimated from sub-distribution proportional hazards models in the analysis 
of each specific cause of death, using the approach proposed by Fine and Gray. 
Cumulative hazard plots from both cause-specific and sub-distribution 
proportional hazards models were produced by randomised treatment arm.  
Three alternative approaches to the analysis of treatment effect were undertaken 
using methods that do not make the assumption of proportional effects over time.  
Firstly, accelerated failure-time models were used to estimate failure time ratios, 
using a Weibull distribution to model failure times.  Secondly, milestone analyses 
were used to compare the difference in the proportion of subjects experiencing the 
event of interest at the milestone time of 18 years.  The proportion of patients 
experiencing the event at the milestone time was estimated using the Kaplan Meier 
method and the Greenwood formula was used to calculate the standard errors 46–48.   
The milestone time was chosen as 18 years since randomisation, because this was 
close to the median subject follow-up of 17.4 years.  
Lastly, RMST was calculated for each randomised treatment arm up to the same 
fixed milestone time of 18 years from randomisation.  RMSTs were modelled using 
flexible parametric models with 3 degrees of freedom, as suggested by Royston and 
Parmar, and the difference in RMST between randomised treatment arms was 
estimated 49.  
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Piecewise proportional hazards models were used to estimate hazards ratios within 
each defined time segments since baseline.  Two approaches were used to define 
time-segments.  Firstly, time was split into within-trial and post-trial periods. The 
within-trial periods differed for BPLA and LLA parts of the trial, and were different 
in length for each subject.  Secondly, time since randomisation was split into 3-year 
time-bands.  Hazard ratios were calculated for each time band, and tests for linear 
trend between intervals were performed to investigate whether the hazard ratios 
differed between time-bands.   
Subgroup analyses were undertaken to investigate whether treatment effects 
differed between: age-groups, sexes, diabetes status at baseline, SBP groups at 
baseline, and total cholesterol groups at baseline.  In addition, a treatment 
interaction was investigated between the randomised BPLA group and the 
randomised LLA group, as well as assessing a difference in BPLA treatment effect 
between those randomised or not to an LLA treatment (LLA vs. non-LLA). 
All adjusted models were adjusted for the pre-specified baseline risk factors: age; 
sex; BMI; SBP; total cholesterol; smoking status; diabetes status; the age at which 
the subject left full-time education; and ethnicity.   
  





This analysis included all 8580 subjects who took part in the ASCOT trial from 
England and Scotland. However, 562 subjects who were alive at the end of the trial 
did not give consent to long-term follow-up.  These subjects were kept in the 
analyses, but censored at the time they ceased trial participation.  Other subjects 
were censored if they were lost to follow-up, died, or at the end of January 2018 if 
they were still alive and in follow-up at that time.  Over the whole long-term period 
of observation including the trial period and beyond, the median follow-up time 
was 17.4 years (IQR: 9.1 to 19.3) with a maximum follow-up of 20.9 years.   
The mean age of this ASCOT legacy cohort was 64 years at randomisation (with a 
SD of 8 years), ranging from 40 to 80 years.  Over 80% were male, and almost 90% 
were of white ethnic background.  On average trial participants were overweight 
based on WHO criteria with mean BMI just over 28 kg/m2.  35% of subjects were in 
the obese category with a BMI over 30 kg/m2, and 9% had a BMI over 35 kg/m2.  
Over 28% of subjects were classed as diabetic at baseline.   
Just over 11% of subjects had suffered a stroke or TIA in the past, and over 17% had 
a history of coronary artery disease.  Over 90% of subjects were on some anti-
hypertensive treatment within the month prior to randomisation. 
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Those who had a baseline total cholesterol of 6.5 mmol/L or higher, or who were 
currently already on statin or fibrate therapy were not further randomised to an LLA 
group.  As a result, those not in the LLA part of the trial were a slightly higher risk 
group for CVD compared to those randomised to a LLA treatment.  Mean total 
cholesterol and LDL cholesterol at baseline were slightly higher in those not eligible 
for the LLA compared to the LLA sub-cohort.   Those who were not further 
randomised to an LLA group had mean total cholesterol at baseline of 6.5 mmol/L 
and over 23% had been on lipid-lowering therapy in the past.  While the LLA cohort 
had mean total cholesterol of 5.5 mmol/L, with a small proportion (1.3%) having 
ever been on lipid-lowering therapy in the past.  
Characteristics between both LLA and BPLA randomised groups were very well 
balanced as was expected from the randomisation process and the large number of 
study participants randomised.  Baseline characteristics are presented in Table 1, 
split by both randomised treatment comparisons. 
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Table 1: Baseline characteristics of the ASCOT legacy cohort by randomised treatment group 
 BPLA (N=8580) LLA (N=4605) 
Characteristic n (%), mean (SD) or median (IQR) 








Age (years)  64 (8) 64 (8) 64 (8) 64 (8) 
Sex Female 813 (18.9%) 807 (18.9%) 301 (13.0%) 284 (12.4%) 
 Male 3492 (81.1%) 3468 (81.1%) 2016 (87.0%) 2004 (87.6%) 
Ethnicity African/Caribbean 222 (5.2%) 237 (5.5%) 162 (7.0%) 154 (6.7%) 
 Asian (East) 7 (0.2%) 3 (0.1%) 2 (0.1%) 2 (0.1%) 
 Asian (South) 130 (3.0%) 109 (2.5%) 72 (3.1%) 80 (3.5%) 
 Mixed/other 85 (2.0%) 86 (2.0%) 36 (1.6%) 33 (1.4%) 
 White/European 3861 (89.7%) 3840 (89.8%) 2045 (88.3%) 2019 (88.2%) 
Height (cm)  170 (9) 170 (9) 171 (8) 171 (9) 
Weight (kg)  84 (16) 84 (15) 85 (15) 84 (15) 
Body mass index (kg/m2) 28.9 (4.7) 28.9 (4.6) 28.8 (4.9) 28.8 (4.6) 
Smoking status Current smoker 1035 (24.0%) 1006 (23.5%) 547 (23.6%) 541 (23.6%) 
 Ex-smoker <12 months 1882 (43.7%) 1874 (43.8%) 995 (42.9%) 984 (43.0%) 
 Non or ex-smoker >12 months 1388 (32.2%) 1395 (32.6%) 775 (33.4%) 763 (33.3%) 
Alcohol status Non-drinker 1088 (25.3%) 1089 (25.5%) 574 (24.8%) 571 (25.0%) 
 1-13 units per week 1816 (42.2%) 1831 (42.8%) 1010 (43.6%) 983 (43.0%) 
 14+ units per week 1401 (32.5%) 1355 (31.7%) 733 (31.6%) 734 (32.1%) 
Units of alcohol consumed per week 6 (0 to 17) 6 (0 to 16) 6 (1 to 16) 6 (1 to 16) 
Systolic blood pressure (mmHg) 162 (18) 162 (17) 162 (17) 162 (18) 
Diastolic blood pressure (mmHg) 92 (10) 92 (10) 92 (10) 93 (10) 
Heart rate (bmp)  71 (13) 71 (12) 70 (12) 71 (13) 
Total cholesterol (mmol/L) 5.9 (1.1) 5.9 (1.1) 5.5 (0.8) 5.5 (0.8) 
HDL-cholesterol (mmol/L) 1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 1.3 (0.3) 
LDL-cholesterol (mmol/L) 3.8 (1.0) 3.8 (1.0) 3.5 (0.7) 3.5 (0.8) 
Triglycerides (mmol/L) 1.6 (1.2 to 2.3) 1.6 (1.2 to 2.3) 1.4 (1.0 to 2.0) 1.4 (1.1 to 2.0) 
Glucose (mmol/L) 5.6 (5.1 to 6.6) 5.6 (5.1 to 6.6) 5.6 (5.1 to 6.5) 5.6 (5.1 to 6.6) 
Creatinine (umol/L) 99 (89 to 109) 98 (89 to 109) 99 (90 to 109) 99 (90 to 109) 
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 BPLA (N=8580) LLA (N=4605) 
Characteristic n (%), mean (SD) or median (IQR) 
Diabetes mellitus 1139 (26.5%) 1145 (26.8%) 621 (26.8%) 630 (27.5%) 
Renal dysfunction 2803 (65.1%) 2813 (65.8%) 1544 (66.6%) 1538 (67.2%) 




2 19 (0.4%) 18 (0.4%) 15 (0.6%) 8 (0.3%) 
3 2036 (47.3%) 2026 (47.4%) 1186 (51.2%) 1133 (49.5%) 
4 1416 (32.9%) 1417 (33.1%) 716 (30.9%) 746 (32.6%) 
5+ 834 (19.4%) 814 (19.0%) 400 (17.3%) 401 (17.5%) 
Prior stroke / transient ischemic attach 507 (11.8%) 492 (11.5%) 233 (10.1%) 239 (10.4%) 
History of coronary artery disease 734 (17.0%) 745 (17.4%) 346 (14.9%) 388 (17.0%) 
Peripheral vascular disease 359 (8.3%) 383 (9.0%) 160 (6.9%) 150 (6.6%) 
Left ventricular hypertrophy 602 (14.0%) 584 (13.7%) 357 (15.4%) 341 (14.9%) 
ECG abnormalities other than LVH 746 (17.3%) 742 (17.4%) 387 (16.7%) 391 (17.1%) 
Atrial fibrillation  60 (1.4%) 60 (1.4%) 36 (1.6%) 32 (1.4%) 
Antihypertensive treatment within last month 3961 (92.0%) 3924 (91.8%) 2118 (91.4%) 2106 (92.0%) 
Prior lipid-lowering therapy 490 (11.4%) 478 (11.2%) 29 (1.3%) 22 (1.0%) 
Prior aspirin use 1083 (25.2%) 1040 (24.3%) 533 (23.0%) 519 (22.7%) 
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2.8.2 Changes in blood pressure and lipid level during the ASCOT trial 
Mean blood pressure was very similar between BPLA treatment groups at baseline.  
SBP was 162 mmHg and DBP was 92 mmHg in both BPLA groups. Blood pressure 
levels dropped most dramatically during the first six months of blood pressure-
lowering treatment initiation, and by the six-month trial visit, mean SBP had 
dropped in both groups to below 150 mmHg, but dropped 4.67 mmHg lower in the 
amlodipine-based arm compared to the atenolol-based arm.  Over the course of 
the trial SBP continued to fall but to a lesser extent, as is evident from Figure 1. 
There remained a small difference in SBP over the course of the trial, with SBP in the 
amlodipine-based group maintaining around a mean difference of 2 mmHg lower 
than the atenolol-based group.    
A similar pattern was observed with DBP over the course of the trial.  Mean DBP 
dropped from 92 mmHg to below 85 mmHg in both blood pressure-lowering 
groups by the six-month visit, but the drop was lower in the amlodipine-based 
group, about 82 mmHg compared to 84 mmHg in the atenolol-based group.   As 
with SBP the difference of about 2 mmHg was maintained for DBP over the 
remainder of the trial period.  
Blood pressure changes over the course of the trial are covered in more detail in 
Chapter 4 (Section 4.2). 
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Figure 1: SBP profile graph by BPLA randomised groups during the trial 
 
Note: Mean SBP is estimated using blood pressure taken at scheduled trial visits from a linear mixed model with a random subject effect and an 
interaction between visit and BPLA treatment groups.     
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At baseline, mean total cholesterol was 5.5 mmol/L in both randomised LLA groups, 
but by the six-month trial visit it was down to just above 4 mmol/L in the statin 
arm, 1.31 mmol/L less than in the placebo arm.  Figure 2 shows mean total 
cholesterol over the course of the whole BPLA trial and Figure 3 shows mean total 
cholesterol only during the blinded LLA period of the trial, split by randomised LLA 
group.  When looking at the whole BPLA trial period, by the final trial visit total 
cholesterol ends up very similar in both LLA groups, just above 4 mmol/L.  This is 
likely a result of those on placebo during the blinded LLA period switching to statin 
therapy following the end of the LLA trial, and hence catching up with observed 
reductions in lipids similar to that in the randomised statin group.  When looking 
only at the blinded LLA period in Figure 3, we see a large sustained difference 
between groups.  After six months, total cholesterol dropped to just over 4 mmol/L 
in the statin group, with only a small drop to 5.4 mmol/L in the placebo arm.  Over 
the course of the LLA trial period, cholesterol levels in the statin group remained 
quite stable at just over 4 mmol/L, and in the placebo group levels fell slightly 
further but remained over 5 mmol/L for the duration of the blinded LLA trial.   
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Figure 2: Total cholesterol profile graph by LLA group during the whole trial (both blinded LLA period and beyond) 
 
 
Note: Mean total cholesterol is estimated from a linear mixed model with subject random intercepts and an interaction between visit and LLA treatment 
groups.   
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Figure 3: Total cholesterol profile graph by LLA group during the trial – only including measurements taken during the 
blinded LLA phase 
 
Note: Mean total cholesterol is estimated from a linear mixed model with subject random intercepts and an interaction between visit and LLA treatment 
groups.  
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2.8.3 Differences in mortality between those allocated to amlodipine-based 
treatment and those allocated to atenolol-based treatment in the blood 
pressure-lowering arm of the trial 
2.8.3.1 Overall and cause-specific mortality 
A total of 718 (8.4%) subjects died out of 8580 subjects in the ASCOT legacy cohort 
by the end of the BPLA trial period, 370 (8.7%) assigned to atenolol-based 
treatment and 348 (8.1%) assigned to amlodipine-based treatment.   
Over the long-term, median 17.4-year observational period from randomisation 
until the end of January 2019, a total of 4040 (47.0%) deaths had occurred: 2015 
(47.1%) in the atenolol-based group and 2025 (47.0%) in the amlodipine-based 
group.  1402 (34.7%) of the total deaths were classified as having resulted from CV-
related causes (through independent cause of death adjudication), 725 (17.0%) in 
the atenolol-based group and 677 (15.7%) in the amlodipine-based group (see 
Table 2). 
Figure 4 presents cause-specific cumulative incidence curves that have been 
stacked to give the overall cumulative incidence death from all causes, using the KM 
method.  The cumulative incidence of mortality from any cause reaches 50% after 
19.06 years from baseline.  Median survival time for all-cause mortality was similar 
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in the amlodipine-based group to that in the atenolol-based group, 19.11 (p25: 
11.91) and 19.01 (p25: 11.67), respectively.            
Figure 4: Stacked cumulative incidence plot of cause-specific mortality  
 
During the BPLA trial period, amlodipine-based treatment was associated with a 
reduction in CV-related mortality compared to atenolol-based treatment (HR=0.75, 
p=0.018).  Somewhat weak evidence for an estimated 26% reduction in hazard of 
CHD-related death associated with the amlodipine-based group was observed 
(adjusted HR=0.74, p=0.066), and although there was a large estimated relative 
effect for stroke-related mortality (adjusted HR = 0.69), statistical evidence for the 
estimated effect was lacking (p=0.186).   Overall, for all-cause mortality, there was 
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a lack of evidence of a treatment effect during the BPLA trial period (adjusted HR: 
0.91, p=0.197).  See Table 6 for within BPLA treatment effect estimates. 
By the end of follow-up, evidence of a treatment effect for stroke-related mortality 
had strengthened, with amlodipine-based treatment being associated with an 
estimated decrease in hazard of stroke death by 27% (adjusted HR=0.73, p=0.011).  
There was no treatment effect observed for CHD-related mortality after the BPLA 
trial phase, and hence overall a lack of evidence for a sustained treatment effect 
over all follow-up (adjusted HR=0.92, p=0.283).  For overall CV-related mortality 
there was evidence for a reduction in hazard associated with the amlodipine-based 
group, although the estimated effect size had reduced quite substantially compared 
to that seen during the trial period (adjusted HR=0.90, p=0.039). 
There was no evidence of interactions with any of the baseline characteristics, 
having tested those pre-specified in the methods section.  
For all models, there was no formal statistical evidence of a violation of the 
proportional hazards assumption, from tests based on scaled Schoenfeld residuals.  
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Table 2: Number and rate of deaths by BPLA treatment allocation, HRs (95% CI) from Cox PH models 
  Total follow-up      
  
Atenolol  
(N=4275)   
Amlodipine  
(N=4305) 
     
Cause of death n (%) Rate*   n (%) Rate*  Crude HR (95% CI) p-value Adjusted HR (95% CI)** p-value 
All-cause 2015 (47.13) 3.30   2025 (47.04) 3.27  0.99 (0.93, 1.05) p=0.729 0.97 (0.91, 1.03) p=0.303 
CV 725 (16.96) 1.19   677 (15.73) 1.09  0.92 (0.83, 1.02) p=0.115 0.90 (0.81, 0.99) p=0.039 
CHD 338 (7.91) 0.55   325 (7.55) 0.52  0.95 (0.81, 1.10) p=0.480 0.92 (0.79, 1.07) p=0.283 
Stroke 150 (3.51) 0.25   113 (2.62) 0.18  0.74 (0.58, 0.95) p=0.017 0.73 (0.57, 0.93) p=0.011 
Other CV 237 (5.54) 0.39   239 (5.55) 0.39  0.99 (0.83, 1.19) p=0.935 0.97 (0.81, 1.16) p=0.718 
Non-CV 1290 (30.18) 2.11   1348 (31.31) 2.18  1.03 (0.95, 1.11) p=0.472 1.01 (0.93, 1.09) p=0.813 
Cancer 687 (16.07) 1.12   702 (16.31) 1.13  1.01 (0.91, 1.12) p=0.915 0.99 (0.90, 1.11) p=0.923 
Infection/respiratory 328 (7.67) 0.54   333 (7.74) 0.54  1.00 (0.86, 1.16) p=0.993 0.96 (0.82, 1.12) p=0.593 
Other 275 (6.43) 0.45   313 (7.27) 0.51  1.12 (0.95, 1.32) p=0.172 1.10 (0.93, 1.29) p=0.259 
*Rate per 100PY 
**Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of education (socio-
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Figure 5: Kaplan Meier cumulative incidence plots for mortality by BPLA treatment group  
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There was no evidence for an interaction between randomised treatment groups 
within the subgroup of subjects who were further randomised to either statin-
therapy or placebo as part of the LLA factor of the trial, for any mortality outcome.  
In other words, the treatment effects in one factor of the trial did not depend on the 
group to which patients were randomised to in the other factor of the trial.   
However, the effect of BPLA treatment was assessed within the subgroup of 3975 
subjects who were not part of the LLA factor of the trial, i.e. the higher-risk group 
of patients who had elevated cholesterol or were already on lipid-lowering therapy 
at baseline, and hence were not randomised to statin-therapy or placebo.   In this 
subgroup there was strong evidence for a reduction in CV-related mortality 
associated with the amlodipine-based treatment (adjusted HR=0.79, p=0.002).  In 
fact, the estimated HR in the subgroup of 4605 subjects who were included in the 
LLA part of the trial was very close to the null of 1 (adjusted HR=1.02, p=0.803), so 
it appeared that the overall effect on CV-related mortality was solely being driven 
by the effect seen only within the non-LLA subgroup.  A test for heterogeneity in 
BPLA effect on CV-related mortality between those who were randomised to an LLA 
treatment group and those who were not provided evidence of heterogeneity 
(interaction p=0.015).   CHD seemed to be the main cause of death that seemed to 
be driving this observed interaction for CV-related mortality.  While there was a lack 
of evidence for an overall BPLA group effect over the whole population, there was 
evidence for a differing effect on CHD-related mortality between non-LLA and LLA 
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groups (interaction p=0.048), with some evidence of a reduction in CHD-related 
mortality associated with amlodipine-based therapy, with an estimated HR of 0.80 
(p=0.036) in the non-LLA group, while the HR was 1.09 (p=0.447) in the LLA 
group.  While there was a lack of evidence for such an interaction for stroke-related 
mortality, the estimated effect (in favour of amlodipine-based treatment) was 
stronger in the non-LLA group (HR=0.63, p=0.011) compared to the LLA group 
(HR=0.83, p=0.288).   This combination of reduced mortality from both CHD and 
stroke gave rise to the overall stronger evidence for the interaction for overall CV-
related mortality.  Estimated effects from amlodipine-based treatment compared to 
atenolol-based in the non-LLA and LLA subgroups are presented in Table 3 along 
with interaction p-values.  Figure 6 presents cumulative incidence plots for these 2 
subgroups for CV-related mortality by BPLA group.   
The percentage and rate of CV-related mortality was similar in the amlodipine-
based group in both LLA and non-LLA subgroups.  In the amlodipine-based group, 
15.70% of subjects died in the non-LLA group, at a rate of 1.08 CV-related deaths 
per 100py, compared to 15.75% in the LLA group at a rate of 1.11 per 100py.  In 
the atenolol-based group, while the percentage that died from CV-related causes 
and rate was very similar to that in the amlodipine-based group at 15.00% and at a 
rate of 1.05 per 100py, the percentage and rate was higher in those in the non-LLA 
subgroup at 19.25% and at a rate of 1.35 per 100py.   
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Figure 6: Kaplan Meier cumulative incidence plots for CV-related mortality by 
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Table 3: Number and rate of deaths by BPLA treatment allocation, HRs (95% CI) from Cox PH models, in non-LLA and LLA 
subgroups with p-values from interaction tests 
  Total follow-up       
  
Atenolol  
(N=4275)   
Amlodipine  
(N=4305) 
      
Cause of death n (%) Rate*   n (%) Rate* 
 Crude HR  
(95% CI) 




All-cause            
Non-LLA 933 (47.38) 3.31   933 (46.51) 3.19  0.96 (0.87, 1.05) p=0.353 0.95 (0.86, 1.04) p=0.237   
LLA 1082 (46.92) 3.29   1092 (47.50) 3.34  1.02 (0.94, 1.11) p=0.686 0.99 (0.91, 1.08) p=0.787 p=0.494 
CV            
Non-LLA 379 (19.25) 1.35   315 (15.70) 1.08  0.80 (0.69, 0.93) p=0.003 0.79 (0.68, 0.92) p=0.002   
LLA 346 (15.00) 1.05   362 (15.75) 1.11  1.05 (0.91, 1.22) p=0.481 1.02 (0.88, 1.18) p=0.803 p=0.015 
CHD            
Non-LLA 195 (9.90) 0.69   165 (8.23) 0.56  0.81 (0.66, 1.00) p=0.049 0.80 (0.65, 0.99) p=0.036   
LLA 143 (6.20) 0.43   160 (6.96) 0.49  1.13 (0.90, 1.41) p=0.300 1.09 (0.87, 1.37) p=0.447 p=0.048 
Stroke            
Non-LLA 76 (3.86) 0.27   50 (2.49) 0.17  0.63 (0.44, 0.90) p=0.012 0.63 (0.44, 0.90) p=0.011   
LLA 74 (3.21) 0.22   63 (2.74) 0.19  0.86 (0.61, 1.20) p=0.370 0.83 (0.60, 1.17) p=0.288 p=0.262 
*Rate per 100PY 
**Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of education (socio-
economic status), and lipid lowering arm randomisation 
***Interaction test between BPLA randomised groups and non-LLA/LLA groups, from adjusted models. 
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2.8.3.2 Sub-distribution hazard approach to comparison of mortality from specific 
causes 
The sub-distribution hazard ratios from Fine and Gray proportional hazards models 
for each cause of death were largely very similar to the cause-specific HR estimates 
from Cox PH models.  There was evidence of a reduction in the sub-distribution 
hazard of stroke-related deaths associated with randomisation to the amlodipine-
based group (adjusted sHR=0.74, p=0.015).  In most cases the estimated sHRs and 
the level of statistical evidence for effects were very slightly reduced in Fine and 
Gray models in comparison to the estimated HRs.  For the outcome of death from 
any CV-related cause, the estimated sHR was the same as the HR, 0.90, but the p-
value was slightly larger (p=0.060) than for the HR in from the cause-specific 
approach.   Results are presented from Fine and Gray models alongside estimates 
from Cox PH models in Table 4. 
Figure 7 presents cumulative hazard curves by randomised BPLA treatment group 
for both the Cox cause-specific PH model approach and the Fine & Gray sub-
distribution PH model.  The cause-specific approach has higher cumulative hazards 
for both groups due to complete censorship, and hence removal from risk set of 
subjects who experience a competing event, inflating the estimated hazards in 
comparison to the sub-distribution hazards method.  
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This slight reduction in effect using Fine & Gray methods was likely because with 
this approach higher risk patients were being retained in the risk set after 
experiencing a competing event, but thereafter they had zero risk of experiencing 
the event of interest, e.g. stroke-related death.  If there were more subjects 
experiencing a competing event in the atenolol-based treatment arm, it would 
reduce the appearance of the risk of death from stroke in that arm compared to 
analyses where these subjects were removed from the risk-set thereafter.  Hence, 
this would result in the amlodipine-based arm appearing to have lower risk from 
stroke in Fine and Gray analyses and hence cause the estimated treatment effect to 
be reduced compared to the cause-specific approach.  
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Table 4: BPLA cause-specific and sub-distribution adjusted hazard ratios for 
mortality from specific causes 
  Cause-specific  Sub-distribution  
Cause of death Adjusted  
HR (95%CI)* 
p-value Adjusted  
sHR (95% CI)* 
p-value 
 CV 0.90 (0.81, 0.99) 0.039 0.90 (0.81-1.00) 0.060 
  CHD 0.92 (0.79, 1.07) 0.283 0.93 (0.80-1.09) 0.379 
  Stroke 0.73 (0.57, 0.93) 0.011 0.74 (0.58-0.94) 0.015 
  Other CV 0.97 (0.81, 1.16) 0.718 0.98 (0.82-1.17) 0.825 
 Non-CV 1.01 (0.93, 1.09) 0.813 1.02 (0.95-1.11) 0.526 
  Cancer 0.99 (0.90, 1.11) 0.923 1.01 (0.91-1.12) 0.890 
  Respiratory/infection 0.96 (0.82, 1.12) 0.593 0.97 (0.83-1.13) 0.705 
  Other non-CV 1.10 (0.93, 1.29) 0.259 1.13 (0.96-1.33) 0.146 
**Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, 




Figure 7: Cumulative hazard plots by BPLA group for stroke death for each 
method 
 
Cumulative hazard from Cox PH model 
 
Cumulative hazard from sub-distribution PH 
model (Fine & Gray) 
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2.8.3.3 Alternative measures to the hazard ratio for describing randomised BPLA 
treatment differences 
Three alternative approaches to the Cox PH model were used to quantify survival 
and estimate differences between treatment groups.  As seen in previous analyses, 
with each different approach to survival analysis there was evidence of a beneficial 
effect on stroke related mortality associated with being in the amlodipine-based 
group compared to the atenolol-based group.  In milestone analysis the stroke-
related mortality cumulative incidence at 18-years post-randomisation was 4.53% 
in the atenolol-based group and 3.27% in the amlodipine-based group, an 
estimated reduction of 1.25% associated with randomisation to the amlodipine-
based arm (p=0.013).   For overall mortality from any CV-related cause, there was 
also a decrease in cumulative incidence associated with the amlodipine-based 
group, an estimated decrease of 1.15%, but there was weak evidence for this 
difference (p=0.250). 
In restricted mean survival time analysis, there was an estimated increase in mean 
survival time for stroke-related mortality over 18 years by close to a month (26.48 
days) in the amlodipine-based arm (p=0.045).  Similarly, for death from any CV-
related cause, there was also an increase in survival time by an estimated 31.61 
days in the amlodipine-based group, but there was weak evidence for this 
(p=0.250). 
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The amlodipine-based group was associated with a relative decrease in hazard of 
stroke-related mortality by an estimated 27%, and in this analysis the group was 
associated with increased stroke-related mortality failure time, by an estimated 21% 
(p=0.012).  
The accelerated failure time approach also gave evidence of an overall CV-related 
mortality effect, with an estimated relative increase in failure time of 7% associated 
with the amlodipine-based group (p=0.042, see Table 5).  
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Table 5: Alternative measures of randomised treatment effect on survival  
  Milestone at 18 years Mean survival time (days), restricted 
to 18 years 
Accelerated failure time (Weibull 
Distribution) 
Cause of death Percentage difference 
(95%CI) 
p-value Mean event-free 
survival time difference 
(95%CI) 
p-value Failure time ratio 
(95%CI) 
p-value 
All-cause -0.12 (-2.33, 2.10) 0.916 19.68 (-55.97, 95.33) 0.610 1.02 (0.98, 1.05) 0.317 
 CV -1.15 (-3.10, 0.81) 0.250 31.61 (-22.44, 86.05) 0.250 1.07 (1.00, 1.13) 0.042 
  CHD -0.08 (-1.55, 1.39) 0.916 2.09 (-39.24, 43.43) 0.921 1.06 (0.95, 1.17) 0.295 
  Stroke -1.25 (-2.24, -0.27) 0.013 26.48 (0.54, 52.42) 0.045 1.21 (1.04, 1.41) 0.012 
  Other CV -0.03 (-1.39, 1.33) 0.967 5.90 (-24.28, 36.08) 0.702 1.02 (0.93, 1.11) 0.727 
 Non-CV 0.80 (-1.42, 3.02) 0.478 -8.82 (-74.47, 56.84) 0.792 0.99 (0.96, 1.04) 0.803 
  Cancer -0.38 (-2.30, 1.54) 0.701 -16.04 (-71.07, 38.99) 0.568 1.00 (0.94, 1.07) 0.925 
  Respiratory/infection 0.03 (-1.53, 1.59) 0.970 24.81 (-7.77, 57.40)  0.136 1.02 (0.96, 1.08) 0.586 
  Other non-CV 1.50 (0.08, 2.92) 0.039 -20.40 (-54.26, 13.46) 0.238 0.95 (0.88, 1.03) 0.240 
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Figure 8 presents two graphs from an analysis conducted on stroke-related 
mortality using a flexible parametric model.  In this model, each BPLA group had 
their own baseline hazard, each modelled using a restricted cubic spline function 
with 3 knots (knot positions at the 25th, 50th, and 75th percentiles).   Hence, the 
relative hazard was not constrained to be proportionate, but was dependent on 
time.  The top plot presents the HR over time, which does not appear to vary to a 
huge extent over the 20-year follow-up, with the estimated HR ranging from about 
0.80 to around to 0.60, with the effect consistently remaining in favour of the 
amlodipine arm throughout.  There even appears to be a slight indication of an 
increased effect in the later years.  The solid line in the plots represents the 
adjusted HR over time and the dashed lines are the 95% CI boundaries.  
The bottom plot shows how the difference in RMST between groups varies over 
time.  With a sustained effect over time, the difference in mean survival time is 
expected to continue to increase, but it appears that there may be some slight 
acceleration in effect in later years, the difference growing somewhat exponentially 
in favour of the amlodipine group over time.  Indeed, these remains fairly weak 
evidence of a difference in RMST between groups over most of follow-up until it 
becomes stronger at about 17 to 18-years post-randomisation.  
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Figure 8: Plots of time-dependent HR and difference in RMST over all follow-up 




Chapter 2: Impact of originally randomised trial treatment on long-term survival 
78 
 
2.8.3.4 Quantifying treatment-time interactions 
While there was some evidence within the BPLA trial period of a reduction in CV-
related mortality risk associated with randomisation to the amlodipine-based arm 
(adjusted HR=0.75, p=0.018), in the post-trial period there was no such evidence 
(adjusted HR=0.93, p=0.249), with test for interaction between periods p=0.102.  
This pattern appeared to be largely driven by CHD-related mortality, which showed 
weak evidence for a reduction in hazard associated with randomisation to the 
amlodipine-based group during the BPLA trial period, with an estimated decrease in 
Hazard of 25% (HR=0.74, p=0.066), but no evidence of an effect in the post-trial 
follow-up period (HR=0.98, p=0.829).    
For the outcome of mortality from stroke, the HRs were very consistent between 
BPLA within-trial and post-trial periods: 0.69 and 0.74 respectively, with weak 
evidence for the within-trial period and stronger statistical evidence emerging with 
a higher number of events thereafter (p=0.186 and 0.030, respectively, see Table 
6).   
Figure 9 presents KM plots of cumulative incidence by BPLA treatment group, 
separated out by BPLA trial period, and post-trial period.  For CHD-related 
mortality, the plot suggests that the reduction in events associated with the 
amlodipine-based group that occurred during the trial period, initially reverses at 
the beginning of the post-trial period, ultimately causing the incidence of CHD-
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related deaths in the amlodipine-based group to catch-up with the atenolol-group. 
The separation between stroke-related mortality cumulative incidence lines appears 
fairly consistent in both periods, but there does appear to be very little difference in 
the first six-years post-trial, after which the treatment effect in favour of the 
amlodipine-based group emerges.   
Splitting follow-up time into smaller sections based on three-year intervals 
provided no evidence of a trend in effect over time between the three-year time-
period post randomisation (see Table 7).  
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Table 6: Hazard ratios from piecewise proportional hazard models within and post- BPLA trial periods 
  Time period (years) 
Cause of death  BPLA trial period  Post-BPLA trial period 
P-value for difference 
in HRs between 
periods 
All  
Deaths in atenolol arm (%), rate 370 (8.65), 1.62 1645 (45.53), 4.30  
Deaths in amlodipine arm (%), rate 348 (8.08), 1.51 1677 (45.48), 4.32  
HR (95% CI)* 0.91 (0.78, 1.05) 0.98 (0.92, 1.05)  
p-value 0.197 0.589 0.346 
Cardiovascular  
Deaths in atenolol arm (%), rate 149 (3.49), 0.65 576 (15.94), 1.51  
Deaths in amlodipine arm (%), rate 115 (2.67), 0.50 562 (15.24), 1.45  
HR (95% CI)* 0.75 (0.58, 0.95) 0.93 (0.83, 1.05)  
p-value 0.018 0.249 0.102 
CHD 
Deaths in atenolol arm (%), rate 86 (2.01), 0.38 252 (6.97)  
Deaths in amlodipine arm (%), rate 66 (1.53), 0.29 259 (7.02)  
HR (95% CI)* 0.74 (0.54, 1.02) 0.98 (0.82, 1.17)  
p-value 0.066 0.829 0.130 
Stroke 
Deaths in atenolol arm (%), rate 30 (0.70), 0.14 120 (3.32)  
Deaths in amlodipine arm (%), rate 21 (0.49), 0.09 92 (2.50)  
HR (95% CI)* 0.69 (0.39, 1.20) 0.74 (0.56, 0.97)  
p-value 0.186 0.030 0.814 
*Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of 
education (socio-economic status), and lipid lowering arm randomisation. 
Note, percentages calculated using the denominators of number of subjects alive at the beginning of the time-period. 
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Table 7: Hazard ratios from piecewise proportional hazard models over follow-up for BPLA randomised comparison 
   Time period (years)  
Cause of 
death 






  N=8580 N=8256 N=7177 N=6460 N=5747 N=4913  
All  
Deaths in atenolol arm 165 (3.7%) 234 (5.7%) 275 (7.8%) 361 (11.2%) 401 (14.1%) 579 (23.8%)  
Deaths in amlodipine arm 154 (3.6%) 224 (5.4%) 310 (8.5%) 329 (10.1%) 407 (14.0%) 601 (24.2%)  
HR (95% CI)* 0.91 (0.73, 1.14) 0.92 (0.77, 1.11) 1.09 (0.93, 1.29) 0.88 (0.76, 1.02) 0.97 (0.85, 1.11) 1.00 (0.89, 1.12)  
p-value 0.421 0.393 0.282 0.089 0.678 0.947 0.636 
Cardiovascular  
Deaths in atenolol arm 75 (1.8%) 89 (2.2%) 92 (2.6%) 118 (3.7%) 149 (5.2%) 202 (8.3%)  
Deaths in amlodipine arm 62 (1.4%) 71 (1.7%) 102 (2.8%) 116 (3.6%) 150 (5.2%) 176 (7.1%)  
HR (95% CI)* 0.81 (0.58-1.13) 0.77 (0.56-1.05) 1.07 (0.81-1.42) 0.95 (0.73-1.22) 0.96 (0.76-1.20) 0.83 (0.68-1.01)  
p-value 0.210 0.095 0.621 0.668 0.715 0.676 0.884 
CHD 
Deaths in atenolol arm 44 (1.0%) 52 (1.3%) 39 (1.1%) 51 (1.6%) 67 (2.4%) 85 (3.5%)  
Deaths in amlodipine arm 36 (0.8%) 42 (1.0%) 52 (1.4%) 57 (1.8%) 70 (2.4%) 68 (2.7%)  
HR (95% CI)* 0.80 (0.51-1.24) 0.77 (0.52-1.16) 1.29 (0.85-1.95) 1.07 (0.73-1.56) 0.99 (0.71-1.39) 0.76 (0.55-1.04)  
p-value 0.309 0.217 0.234 0.722 0.976 0.085 0.886 
Stroke 
Deaths in atenolol arm 18 (0.4%) 16 (0.4%) 22 (0.6%) 27 (0.8%) 27 (1.0%) 40 (1.7%)  
Deaths in amlodipine arm 11 (0.3%) 15 (0.4%) 18 (0.5%) 23 (0.7%) 20 (0.7%) 26 (1.1%)  
HR (95% CI)* 0.60 (0.28-1.28) 0.91 (0.45-1.84) 0.80 (0.43-1.49) 0.82 (0.47-1.44) 0.71 (0.40-1.26) 0.62 (0.38-1.02)  
p-value 0.187 0.798 0.487 0.492 0.242 0.061 0.989 
*Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of education (socio-economic status), and lipid 
lowering arm randomisation.  
Note, percentages calculated using the denominators of the number of subjects alive at the beginning of the time-period. 
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2.8.4 Differences in mortality between those allocated to atorvastatin and those 
allocated to placebo in the lipid-lowering arm of the trial 
2.8.4.1 Overall and cause-specific mortality 
Within the LLA trial period, ending for all trial sites in October 2002, a total of 173 
(3.8%) out of the 4605 patients assigned to a lipid-lowering treatment arm died: 90 
(3.9%) randomised to placebo and 83 (3.6%) randomised to atorvastatin.  By the end 
of follow-up, a total of 2174 (46.8%) patients had died: 1096 (47.9%) in the placebo 
group and 1078 (46.5%) in the atorvastatin group.  708 (32.6%) of the total deaths 
were from CV-related causes, 373 (16.3%) in the placebo group and 335 (14.5%) in 
the atorvastatin group (see Table 8).  
There was insufficient evidence for a treatment effect on all-cause mortality by the 
end of the LLA trial period (HR=0.93, p=0.642).  The treatment difference was 
estimated to be similar by the end of follow-up, with, although stronger, still weak 
evidence of a difference associated with statin treatment compared to placebo 
(HR=0.94, p=0.133).  There was evidence that statin treatment was associated with 
a reduction in CV-related mortality, an estimated 14% reduction in hazard over the 
whole of follow-up (HR=0.86, p=0.044).  
There was no evidence of a treatment effect for death from CHD within the LLA trial 
period with the estimated HR very close to the null (HR=1.02, p=0.950).  However, 
evidence of a randomised treatment group effect emerged by the end of follow-up, 
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with statin treatment associated with a reduction in CHD deaths, an estimated 
reduction in hazards of 24% over the whole of follow-up (HR=0.76, p=0.018).  
There was no evidence of a treatment effect on stroke-related mortality by the end 
of follow-up (HR=0.97, p=0.868).   Figure 10 presents KM cumulative incidence 
plots by LLA treatment group.  
In subgroup analyses, there was some evidence of an interaction with ethnicity for 
death due to CV-related causes (p=0.011).   In those of black ethnic background, 
the HR was 2.86 (95% CI: 1.27-6.47, p=0.011), i.e. those in the statin group had 
increased risk of death from CHD with 8 (5.2%) CV-related deaths occurring in the 
placebo arm versus 21 (13.0%) in the statin arm.  There was 1 (0.6%) death from 
stroke in the placebo group and 7 (4.3%) in the statin group.  There was no 
evidence of any other interactions with baseline characteristics, having tested a 
total of 10 pre-specified baseline risk factors: age; sex; BMI; SBP; total cholesterol; 
smoking status; diabetes status; the age at which the subject left full-time 
education; and ethnicity.    
For all models, there was no formal evidence of a violation of the proportional 
hazards assumption, from statistical tests based on scaled Schoenfeld residuals.  
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Table 8: Number and rate of deaths by LLA treatment allocation, HRs (95% CI) from Cox PH models 
  Total follow-up      
  
Placebo  
(N=2288)   
Atorvastatin  
(N=2317) 
     
Cause of death n (%) Rate*   n (%) Rate*  Crude HR (95% CI) p-value Adjusted HR (95% CI)** p-value 
All-cause 1096 (47.90) 3.40   1078 (46.53) 3.23  0.94 (0.87, 1.03) p=0.176 0.94 (0.86, 1.02) p=0.133 
CV 373 (16.30) 1.16   335 (14.46) 1.00  0.86 (0.74, 1.00) p=0.048 0.86 (0.74, 1.00) p=0.044 
CHD 169 (7.39) 0.52   134 (5.78) 0.40  0.76 (0.61, 0.96) p=0.019 0.76 (0.61, 0.95) p=0.018 
Stroke 68 (2.97) 0.21   69 (2.98) 0.21  0.98 (0.70, 1.36) p=0.882 0.97 (0.69, 1.36) p=0.868 
Other CV 136 (5.94) 0.42   132 (5.70) 0.40  0.93 (0.73, 1.18) p=0.545 0.93 (0.73, 1.18) p=0.526 
Non-CV 723 (31.60) 2.24   743 (32.07) 2.23  0.99 (0.89, 1.09) p=0.784 0.98 (0.88, 1.08) p=0.664 
Cancer 390 (17.05) 1.21   393 (16.96) 1.18  0.97 (0.84, 1.11) p=0.650 0.96 (0.84, 1.11) p=0.577 
Infection/respiratory 180 (7.87) 0.56   195 (8.42) 0.58  1.04 (0.85, 1.27) p=0.731 1.02 (0.84, 1.25) p=0.817 
Other 153 (6.69) 0.47   155 (6.69) 0.46  0.97 (0.78, 1.21) p=0.801 0.97 (0.77, 1.21) p=0.766 
*Rate per 100PY 
**Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of education (socio-
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Figure 10: Kaplan Meier cumulative incidence of mortality plots by LLA treatment group 
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2.8.4.2 Sub-distribution hazard approach for specific causes of mortality 
Consistent with results from the cause-specific analysis approach, there was 
evidence for a reduction in CHD-related mortality associated with randomisation to 
the atorvastatin group compared to placebo from a Fine and Gray sub-hazards 
model.  The statin group was associated with an estimated reduction in sub-
distribution hazard of 21% (sHR=0.079, p=0.038).  Similarly, for overall CV-related 
mortality the estimated sHR of 0.88 (p=0.094) was fairly similar to the cause-
specific HR or 0.86 (p=0.044).  
As with the BPLA analysis, the sub-distribution hazard ratios tended to be slightly 
reduced in effect size and level of statistical evidence compared to the cause-
specific HRs from Cox Proportional Hazards models (see Table 9 for all cause-
specific and sub-distribution HR estimates, and Figure 11 for cumulative hazard 
plots for CHD-related mortality for the cause-specific HR approach and the sub-
distribution HR approach by treatment group).   
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Table 9: LLA cause-specific and sub-distribution adjusted hazard ratios for 
mortality from specific causes 
  Cause-specific  Sub-distribution  
Cause of death Adjusted  
HR (95%CI)* 
p-value Adjusted  
sHR (95% CI)* 
p-value 
All-cause 0.94 (0.86-1.02) 0.133   
 CV 0.86 (0.74-1.00) 0.044 0.88 (0.76-1.02) 0.094 
  CHD 0.76 (0.61-0.95) 0.018 0.79 (0.63-0.99) 0.038 
  Stroke 0.97 (0.69-1.36) 0.868 1.01 (0.72-1.41) 0.955 
  Other CV 0.93 (0.73-1.18) 0.526 0.96 (0.75-1.22) 0.728 
 Non-CV 0.98 (0.88-1.08) 0.664 1.00 (0.90-1.11) 0.968 
  Cancer 0.96 (0.82-1.11) 0.577 1.00 (0.87-1.15) 0.964 
  Respiratory/infection 1.02 (0.84-1.25) 0.817 1.06 (0.86-1.30) 0.601 
  Other non-CV 0.97 (0.77-1.21) 0.766 1.00 (0.80-1.25) 0.978 
**Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, 
diabetes, smoking status, years of education (socio-economic status), and lipid lowering arm 
randomisation 
 
Figure 11: Cumulative hazard plots by LLA group for CHD death for each 
method 
 
Cumulative hazard from Cox PH model 
 
Cumulative hazard from sub-distribution PH 
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2.8.4.3 Alternative measures to the hazard ratio for describing randomised LLA 
treatment differences 
From each alternative approach to survival analysis comparing mortality between 
placebo and statin randomised groups, there was evidence for a difference in CHD-
related death in favour of the statin group.   
In the placebo group, the cumulative incidence of CHD-related death at the 18-year 
milestone time-point was 9.53%.  The cumulative incidence was estimated to be 
2.50% lower in the statin group at the milestone time-point (p=0.010).   
Figure 12 presents two plots from an analysis conducted on CHD-related mortality 
using a flexible parametric survival model to assess survival differences between 
LLA groups (methods as previously described).  The bottom plot of Figure 12 shows 
how the difference in RMST between groups varied over time.  The difference in 
survival time appears to have grown somewhat exponentially in favour of the statin 
group, such that, by 18-years post-randomisation the survival time is estimated to 
be 54.59 days longer in the statin group compared to those randomised to placebo 
(95% CI: 1.87, 107.32, p=0.042).  The top plot of Figure 12 shows relative hazard 
over time, giving the impression that relative hazards appeared to remain quite 
consistent over time, in favour of the statin group.  In addition, the relative failure 
time was estimated to be 20% higher in the statin group to the placebo group 
(p=0.020).   
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Overall CV-related mortality was reduced in the statin group for each different 
measure of survival, with somewhat borderline evidence at the 5% level. There was 
also evidence of a difference in all-cause mortality in RMST at 18 years, with the 
statin arm associated with an increase in survival time of over 3 months (104.66 
days, p=0.046).  Table 10 presents estimates from each of the three alternative 
survival analysis approaches.  
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Table 10: Alternative measures of randomised treatment effect on survival  
  Milestone at 18 years Mean survival time (days), restricted 
to 18 years 
Accelerated failure time (Weibull 
Distribution) 
Cause of death Percentage difference 
(95%CI) 
p-value Mean event-free 
survival time difference 
(95%CI) 
p-value Failure time ratio 
(95%CI) 
p-value 
All-cause -1.93 (-4.96, 1.11) 0.214 104.66 (2.05, 207.28) 0.046 1.04 (0.99, 1.08) 0.129 
 CV -2.81 (-5.47, -0.15) 0.038 69.40 (-1.74, 140.54) 0.056 1.09 (1.00, 1.19) 0.044 
  CHD -2.50 (-4.41, -0.59) 0.010 54.59 (1.87, 107.32) 0.042 1.20 (1.03, 1.41) 0.020 
  Stroke -0.40 (-1.76, 0.97) 0.568 5.57 (-28.17, 39.31) 0.746 1.02 (0.84, 1.23) 0.858 
  Other CV -0.29 (-2.22, 1.64) 0.765 14.39 (-26.93, 55.71) 0.495 1.04 (0.93, 1.16) 0.517 
 Non-CV -0.11 (-3.17, 2.95) 0.945 54.74 (-35.89, 145.37) 0.236 1.01 (0.96, 1.07) 0.667 
  Cancer -0.55 (-3.22, 2.12) 0.684 24.84 (-52.63, 102.31) 0.530 1.02 (0.94, 1.12) 0.574 
  Respiratory/infection 0.27 (-1.94, 2.48) 0.814 15.87 (-28.87, 60.60) 0.487 0.99 (0.92, 1.07) 0.823 
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Figure 12: Plots of time-dependent hazard ratio and difference in RMST over all 
follow-up time, estimated from a flexible parametric model  
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2.8.4.4 Quantifying LLA treatment-time interactions 
The estimated effect (adjusted HRs) comparing LLA groups was similar for CV-
related mortality during the LLA trial period (HR: 0.85) to that in the post-trial 
period (HR: 0.87), but statistical evidence for the treatment effect was a lot stronger 
in the post-trial period due to the larger number of events.  There was no evidence 
of an interaction in effect between within-trial and post-trial periods (p=0.939).   
There was no evidence of a CHD-related mortality difference between randomised 
LLA groups during the LLA trial period, with an adjusted HR of 1.02 (p=0.950).  The 
effect on CHD-related mortality emerged during the post-trial period with the 
reduction associated with the randomised atorvastatin group, with an estimated 
adjusted HR of 0.75 (p=0.023).  From Figure 13 this post-trial effect can be 
visualised in the KM plot split by LLA trial period and post-trial period, showing 
little difference between cumulative incidence curves during the LLA trial period, 
but clear separation in the post-LLA period.  Despite this, there was no evidence of 
an interaction between within and post-LLA periods for CHD-related mortality 
(interaction p=0.380), nor was there evidence of a trend over time when splitting 
time into 3-year periods (test for trend p=0.457, see Table 12).   
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Table 11: Hazard ratios from piecewise proportional hazard models within and post- LLA trial periods 
  Time period (years) 
Cause of 
death 
 LLA trial period  Post-LLA trial period 
P-value for difference 
in HRs between 
periods 
All  
Deaths in placebo arm, rate 90 (3.93), 1.28 1006 (45.77), 3.98  
Deaths in atorvastatin arm, rate 83 (3.58), 1.18 995 (44.54), 3.78  
HR (95% CI)* 0.93 (0.69-1.26) 0.94 (0.86-1.02)  
p-value 0.642 0.154 0.966 
Any 
Cardiovascular  
Deaths in placebo arm, rate 36 (1.57), 0.51 337 (15.33), 1.33  
Deaths in atorvastatin arm, rate 30 (1.29), 0.43 305 (13.65), 1.16  
HR (95% CI)* 0.85 (0.52-1.38) 0.87 (0.74-1.01)  
p-value 0.509 0.073 0.939 
CHD 
Deaths in placebo arm, rate 19 (0.83), 0.27 150 (6.82), 0.59  
Deaths in atorvastatin arm, rate 19 (0.82), 0.27 115 (5.15), 0.44  
HR (95% CI)* 1.02 (0.54-1.93) 0.75 (0.59-0.96)  
p-value 0.950 0.023 0.380 
Stroke 
Deaths in placebo arm, rate 8 (0.35), 0.11 60 (2.73), 0.24  
Deaths in atorvastatin arm, rate 6 (0.26), 0.09 63 (2.82), 0.24  
HR (95% CI)* 0.78 (0.27-2.25) 1.00 (0.70-1.42)  
p-value 0.644 0.993 0.663 
*Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, 
years of education (socio-economic status), and lipid lowering arm randomization 
Note, percentages calculated using the denominators of how many subjects alive at the beginning of the time-period. CHD: 
coronary heart disease. 
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Table 12: Hazard ratios from piecewise proportional hazard models over follow-up for LLA randomised comparison 
   Time period (years)  
Cause of 
death 





  N=4605 N=4442 N=3844 N=3447 N=3068 N=2603  
All  
Deaths in Placebo arm 81 (3.5%) 127 (5.8%) 174 (9.1%) 196 (11.6%) 209 (14.0%) 309 (24.3%)  
Deaths in Atorvastatin arm 80 (3.5%) 115 (5.1%) 156 (8.1%) 167 (9.5%) 238 (15.1%) 322 (24.2%)  
HR (95% CI)* 0.99 (0.73-1.34) 0.90 (0.70-1.16) 0.85 (0.69-1.06) 0.80 (0.65-0.98) 1.07 (0.89-1.29) 0.99 (0.85-1.15)  
p-value 0.944 0.408 0.152 0.030 0.474 0.872 0.320 
Cardiovascular  
Deaths in Placebo arm 36 (1.6%) 40 (1.8%) 52 (2.7%) 64 (3.8%) 70 (4.7%) 111 (8.7%)  
Deaths in Atorvastatin arm 32 (1.4%) 32 (1.4%) 49 (2.5%) 51 (2.9%) 77 (4.9%) 94 (7.1%)  
HR (95% CI)* 0.90 (0.56-1.45) 0.80 (0.50-1.27) 0.91 (0.61-1.34) 0.75 (0.52-1.08) 1.03 (0.74-1.42) 0.80 (0.61-1.05)  
p-value 0.664 0.347 0.626 0.125 0.860 0.108 0.931 
CHD 
Deaths in Placebo arm 20 (0.9%) 25 (1.1%) 19 (1.0%) 33 (2.0%) 29 (2.0%) 43 (3.4%)  
Deaths in Atorvastatin arm 22 (1.0%) 13 (0.6%) 24 (1.2%) 14 (0.8%) 30 (1.9%) 31 (2.3%)  
HR (95% CI)* 1.12 (0.61-2.05) 0.52 (0.27-1.02) 1.22 (0.67-2.22) 0.40 (0.21-0.75) 0.96 (0.58-1.61) 0.67 (0.43-1.07)  
p-value 0.719 0.057 0.521 0.004 0.891 0.092 0.457 
Stroke 
Deaths in Placebo arm 7 (0.3%) 7 (0.3%) 14 (0.7%) 9 (0.5%) 10 (0.7%) 21 (1.7%)  
Deaths in Atorvastatin arm 4 (0.2%) 10 (0.5%) 7 (0.4%) 17 (1.0%) 14 (0.9%) 17 (1.3%)  
HR (95% CI)* 0.58 (0.17-1.99) 1.44 (0.5-3.77 0.49 (0.20-1.20) 1.76 (0.79-3.95) 1.31 (0.58-2.4) 0.77 (0.41-1.45)  
p-value 0.386 0.462 0.119 0.168 0.512 0.412 0.865 
*Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of education (socio-economic status), and 
lipid lowering arm randomisation.  
Note, percentages calculated using the denominators of how many subjects alive at the beginning of the time-period. CHD: coronary heart disease. 
 




2.9.1 Summary of findings 
This study provided evidence of the long-term benefits on cardiovascular mortality 
of lipid-lowering statin-therapy and of antihypertensive treatment based on the 
CCB amlodipine with the addition of the ACEi perindopril in patients with 
hypertension, with no previous coronary-related events, but considered high risk 
for CVD.   
Randomisation to atorvastatin led to a decrease in mortality from CHD compared to 
those randomised to placebo and there were fewer deaths from stroke in those 
randomised to amlodipine-based treatment compared to those randomised to 
atenolol-based treatment.  These effects extended beyond the end of the trial 
periods over the median 17.4 years of follow-up, suggesting that benefits can be 
long-lasting.   
2.9.2 Long-term impact of blood pressure lowering treatment  
The BPLA period of the ASCOT trial was ceased early after a median 5.5-years 
follow-up due to an excess in deaths associated with the atenolol-based group as 
well as worse outcomes on a number of other secondary endpoints 14.  The trial 
reported an estimated 24% reduction in hazard of CV-related mortality at the end of 
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the trial (p=0.001) and an 11% reduction in hazard of all-cause mortality (p=0.025) 
associated with the amlodipine-based treatment arm.   
In the ASCOT legacy sub-population cohort of 8580 subjects from England and 
Scotland, while there was also evidence of a reduction in CV-related mortality 
during the BPLA trial period, while this effect seemed to diminish a little after the 
trial, overall there was a sustained effect of a reduction in CV-related mortality over 
the long-term follow-up.  
More specifically, there was evidence of a reduction in the risk of stroke-related 
mortality over the whole of follow-up associated with randomisation to amlodipine-
based treatment.  The estimated adjusted HRs were similar within-trial to that post-
trial (0.70 and 0.73, respectively), suggesting a continued and consistent beneficial 
effect on stroke-related mortality even after the trial.  There was no evidence that 
hazards were not proportionate over time.     
The beneficial effect on CV-related mortality seen with amlodipine-based therapy 
compared to atenolol-based therapy was only evident in the higher risk group that 
were not randomised into the LLA part of the trial.  There was evidence for this 
interaction between LLA and non-LLA groups, with no effect seen at all in those 
who took part in the LLA factor of the trial.  However, the underlying rate of CV-
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related mortality was very similar between non-LLA and LLA subgroups for those 
randomised to amlodipine-based therapy, indicating that amlodipine had a similar 
effect in both groups.  Within the atenolol-based group however, those not in the 
LLA factor of the trial had higher rates of CV-related mortality, while those in the 
LLA factor had similar rates of CV-related mortality to rates seen in those 
randomised to amlodipine-based therapy.  Hence, it appeared the effect of 
atenolol-based treatment seemed inconsistent across subgroups, with poorer 
outcomes in the non-LLA group compared to the LLA group.  The effect of 
amlodipine-based therapy appeared consistent in both subgroups, and while the 
effect of atenolol-based treatment was also similar in the LLA cohort, this implies 
that atenolol-based therapy was less effective in those at a higher CVD risk with a 
higher lipid profile at baseline.  
 Although there was no evidence of a BPLA effect on CHD-related mortality across 
the whole population, this pattern of differing effect on CV-related mortality 
between non-LLA and LLA subgroups was largely being driven by the differing 
effects on CHD-related mortality between subgroups.  Rates of CHD-related 
mortality were similar in both BPLA treatment groups in the LLA group, and as 
expected higher overall and in both treatment groups in the higher risk non-LLA 
subgroup.  However, the rate of CHD-related death was higher in the atenolol-
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based group compared to amlodipine-based, within that higher risk non-LLA 
subgroup.  Again this implies that while atenolol-based therapy may be as effective 
as amlodipine-based in the lower risk LLA subgroup, it was less effective in 
reducing CHD mortality in the higher non-LLA risk group.  Other studies have 
shown beta blockers to be less effective in older subjects at reducing stroke and 
other CV events compared to other anti-hypertensive treatments, while at younger 
ages found similar efficacy between anti-hypertensive treatments 50–52.  Although 
there was no difference in age between non-LLA and LLA subgroups, the 
differences observed in other studies related to the increase CV-risk, which of 
course is associated with increased age.  Other studies have found that atenolol 
demonstrated no reduction effect on mortality in those with coronary syndrome or 
heart failure, while alternative beta-blockers were found to reduce mortality in such 
patients 53,54.  
Biological mechanisms behind the observed differences between BPLA trial groups 
are not entirely understood.  While blood pressure control was slightly better in the 
amlodipine-based group, by about one-year post-baseline this difference was 
small, at around 2 mmHg for the duration of the trial.  This small difference in 
blood pressure does not represent a large difference from a clinically important 
perspective, and cannot explain the differences in mortality between trial groups.  
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Another possibility is that the difference in visit-to-visit blood pressure variability 
between the treatment arms plays a role.  Blood pressure variability was much lower 
in the amlodipine-based group compared to the atenolol-based group.   Blood 
pressure variability is explored in depth in Chapter 4 of this thesis. 
2.9.3 Long-term impact of lipid lowering treatment  
The LLA part of the ASCOT trial also ceased early after a median 3.3-years follow-
up due to the large reduction in the primary outcome of non-fatal myocardial 
infarction or fatal CHD that emerged in the atorvastatin arm, a final HR of 0.64 
(p<0.001).  The trial also reported reductions associated with statins for other 
outcomes including all coronary events and stroke events 13.  Although fewer deaths 
from any cause occurred in the statin arm compared to the placebo arm (185 vs. 
212, respectively), statistical evidence was weak (p=0.16).    
A difference in CHD-related mortality did not emerge between BPLA trial groups 
during the LLA trial period.  However, over long-term follow-up there was evidence 
for a reduction in risk of CHD-related deaths in the statin arm, an estimated 
adjusted relative reduction in hazard of 24%.  The LLA period was short with a 
median of 3.3 years and had relatively few events so it was hard to assess whether 
there might have been a delayed effect on CHD mortality or whether this apparent 
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delay in materialisation of effect was merely by chance.  There was no statistical 
evidence of a change in effect on CHD-related mortality over time. 
There was evidence for a reduction in overall CV-related deaths associated with the 
statin group, with an adjusted HR of 0.86 (p=0.044), but this was entirely a result 
of the effect on death from CHD, with no evidence for a difference in other CV-
related causes of death.  
Evidence for an interaction was found between ethnic background and LLA 
treatment group for CV-related mortality.  There were more deaths due to CV-
related causes in the statin group than in the placebo group for those of black 
ethnic background, while there were fewer deaths in the statin group in those of 
non-black background.  This could not be explained by a difference in lipid profile, 
since those of black origin had a very similar cholesterol profile in both placebo and 
statin groups to those of non-black origin.  Other studies have presented 
conflicting evidence.  The ALLHAT researchers conducted a study to see if the 
apparent differences between ethnicities in the effect of assignment to statins on 
CHD compared to the standard of care could be explained by differences in baseline 
characteristics, adherence to medication or achieved blood pressure or lipid 
lowering.  Results suggested that statin therapy was effective in preventing CHD in 
those of black origin but not in those of non-black origin 55.  On the other hand, 
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some studies have reported smaller effects of statins in black subjects compared to 
non-black.  Often this seems to be because subjects of black ethnicity had higher 
baseline cholesterol and were associated with poorer adherence to statins 
compared to non-black subjects 56.  Then a number of other trials that have 
conducted subgroup analyses have found little difference in the effects of statins on 
lipid control 57–59.  However, there seems to be a lack of data on the effects of 
statins on those of black ethnicity, as most of the large clinical trials contain 
predominantly white subjects.  Some studies have suggested that there is a lower 
prevalence of statin use among those of black ethnicity compared to those of non-
black origin.  Reasons for this seem to still be unclear 60. 
There was a marked and sustained difference in lipid control during the blinded LLA 
trial period between statin and placebo arms.  While mean total cholesterol had 
plummeted by the 6-month visit and remained consistently around 4 mmol/L 
throughout the blinded LLA trial phase in those assigned to statin therapy, the 
mean level remained over 5 mmol/L in the placebo arm throughout the LLA trial 
period.  A slight reduction in total cholesterol in the placebo arm was likely due to 
changes in related factors over the trial as well as possibly some regression to the 
mean.  If this sustained difference in lipid levels was responsible in part for 
sustained benefit in reduction in deaths from CHD, then it may indicate that even 
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relatively short periods of lipid control can have much longer-lasting clinically 
important benefits on coronary health.  By the end of the BPLA trial, the difference 
in total cholesterol between statin and placebo arms had gone due to placebo 
patients being permitted to cross-over to atorvastatin.  Mechanisms behind the 
long-lasting benefits associated from statins are somewhat unclear.  Statin therapy 
is known to induce plaque stabilisation and even regression.  Perhaps the 
occurrence of plaque stabilisation during the trial period is somewhat responsible 
for these long-term benefits to CV outcomes 61,62.  
There have been consistent findings from other clinical trials of a relationship 
between statin use and reduction in CV mortality over long-term follow-up 35–
37,63,64.  The WOSCOPS study concluded that their observation of long-term legacy 
benefit (20-year follow-up) after 5 years of LDL lowering by statin therapy could 
suggest that treatment might not need to be lifelong.  However, the long-term 
effect they witnessed reduced slightly in the post-trial period compared to within-
trial, suggesting that subjects might not have fully experienced the maximum long-
term benefits.  What is unknown is whether there could be a limited period of statin 
exposure that could give optimal sustained long-term benefits without the need for 
lifelong therapy, or whether continued statin therapy would always result in greater 
benefits.  It is difficult to see how this could be studied.  
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2.9.4 Strengths & Limitations  
The ASCOT legacy study provides a unique and valuable opportunity to study the 
effects of allocated treatment over a long follow-up time in subjects presenting 
with hypertension and at high risk for CVD.  The long follow-up combined with the 
benefit from of the randomisation process in the allocation of treatment, gives this 
study an advantage over similar non-randomised observational studies.  The 
greatest strength of this legacy study is its large cohort consisting of hypertensive 
patients with the opportunity to investigate the long-term impact of both lipid-
lowering and blood pressure-lowering treatments on mortality, giving sizeable 
power to estimate effects between treatments.  
As mentioned, the ASCOT legacy study, as with other studies born out of 
randomised trials, benefits from the randomisation process balancing known and 
unknown risk factors between trial groups.  If the randomisation process is 
conducted well, then groups should differ only by chance.  This allows for an 
unbiased comparison of effect between randomised groups.  While in a randomised 
trial setting one can reasonably interpret associations as being causal, beyond the 
randomised trial it is more difficult to make such causal claims.   One of the biggest 
limitations of the study is that there was no access to data on treatments that 
subjects went on to after the trial.  As well as post-trial lipid-lowering and blood 
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pressure-lowering treatments, and any other treatments being unknown, risk 
factors, behavioural and lifestyle factors were also not known.  This meant that 
there was the potential for a degree of unidentified and unmeasured confounding 
which may have emerged more and more as time passed from randomisation if 
individual subject choices were related to their original treatment allocation in some 
way.  The only way one could make the assumption that randomised groups stayed 
balanced over time is if treatment groups were not influenced or affected in 
different ways to each other.  In that case, one might expect changes in each group 
over time to vary in a similar way, and continue to only differ only by chance. 
However, by the very nature of the interventions, randomised groups have different 
experiences as a result of their treatment.  Therefore, randomised groups are likely 
to systematically become increasingly different as time passes.  If the groups differ 
in terms of attributes that are on the causal pathway towards the outcomes, that 
won’t bias estimation of treatment effects as the modification of these attributes 
are the mechanisms through which the treatments take effect.   Some might be 
known mechanisms, such as the lowering of blood pressure or cholesterol levels, 
and others might be unknown biological or behavioural changes.  These changes 
matter if we wish to understand the mechanisms involved in treatment effects, but 
won’t stop us from being able to conclude that the treatment effect exists.  
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Problems arise when we face fundamental differences between groups that have 
arisen from the study design that may not be reflective of real-life.   
As mentioned, a key limitation was that post-trial treatments were not available for 
these analyses.  If post-trial treatment choices were balanced across originally 
randomised trial treatment groups, then estimated effects would be easier to 
interpret as we could be more confident of less bias from unknown future treatment 
differences between groups.  However, as data on post-trial treatment choices was 
not available, the extent to which post-trial treatments and other potential 
unknown confounding factors impact the estimated effects over time were unknown 
and hence could not be analysed or taken into account in analyses.  Interpretation 
of results must therefore be kept within the context of these limitations.   
One could argue that if taking allocation to a specific treatment was related to 
future treatment choices and behaviours as well as the biological changes that take 
place, then these mechanisms could be seen as valid components of causal effects.  
However, this setting is not representative of a usual patient journey outside of this 
randomised blinded trial setting, and these mechanisms are unknown so we are not 
able to fully understand them.   
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Analyses were conducted on an intention-to-treat (ITT) basis, i.e. subjects were 
analysed according to the original treatment groups to which they were randomly 
assigned, regardless of the treatments they actually received during the trial.  If 
some patients were to cease taking assigned treatment or to switch treatments, 
then groups could become more similar in terms of the actual treatment taken and 
estimated effects could have been diluted.  Bias could arise if treatment adherence 
was systematically different between treatment groups.  Although, if differences in 
adherence or likeliness to change treatments was a consequence of the treatment 
allocation, then this might reflect behaviours in a real-life setting out of the trial 
context, keeping treatment comparisons pragmatic.   
Indeed, the ITT analysis approach is pragmatic, which is one of the reasons why it is 
a popular approach to analysis for many randomised clinical trials.  The treatments 
in the two BPLA groups were drug-led regimens: one a CCB-led regimen with the 
option of an ACE-i as needed; and the other a BB-led regimen with the option of a 
diuretic as needed.  Hence, the BPLA comparison was not a single drug comparison, 
but a treatment regimen strategy comparison.  An ITT population was fitting for 
analysis in that it was reflective of how a treatment strategy might be conducted in 
real life clinical practice, where modifications to treatments occur as required.  
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Conducting a per protocol analysis can pose problems when those who are removed 
from the analysis due to protocol violations are systematically different to those 
who are not excluded from analyses.  This can introduce bias.  
In the ASCOT trial in general if a subject ceased trial medication or switched 
treatment, they would be withdrawn from the trial at that point.  For the LLA factor 
of the trial, statin therapy was compared to placebo, so the interpretation of effect 
during the trial could be a fairly pure comparison if patients were able to remain 
fully unaware of which treatment they were taking, active or placebo.  In the 
ALLHAT trial this wasn’t the case, pravastatin was compared to the usual standard 
of care.  As a result, many subjects in the usual care group received statins during 
the trial, and hence a smaller difference in cholesterol levels between the groups 
was detected.  Total cholesterol dropped by 17.2% in the pravastatin group and by 
7.6% in the usual care group at year 4 in the ALLHAT trial, with no significant 
difference 65.  While in the ASCOT trial total cholesterol dropped by 25.3% in the 
atorvastatin group and by 7.4% in the placebo group by the end of year 3 (24.5% 
and 8.1%, respectively by the end of year 4, although there were few subjects 
remaining in the LLA part of the trial for 4 years or more, n=389).  Total cholesterol 
was 0.99 mmol/L less in the atorvastatin arm compared to placebo at the end of 
year 3 (p<0.001), and 0.90 mmol/L less at the end of year 4 (p<0.001) in the 
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ASCOT trial.   In addition, baseline total cholesterol was slightly higher in ALLHAT 
subjects (5.82 & 5.81 mmol/L in the statin and usual care groups, respectively) 
compared to ASCOT (5.48 mmol/L in both groups).  Hence, the ALLHAT trial may 
have been underpowered to detect effects in CV endpoints, and evidence for a 
difference in all-cause mortality and CV-related mortality over long-term follow-up 
was non-significant 65–67. 
The main analysis approach used the Cox Proportional Hazards model.  This model 
can be used in the context where competing risks are present and the cause-
specific hazards are estimated.  When a subject has a competing event, the subject 
is censored and hence removed from the risk-set thereafter, in the same way that a 
subject would be censored if they were lost to follow-up or did not give consent for 
follow-up beyond the end of the trial.   The assumption in this approach is that 
censoring is not informative, given the other covariates in the model.  If censorship 
is informative then estimated effects can be biased in one way or another.  
It might be that a subject dying from a competing cause of death was informative 
about the level or risk that subject was also at for death from the cause of interest.  
For example, patients who died from a cause other than stroke may have been at 
increased risk of dying from stroke.  We know that death from CHD has some 
common risk factors with death due to stroke, for example.  Also, death from non-
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CV causes, such as cancer, share some common risk factors with stroke-related 
death.  Hence, if subjects who die from CHD were also at higher risk of dying from 
stroke, then to ignore this would mean that the hazard of stroke may be 
underestimated when CHD-related deaths are occurring, and vice-versa.  If a higher 
rate of CHD-related death was occurring in one treatment group than another, then 
this could mean the estimated hazard of stroke-related death in that group was 
lower than it truly theoretically would be in relation to the alternative group, had we 
been able to observe a future stroke event if the competing event of CHD had not 
occurred. 
Although there was weak statistical evidence, there was a slightly higher rate of 
CHD-related death in the atenolol-based group compared to the amlodipine-based 
group.  If those censored at death by this competing cause were actually also at 
higher risk of stroke-related death, then this would mean the risk of stroke-related 
death in the atenolol-based arm was underestimated since those subjects who died 
from CHD were also at higher risk of dying from stroke.  
Fine & Gray introduced sub-distribution hazard regression as a way to model the 
influence of covariates on the cumulative incidence function.  The cumulative 
incidence function is preferable over Kaplan Meier estimates of the survival function 
in contexts where the desire is to estimate the empirical distribution of events 
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instead of the hypothetical distribution that is applicable in the context where no 
competing risks exist 68.  The sub-distribution proportional hazards model has 
become a popular alternative to the Cox PH model, and in some fields has become 
the standard approach when competing risks are present.  This is because the Fine 
& Gray approach does not make the explicit assumption of non-informative 
censoring when a competing event occurs.  Instead, when a competing event 
occurs, the subject is not censored but remains in the risk-set.  While this does 
bypass the assumption of non-informative censoring, it poses a different problem 
in the context of causal analysis because whenever a competing event occurs this 
eliminates the possibility of any other competing event occurring in those subjects 
from that point on. For example, if there was a higher rate of death from CHD in the 
atenolol-based group, then this would reduce the estimate of the sub-distribution 
hazard of stroke-related death or any other competing cause of death.  Hence, if 
competing events of death from CHD and stroke are both occurring more in the 
atenolol-based group, then the estimated effect will be reduced for each cause 
because of the higher occurrence of death from the competing cause.    
There was little difference in HRs between the cause-specific and sub-distribution 
approaches.  The effect was slightly reduced with the Fine & Gray method for 
stroke-related mortality for the BPLA comparison (cause-specific HR was 0.72 and 
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the sHR was 0.73).  This could be a consequence of there also being a higher 
occurrence of CHD events in the atenolol-based arm (although no statistical 
evidence).  There was also a slightly reduced effect with the Fine & Gray method for 
CHD-related mortality for the LLA comparison (cause-specific HR was 0.76 and the 
sHR was 0.79).  These differences are small, likely because in each case there were 
no strong effects observed from competing causes of death.   
While the Fine & Gray approach estimates the true cumulative incidence of events, it 
can lead to bias in causal analysis 69.  This is because the theoretical underlying risk 
will be underestimated.  Hence, the Kaplan Meier cumulative incidence cause-
specific approach would be more appropriate when trying to estimate a causal 
effect as long as censoring due to a competing event is non-informative.   
Ultimately, we cannot test this assumption 70, but since the assumption of 
competing event censoring being non-informative is conditional on covariates in 
the model, the most important way to increase the plausibility of the assumption is 
to include common risk factors for all causes of death.  In this study, all adjusted 
analyses adjust for pre-specified known baseline risk factors.   
Although many researchers see the Fine and Gray approach as the appropriate 
method when faced with competing risks, currently there is no perfect solution.  
Estimates from different methods represent slightly different things, and so need to 
Chapter 2: Impact of originally randomised trial treatment on long-term survival 
114 
 
be interpreted differently.  There are many other methods that have been proposed 
for analysis in the presence of competing risks, such as the use of multiple 
imputation to impute theoretical failure times for those subjects that experience a 
competing event 71.    
In addition to competing risks causing bias, the specific cause of death of interest 
can itself cause bias over time.  Miguel describes the hazard ratio as having a built-
in selection bias 72.  If a favourable treatment group has a reduced rate for an 
outcome compared to an unfavourable group, then one way to look at it is that 
more subjects would be being preferentially removed from follow-up from the 
unfavourable group, leaving a higher risk population in the favourable group as a 
result.  As a consequence, over time the favourable group would end up with a 
population that was increasingly higher risk of the outcome compared to the 
unfavourable group.  Eventually this would lead to an increase in events in the, once 
favourable arm, relative to the unfavourable.  The clearest example of this 
occurrence is with the outcome of death from any cause.  If one treatment is able to 
deliver longer survival time compared to another, eventually this favourable 
treatment group would catch-up simply because everyone would die at some point 
in time.  Therefore, what was a reduction in death rate in one group initially would 
eventually reduce and reverse in some form until the proportion of deaths was 
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equal between arms, i.e. everyone.  The impact of this problem would be to reduce 
the overall effect when considering a fixed effect over all of follow-up time, or when 
considering how the effect changes over time.  It would cause the effect to change 
(reduce) due to this evolving selection bias, rather than for the reason of a genuine 
change in treatment effect over time.  Hence, an overall measure of effect might 
become more and more misleading or meaningless with time, and even time-
updated effects could be biased.   
Although there was no formal evidence against proportional hazards for each 
outcome, comparing treatment groups, conceptually one could argue that the 
assumption of proportional hazards may not be completely appropriate in this 
setting.  It is likely that to some extent treatment groups became more similar to 
each other after the trial in terms on ongoing treatment, compared to within-trial.  
It seems logical that effects of trial treatment over long-term follow-up post-trial 
would be somewhat different to that during the trial.  The treatment effects that 
were observed in this study came with fairly borderline evidence at the 5% 
significance level, so it may just be that there was a lack of power to detect any 
subtle changes in effect over time.  However, there were no large deviations from 
proportional hazards observed for the outcomes for each treatment comparisons.  
The estimated treatment effect between antihypertensive groups on stroke-related 
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death and the estimated reduction in CHD-related death associated with statins 
compared to placebo, both appeared reasonably consistent and sustained over the 
whole of the long follow-up period.  There may have been a hint of a delayed effect 
on CHD-related mortality associated with the statin therapy in the first few years 
from randomisation.  This may have been a legitimate initial delay in effect, but few 
events early on makes it difficult to draw that conclusion.   
Largely, results from alternative approaches to quantifying differences in survival 
between treatment groups were consistent with the findings from Cox PH models.   
Within this analysis, multiple statistical tests were performed.  No adjustment for 
multiple testing was applied, and hence p-values do not represent the true 
probability of observing an effect purely by chance, i.e. a false positive.  In this 
analysis, a significant effect was not defined in a dichotomous way, but instead p-
values represented a continuous scale of evidence that each need to be taken in the 
context of multiple testing.  In this study, despite having a relatively large cohort of 
subjects, overall treatment effects, when observed for certain causes of mortality, 
do not come with extremely high levels of statistical evidence (i.e. very low p-
values).  Hence, discussion and conclusions from this analysis have remained in the 
context of what is plausible and alongside consideration of previous published 
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studies, recognising that this research serves to strengthen existing evidence and 
act as hypothesis generating.  
In conclusion, this study provides evidence of both the long-term sustained 
beneficial effect of statins on CHD-related mortality and reduction in stroke-related 
mortality associated with amlodipine-based treatment compared to atenolol-based 
treatment.  The study benefits from the large sample size of the ASCOT legacy 
cohort, and the long length of follow-up.  While interpretation of results from this 
study come with the limitation of unknown treatments that subjects were taking 
post-trial, effects have appeared to be sustained over time, and results have shown 
to be robust to alternative analysis approaches.  Hence, this study delivers strong 
and robust messages and there is tremendous value in these findings.  This study 
presents important evidence to help strengthen and build upon existing evidence of 
long-term impacts of these treatments.  
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Blood pressure is considered one of the most important risk factors for CVD.  Both 
diastolic and systolic components of blood pressure are known important biological 
markers for CVD and mortality.  Present guidelines focus on both of these 
components for the management of blood pressure and treatment of hypertension 
73,74.  However, there is growing evidence to suggest that PP is also an important 
component of blood pressure, and that perhaps the focus should be on SBP and PP, 
since there is much evidence to suggest that both are stronger predictors of CVD 
than DBP 75–78.  
PP is the difference in pressure between the maximum and the minimum pressure 
exerted on the walls of the arteries during a cardiac cycle.  It is the increase in 
blood pressure when the cardiac cycle moves from its diastolic state to its systolic 
(see Figure 14).   
Figure 14: Schematic of a blood pressure wave over a cardiac cycle 
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While DBP was once the main focus in blood pressure management due to its less 
variable nature compared to SBP, it is now widely accepted that SBP is the stronger 
predictor of CVD risk.  Kannel et al. compared the contribution of SBP versus DBP to 
risk of CHD and found that as age increased there was a trend of declining 
importance of DBP with corresponding increase in importance of SBP 79.   Some 
studies have found DBP to be of little prognostic value over that of SBP in relation to 
CVD risk in older populations 80–83. 
While guidelines for the management of blood pressure focus on targeting 
hypertension, suggesting healthy limits under which SBP and DBP should be 
controlled, both SBP and DBP have often been observed having a U- or J-shape 
association with CVD risk, with both low and high values associated with increased 
risk, particularly for DBP 84,85.  
The pulsatile component of blood pressure has more recently been identified as an 
important risk factor for CVD 75,86–88. It first gained interest as a potentially 
important risk factor for CVD when a link was found between the combination of 
both high SBP and low DBP with elevated CVD risk.  Darne et al. were among the 
first to report PP as an independent risk factor for CVD 89.  Gasowski et al. describe 
the arterial pressure wave being better represented as a mean pressure and 
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pulsatile component.  From their meta-analysis combining control-group data from 
7 randomised clinical trials in patients with systolic-diastolic or isolated systolic 
hypertension, they conclude that PP and not mean pressure was independently 
associated with the increased risk of fatal events 90.  Other studies have suggested 
that PP is superior to both SBP and DBP individually as a predictor for CV disease 
risk, particularly in older subjects 76.  Glynn et al. analysed data from a population-
based study in elderly subjects, aged 65 years and above, and concluded that PP 
appeared the best single measure of blood pressure in predicting mortality in older 
people 91.  PP is strongly correlated with SBP, and it may be that PP has the benefit 
of both being able to indicate risk associated with high SBP as well as picking up on 
risk associated with lower DBP.  Glynn et al. also concluded that PP helped to 
explain the apparent J-shape relationship between DBP with risk, as those with low 
DBP most commonly had higher PP.   
Some studies have highlighted the importance of mean arterial pressure (MAP), as a 
risk factor for CVD 92,93.  MAP represents the mean blood pressure over a complete 
cardiac cycle.  MAP is most commonly estimated as 94:  
𝑀𝐴𝑃 =
(2 × 𝐷𝐵𝑃) + 𝑆𝐵𝑃
3
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Studies have shown that SBP increases while DBP decreases with age, and hence, PP 
increases with age 95.  In addition, there is evidence that the relationship between 
both SBP and DBP with CVD alters with age 4.  It may be that this differing in 
relationship between components of blood pressure and risk with age might result 
in PP being the better predictor in older people, which has been shown to be as 
good as or better than other blood pressure components in the middle-aged and 
older 75–78.  However, in the face of this emerging evidence, there still remains some 
controversy as to which component of blood pressure is the superior predictor of 
CVD and mortality, SBP or PP, with some conflicting research.  Some studies have 
found that while PP is important, it is inferior to SBP in the prediction of CVD risk 
92,96. Evidence for the importance of MAP is also somewhat conflicting, with some 
studies reporting associations with CVD 93,97, and others not 92,98.  
Components of blood pressure in combination have been shown to be stronger in 
predicting CVD risk compared to single measures.  Some evidence suggests that 
combining SBP with DBP, and PP with MBP leads to superior CVD prediction 
compared to single blood pressure components alone 99.  However, other studies 
suggest that there is no additional gain over adding DBP once SBP is considered, 
and adding MAP once PP is considered 90.  Hence, there is still uncertainty as to 
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which components of blood pressure, alone or in combination, are best at 
predicting the risk of CV-related morbidity and mortality.  
The ASCOT legacy population spans a wide age range from 40 to 80 years, 
providing a good opportunity to study relationships between distinct components 
of blood pressure across a wide age-range in this hypertensive cohort from England 
and Scotland.  The long-term follow-up provides a strong basis to assess the 
predictive ability of baseline measures of blood pressure in the prediction on long-
term CV-related mortality. 
 Aims 
Through the use of blood pressure measures collected at baseline (ASCOT trial 
randomisation visit), the aim in this chapter was to evaluate how components of 
blood pressure (SBP, DBP, PP, & MAP) relate to mortality, with a focus on mortality 
from CV-related causes, while considering the influence of age.  The aim was to 
compare the predictive ability of each component to assess which might be the 
most powerful predictive marker, comparing single components alone and also 
pairs of components as to their joint predictive ability, and to assess whether 
prognostic ability varies with age.    
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As SBP and PP are already widely believed to be the strongest individual predictors 
of CV-related mortality, the main focus was to make the comparison between these 
two single components of blood pressure.  In addition, the aim was to assess 
whether combinations of blood pressure components could improve prediction by 
evaluating the predictive gain when pairing DBP with SBP, and MAP with PP, to see if 
one coupling showed stronger prognostic ability than the other. 
Analyses were repeated using blood pressure measures collected at the 1-year trial 
visit in order to assess whether conclusions change following the initial decline in 
SBP and DBP levels as a result of blood pressure-lowering therapy during trial 
participation.  However, the main approach was on the analysis of baseline 
measurements, in order to assess how predictive measurements were at the point 
at which patients present with uncontrolled hypertension prior to trial treatment 
initiation, so as to reflect a patient presenting with hypertension at a clinical visit.  
 Methods 
3.3.1 The collection of blood pressure during the ASCOT trial   
As well as other characteristics, SBP and DBP were recorded at baseline for all 8580 
ASCOT legacy subjects.  In addition, blood pressure was routinely measured at 
scheduled visits (and unscheduled visits) throughout the trial, initially at the six-
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week, three-month and six-month visits, thereafter at scheduled visits every six 
months until the end of the trial or until a subject left the trial early.  
At baseline and subsequent visits, the procedure was to take three blood pressure 
measurements (although on some occasions less than three were recorded).  In this 
analysis, the mean of the second and third blood pressure readings was used to 
represent an estimate of the blood pressure level at a trial visit, discarding the first. 
If only two measurements were available for at a single trial visit then the mean of 
those two was used, and if only a single measurement was recorded then the single 
value alone was used to represent blood pressure level at that visit. 
PP was calculated as the difference between SBP and DBP, and MAP was calculated 
as the addition of DBP and one third PP.  
3.3.2 Statistical methods 
3.3.2.1 Relationship between components of blood pressure and other risk factors 
Before conducting prognostic analyses, an assessment was made as to the 
relationship between blood pressure measures collected at baseline with other 
baseline characteristics.  Summary statistics were produced and adjusted linear 
regression models used to estimate the adjusted associations between other risk 
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factors and blood pressure.  This analysis was repeated for each of the four 
components of blood pressure.    
The correlation between components of blood pressure was assessed by calculating 
the correlation coefficients between all pair-wise blood pressure components.   
3.3.2.2 Relationship of components of blood pressure with mortality 
Survival analyses were undertaken in order to assess the relationship of each of the 
four blood pressure components with mortality risk.  The main focus was on the 
outcome of cause-specific mortality from any type CVD, however, the CV sub-
categories of stroke-related and CHD-related mortality were also analysed, as well 
as mortality from any cause.   
Cox proportional hazards (PH) models were used to model this survival data.  
Baseline blood pressure measurements were initially split into quintiles by number 
of subjects.  These quintile groups were not completely even in number as some 
measures on quintile boundaries had the same values, and therefore, groups were 
split to be as even in number as possible while keeping all those with the same 
blood pressure values were in the same group.  
Relationships between blood pressure quintiles and mortality was first explored in 
models containing only single components of blood pressure, and then modelled as 
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pairs of blood pressure components.  SBP was jointly modelled with DBP, and PP 
with MAP, in order to gauge whether relationships changed when modelled with 
others, and whether there was evidence of independent associations once adjusted 
for another component.  
Each model was adjusted for the pre-specified known baseline risk factors: age, 
sex, ethnicity, age subject left full-time education, body mass index, total 
cholesterol, presence of type II diabetes, and smoking history. 
3.3.2.3 Relating components of blood pressure to CV-mortality, modelled 
continuously 
Each component of blood pressure was then modelled as a continuous variable.  In 
order to explore the shape of the relationship between each component of blood 
pressure with risk, each component was modelled continuously using restricted 
cubic spline transformations to allow for possible non-linear relationships with CV-
related mortality.  A spline is a function made up of piecewise polynomials that 
connect-up at knots (locations of connecting intervals).  Restricted cubic splines are 
a transformation of the blood pressure measures, such that they are split up at the 
knot points and one obtains a continuous and smooth function that is linear below 
the lowest knot, linear above the highest knot, and a piecewise cubic polynomial 
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between adjacent knots.  In each case, for each blood pressure component, three 
knots were used at locations of the 10th, 50th, and 90th percentile of the data.  
Hence the functions were linear in the lowest decile of the data, piecewise cubic 
polynomials between the 2nd decile and the 9th decile, and linear again in the 
highest decile. The overall function is smooth since the 1st and 2nd derivatives (the 
slope gradient and rate of change in slope gradient) are continuous at the knots.  
Restricting the functions to be linear at the tails helps to avoid poorly fitting and 
unrealistic extremities, which could arise if using polynomial functions that are not 
restricted.  Three knots were used because this allowed relationships to be non-
linear, while limiting the potential for overfitting the data with a higher number of 
knots, as suggested by Harrell 100. 
For this stage of analysis, CV-related mortality was the focus and results for all-
cause mortality and other specific causes of death are not presented.  As before, 
Cox PH models were used to model the relationship between components of blood 
pressure with CV-related mortality, both as single-components, and also as paired 
components as previous described.  Adjusted models were adjusted for the pre-
specified risk factors as mentioned above.  
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Interaction tests were conducted in paired component models to see whether the 
relationship between one blood pressure component with risk was dependent on 
the other.  
3.3.2.4 The influence of age on the association between components of blood 
pressure and CV-related mortality 
ASCOT legacy subjects were split into three age-groups: 40 to 59, 60 to 69, and 70 
to 80 years at baseline.  The relationship between each blood pressure component 
and CV-related mortality was assessed in these subgroups in models containing 
single, and then pairs of blood pressure components with an interaction with age 
group, hence allowing effects to differ between age groups.   Cox PH models were 
used, and components of blood pressure were modelled as continuous variables 
with restricted cubic spline transformations, as described above.  Models were 
adjusted for the aforementioned pre-specified baseline risk factors.  
3.3.2.5 Blood pressure model comparison 
The fit and discrimination of models containing blood pressure components 
modelled continuously with RCS transformations (as described above), were 
compared.   
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The goodness-of-fit was compared between models using Akaike information 
criterion (AIC) 101,102.  In addition, R2 (the variability explained by the model) was 
calculated for each model, using the approach proposed by Royston and Sauerbrei 
for survival analysis settings 39,103. R2 is the proportion of variation in the dependent 
variable (survival time) that is accounted for by the predictor variables in the model.  
In addition, the discriminative ability of each model was assessed by calculating the 
concordance statistic (C-statistic). The C-statistic is a measure of model 
discrimination that is based on ranked correlations between the predicted and 
observed values, and is the probability of concordance between predicted and 
observed survival.  Hence, the C-statistic ranges from 0 to 1, where c= 0.5 would 
represent completely random predictions, and c= 1 would represent a perfect 
correctly discriminating model.  In this survival analysis context, the C-statistic is 
the proportion of all pairs of subjects whose survival time can be ordered such that 
the subject with the higher predicted survival is the one who survived longer.   
All models being compared were adjusted for pre-specified risk factors. 
3.3.2.6 Analysis of blood pressure at 1-year post randomisation 
All analyses were repeated using blood pressure measurements taken at the 1-year 
visit.  This gave the opportunity to assess whether patterns in relationships 
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observed with baseline measurements were evident in measurements taken once 
patients had initiated blood pressure-lowering therapy and average blood pressure 
levels had reduced and were more controlled.  This also allowed the assessment of 
relationships between blood pressure components and mortality at slightly different 
ranges, since the baseline blood pressure measurements were elevated and 
restricted, as a consequence of the trial selection process and inclusion criteria into 
the trial.    
 Results 
3.4.1 Relationships between baseline blood pressure measures with other 
baseline characteristics  
Mean (SD) baseline SBP and DBP were 161.9 (17.5) mmHg and 92.1 (9.9) mmHg, 
respectively, and hence mean PP was 69.8 (16.4) mmHg and mean MAP was 115.4 
(10.4) mmHg.   As patients were recruited to the ASCOT trial based on being 
hypertensive, patients had an SBP of 140 mmHg or higher or a DBP of 90 mmHg or 
higher (except for three subjects that had SBP < 140 mmHg and DBP < 90 mmHg).    
The mean of each blood pressure component at baseline is presented in Table 13 
and Table 14, by categories of other baseline risk factors.  In addition, mean 
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differences (95% CIs) in blood pressure components and p-values from tests of 
overall effect are presented from adjusted multivariable linear regression models.  
SBP was markedly higher with increasing age of subjects while DBP was lower (see 
Figure 15).  Those aged 75 years and over had mean SBP of almost 170 mmHg, an 
adjusted difference of 11.8 mmHg higher than those under 60 years (p<0.001).  
Mean DBP was just over 95 mmHg in those younger than 60 years, and was an 
estimated 6.5 mmHg lower in those 75 years and over (p<0.001, from adjusted 
analysis).  As a result of these changes in SBP and DBP with age being in opposite 
directions, mean PP was even more strikingly different between age-groups: 18.3 
mmHg higher in those aged 75 years and over compared to those between 40 and 
59 years (p<0.001, from adjusted analysis).   
While SBP was similar for both sexes, females had lower DBP (88.5 versus 92.9 
mmHg), an adjusted difference of 3.7 mmHg (p<0.001), and hence females had 
higher baseline PP (73.5 versus 68.9 mmHg).   
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Figure 15: Mean (SD) baseline blood pressure by age category and sex 
 
Those of White ethnic origin had the highest SBP (mean: 162.4 mmHg) compared to 
those of Asian, Black, or mixed/other ethnicity (p<0.001, from adjusted analysis).  
Those of Asian ethnicity had the lowest SBP (mean: 155.5 mmHg), an adjusted 
difference of 3.9 mmHg compared to those of White Ethnicity.  Those of Black or 
mixed/other ethnic background had mean SBP just over 158 mmHg.  There was less 
of a difference in DBP between the ethnicities (p=0.035, from adjusted analysis), 
although those of Asian ethnicity also had a lower DBP than those of alternative 
ethnicity.  From adjusted analysis the difference in DBP appeared to come only from 
Asian subjects having slightly lower DBP compared to all other ethnic backgrounds, 
an estimated mean DBP 1.8 mmHg less than White subjects.   
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There seemed to be a trend with lower SBP associated with increasing age at which 
subjects left full-time education (p=0.057), however, there was a slight increase in 
DBP (p=0.002) and hence a reduction in PP (p<0.001) with increased age at which 
subjects left education.  Mean PP was 75.5 mmHg in the group that left full-time 
education by age 14 and was over 10 mmHg less in those who left at 19+ years at 
65.3 mmHg, although the adjusted difference was a lot less: 2.9 mmHg less in 
those who left at 19+ years (p<0.001).    
There was no evidence of a difference in SBP over the categories of BMI (p=0.226), 
but there was evidence of differing DBP between BMI categories (p<0.001), with DBP 
higher in those with higher BMIs.  There was also evidence of lower PP in those with 
higher BMI (p<0.001, see Figure 16).  Those who were diabetic at baseline had a 
slightly higher SBP compared to those who were non-diabetic (p=0.009) and 
notably lower DBP (p<0.001), hence a larger mean PP (3.5 mmHg larger adjusted 
difference, p<0.001). 
SBP was associated with level of alcohol intake, with increased SBP in those with 
higher alcohol intake compared to those with lower intake.  There was less evidence 
of an association with alcohol intake for DBP.  There was no evidence for a 
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difference in blood pressure levels between smokers and non-smokers for any of 
the blood pressure components.  
Those with higher total cholesterol at baseline also had higher SBP and DBP 
(p=0.025 and p=0.001, respectively).  Those with total cholesterol of 8 mmol/L or 
higher had nearly 4 mmHg higher SBP and 2.5 mmHg higher DBP compared to 
those with total cholesterol below 4 mmol/L.  
Overall, risk factors that showed the strongest association with PP were age, sex, 
BMI and diabetes.  Age was clearly the dominant factor of PP variation, with SBP 
increasing and DBP decreasing with increasing age, there was a striking difference 
in PP across the ages. 
Figure 16: Mean (SD) baseline blood pressure by BMI category and diabetes 
status 
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Table 13: Mean difference in systolic and diastolic blood pressure by categories of other baseline risk factors 
   Systolic blood pressure Diastolic blood pressure 




Adjusted difference  
(95% CI)* 
P-value** Mean (SD) 






40-59 2605 157.0 (15.8) ref   95.1 (9.0) ref   
60-64 1856 160.3 (16.6) 3.3 (2.3, 4.3)   92.7 (9.5) -2.0 (-2.6, -1.5)   
65-69 1881 163.3 (17.3) 6.0 (4.9, 7.1)   91.2 (9.9) -3.4 (-4.0, -2.8)   
70-74 1437 166.7 (18.0) 9.2 (7.9, 10.4)   89.4 (10.2) -5.2 (-5.8, -4.5)   
75+ 801 169.3 (19.5) 11.8 (10.3, 13.3) p<0.001 87.8 (10.1) -6.5 (-7.3, -5.7) p<0.001 
Sex 
Female 1620 162.0 (18.8) ref   88.5 (10.0) ref   




White  7701 162.4 (17.6) ref   92.1 (10.0) ref   
Black 459 158.4 (17.3) -2.2 (-3.9, -0.6)   92.4 (9.5) 0.0 (-0.9, 1.0)   
Asian (east/south) 249 155.5 (16.2) -3.9 (-6.1, -1.6)   91.5 (8.5) -1.8 (-3.1, -0.6)   
Mixed/other  171 158.1 (15.3) -2.8 (-5.4, -0.2) p<0.001 91.8 (10.3) 0.3 (-1.2, 1.7) p=0.035 
Age left full-time 
education (years) 
(5 missing) 
12-14 2554 165.5 (18.5) ref   90.0 (10.2) ref   
15-16 4256 160.6 (17.0) -0.6 (-1.6, 0.4)   92.8 (9.6) 0.1 (-0.4, 0.7)   
17-18 949 160.0 (16.6) -1.7 (-3.1, -0.4)   93.1 (9.7) 0.8 (0.0, 1.5)   
19+ 816 159.3 (16.6) -1.5 (-3.0, -0.1) p=0.057 94.0 (9.7) 1.3 (0.5, 2.1) p=0.002 
BMI (kgm-2) 
<25 579 163.4 (18.4) ref   89.8 (10.4) ref   
25- <30 4986 162.4 (17.6) -0.6 (-2.1, 0.9)   91.9 (9.8) 1.4 (0.6, 2.2)   
30- <35 2208 160.7 (17.0) -1.3 (-2.9, 0.3)   92.9 (9.6) 2.2 (1.3, 3.1)   
≥35 807 160.9 (17.6) -0.2 (-2.1, 1.6) p=0.226 93.0 (10.5) 2.6 (1.6, 3.6) p<0.001 
Smoking status 
within 1 year 
Non-smoker 6539 162.1 (17.5) ref   92.0 (9.8) ref   
Current/ex 2041 161.0 (17.7) 0.0 (-0.9, 0.9) p=0.950 92.5 (10.2) -0.2 (-0.7, 0.3) p=0.403 
Average weekly 
units of alcohol 
consumed 
No intake 2177 161.6 (18.2) ref   90.6 (10.0) ref   
Intake 1 - <14 4054 161.7 (17.4) 0.1 (-0.8, 1.0)   92.0 (9.9) 0.3 (-0.2, 0.8)   
Intake 14 - < 28 1448 162.2 (17.2) 1.4 (0.2, 2.6)   93.1 (9.6) 0.4 (-0.3, 1.1)   
Intake 28+ 901 162.8 (17.1) 2.8 (1.4, 4.2) p<0.001 94.4 (9.8) 1.0 (0.2, 1.8) p=0.094 
Diabetes mellitus 
No 6125 161.7 (17.5) ref   92.9 (9.9) ref   
Yes 2455 162.3 (17.5) 1.1 (0.3, 1.9) p=0.009 90.1 (9.8) -2.5 (-2.9, -2.0) p<0.001 
Total  < 4 219 160.8 (16.0) ref   90.8 (9.3) ref   
cholesterol 4 - <8 8025 161.8 (17.5) 1.4 (-0.9, 3.7)   92.1 (9.9) 0.6 (-0.7, 1.9)   
(mmol/L) ≥8 336 164.3 (19.2) 3.7 (0.8, 6.7) p=0.025 92.7 (11.1) 2.5 (0.8, 4.1) p=0.001 
* Adjusted for all other baseline risk factors shown in the table as well as baseline total cholesterol in multivariable linear regression models.  Subjects with 
missing values for “age left education” were included in multivariable models, grouped into a missing category when missing.    
** P-values from likelihood ratio tests.  
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Table 14: Mean difference in pulse pressure and mean arterial pressure by categories of other baseline risk factors 
   Pulse pressure Mean arterial pressure 




Adjusted difference  
(95% CI)* 
P-value** Mean (SD) 






40-59 2605 61.9 (13.8) ref   115.8 (9.7) ref   
60-64 1856 67.6 (14.6) 5.3 (4.4, 6.2)   115.3 (10.2) -0.2 (-0.9, 0.4)   
65-69 1881 72.1 (15.1) 9.4 (8.5, 10.4)   115.2 (10.7) -0.3 (-1.0, 0.4)   
70-74 1437 77.3 (16.1) 14.3 (13.3, 15.4)   115.1 (10.9) -0.4 (-1.1, 0.4)   
75+ 801 81.5 (17.7) 18.3 (17.0, 19.6) p<0.001 115.0 (11.2) -0.4 (-1.3, 0.5) p=0.839 
Sex 
Female 1620 73.5 (17.5) ref   113.0 (10.8) ref   
Male 6960 68.9 (16.0) -3.4 (-4.2, -2.5) p<0.001 115.9 (10.2) 2.6 (2.0, 3.2) p<0.001 
Ethnic background 
  
White  7701 70.3 (16.5) ref   115.5 (10.4) ref   
Black 459 65.9 (15.7) -2.3 (-3.7, -0.8)   114.4 (10.3) -0.7 (-1.7, 0.3)   
Asian (east/south)  249 64.0 (15.7) -2.1 (-4.0, -0.1)   112.8 (9.0) -2.5 (-3.9, -1.1)   
Mixed/other  171 66.3 (14.7) -3.0 (-5.3, -0.7) p<0.001 113.9 (10.0) -0.8 (-2.3, 0.8) p=0.002 
Age left full-time 
education (years) 
(5 missing) 
12-14 2554 75.5 (17.1) ref   115.2 (10.9) ref   
15-16 4256 67.8 (15.6) -0.7 (-1.6, 0.1)   115.4 (10.2) -0.1 (-0.7, 0.5)   
17-18 949 66.9 (15.2) -2.5 (-3.7, -1.3)   115.4 (10.2) -0.1 (-0.9, 0.8)   
19+ 816 65.3 (15.1) -2.9 (-4.2, -1.6) p<0.001 115.8 (10.2) 0.4 (-0.5, 1.3) p=0.480 
BMI (kgm-2) 
<25 579 73.6 (17.1) ref   114.3 (11.0) ref   
25- <30 4986 70.5 (16.6) -2.0 (-3.3, -0.7)   115.4 (10.3) 0.7 (-0.2, 1.6)   
30- <35 2208 67.8 (16.0) -3.5 (-4.9, -2.1)   115.5 (10.1) 1.0 (0.1, 2.0)   
≥35 807 67.9 (15.5) -2.8 (-4.5, -1.2) p<0.001 115.6 (11.1) 1.6 (0.5, 2.8) p=0.023 
Smoking status within 1 
year 
Non-smoker 6539 70.2 (16.3) ref   115.4 (10.3) ref   
Current/ex 2041 68.5 (16.7) 0.2 (-0.5, 1.0) p=0.548 115.3 (10.6) -0.1 (-0.7, 0.4) p=0.636 
Average weekly units of 
alcohol consumed 
No intake 2177 71.0 (17.3) ref   114.3 (10.5) ref   
Intake 1 - <14 4054 69.7 (16.3) -0.2 (-1.0, 0.6)   115.2 (10.3) 0.2 (-0.3, 0.8)   
Intake 14 - < 28 1448 69.1 (15.7) 1.0 (-0.0, 2.0)   116.1 (10.2) 0.7 (0.0, 1.5)   
Intake 28+ 901 68.4 (15.5) 1.8 (0.6, 3.0) p<0.001 117.2 (10.4) 1.6 (0.7, 2.4) p=0.001 
Diabetes mellitus 
No 6125 68.8 (16.3) ref   115.8 (10.4) ref   
Yes 2455 72.2 (16.5) 3.6 (2.8, 4.3) p<0.001 114.2 (10.3) -1.3 (-1.8, -0.8) p<0.001 
Total  < 4 219 70.0 (14.7) ref   114.1 (9.7) ref   
cholesterol 4- <8 8025 69.7 (16.5) 0.8 (-1.2, 2.8)   115.3 (10.3) 0.9 (-0.5, 2.3)   
(mmol/L) ≥8 336 71.6 (16.9) 1.3 (-1.3, 3.8) p=0.619 116.6 (11.9) 2.9 (1.1, 4.7) p=0.001 
* Adjusted for all other baseline risk factors shown in the table as well as baseline total cholesterol in multivariable linear regression models.  Subjects with 
missing values for “age left education” were included in multivariable models, grouped into a missing category when missing.    
** P-values from likelihood ratio tests. 
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3.4.2 Relationships between baseline blood pressure measures 
Patients with higher SBP at baseline tended to have higher DBP (overall correlation 
coefficient r=0.391, p<0.001).  In the youngest age group, those between 40 and 
49 years of age, the correlation between SBP and DBP was the strongest (r=0.609), 
and was weaker in those over 50.   
PP was highly positively correlated with SBP (overall r=0.831, p<0.001), which was 
fairly consistent in magnitude over all age groups.  PP had a slight negative 
correlation with DBP at baseline (overall r=-0.186, p<0.001).  In subjects between 
40 and 49 years of age there was no evidence of a correlation between PP and DBP 
at all, but in those 50 years and older the slight negative correlation was observed.  
PP was positively correlated with MAP, but to a much lesser degree than the 
correlation between SBP and PP, which is expected given its formation and how PP 
correlates with both DBP and SBP (see Table 15).    
Table 15: Pair-wise correlations between blood pressure component measurements 
collected at baseline, by subgroups of age 
 Correlation coefficient (p-value) between pairs of blood pressure measurements 
Age group (years) SBP & DBP SBP & PP PP & DBP PP & MAP 
40 - <50 (n=443) 0.609 (p<0.001) 0.820 (p<0.001) 0.044 (p=0.355) 0.452 (p<0.001) 
50 - <60 (n=2162) 0.478 (p<0.001) 0.824 (p<0.001) -0.103 (p<0.001) 0.384 (p<0.001) 
60 - <70 (n=3737) 0.482 (p<0.001) 0.823 (p<0.001) -0.101 (p<0.001) 0.384 (p<0.001) 
70 – 80 (n=2238) 0.440 (p<0.001)  0.840 (p<0.001) -0.118 (p<0.001) 0.399 (p<0.001) 
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3.4.3 Relationship between single baseline blood pressure components with 
mortality 
When modelled as single components of blood pressure, there was strong evidence 
that each component was associated with all-cause mortality, using this long-term 
ASCOT legacy data with median 17.4-years follow-up.  Figure 17 presents plots of 
relative hazard comparing quintiles of the data for each blood pressure component.  
HRs for both SBP and PP are in relation to the lowest level quintile group, and DBP 
and MAP have their reference group as the middle (3rd) quintile group.   
The relationship between SBP and all-cause mortality appeared to hint at a slight J-
shape type relationship, with little difference in risk between the first 3 quintiles, 
with increased risk emerging in the highest 2 quintiles.  The hazard of death was an 
estimated 25% higher (95% CI: 14%-39%) in the top quintile of SBP, those with SBP 
over 175 mmHg compared to those with SBP less than 147 mmHg.     
While the highest quintile of SBP had the highest proportion of deaths (59.39%), for 
DBP it was the lowest quintile (those with less than 85 mmHg) that had the highest 
proportion of deaths (60.50%).  For DBP the adjusted HRs compared to the middle 
quintile group (those with 90 to less than 95 mmHg) showed increased mortality 
hazard for both the lowest quintile and the highest, HRs of 1.20 (95% CI: 1.10-1.32) 
and 1.17 (95% CI: 1.05-1.30), respectively, suggesting this U-shape association.    
Chapter 3: Comparison of prognostic performance between components of blood pressure for cardiovascular 
mortality using baseline measurements 
140 
 
The relationship between PP and mortality risk was rather more monotonically linear 
compared to that for SBP.  There appeared a steady increase in mortality risk with 
increasing PP.  There was also a notably larger range of proportions of deaths 
between the most extreme quintiles of PP compared to any other component.  The 
proportion of deaths over follow-up ranged from 30.60% in those with PP lower 
than 57 at baseline (the lowest quintile group) to almost 65% in those with a 
baseline PP of 83 or higher (the highest quintile group).   From adjusted analysis, 
those in the highest quintile had an estimated 41% increased hazard of death (95% 
CI: 26%-58%) compared to the lowest quintile group of PP.  
The relationship between MAP and all-cause mortality appeared to be somewhere 
between that for SBP and DBP, showing slightly more curvature than SBP, but not as 
much as with DBP.  Being a mixture of both DBP and SBP, MAP showed a similar J-
shaped relationship with risk to DBP, but, diluted by the SBP, there was only a 
slightly raised risk associated with low MAP, but a more markedly raised risk with 
higher MAP levels.  MAP showed the least variation in proportion of deaths across 
its quintile categories compared to other components.  
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Figure 17: Adjusted relative hazard of all-cause mortality by quintiles of 
baseline blood pressure components  
 
Note, p-values are from global likelihood ratio tests across quintile groups.  Estimates are from 
models adjusted for pre-specified baseline risk factors.
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For CV-related mortality, relationships between components of blood pressure with 
risk were a similar shape as for all-cause mortality, but as expected were more 
pronounced (see Figure 18).  The proportion of subjects dying from CV-related 
causes ranged from just over 12% to over 22% comparing the lowest SBP quintile 
group to the highest, respectively, with an estimated adjusted HR of 1.49 (95% CI: 
1.25-1.77) comparing highest to lowest quintile groups.  As with all-cause death, 
PP quintiles showed the largest difference in the proportion of deaths from CV-
related causes, with just over 10% in the lowest quintile compared to close to 25% 
of subjects in the highest quintile, an estimated adjusted HR of 1.66 (95% CI: 1.37-
2.00) comparing the highest to the lowest quintiles.  Although DBP showed a similar 
trend with its association with CV-related mortality as with all-cause mortality, 
there was only weak statistical evidence for an overall association between DBP and 
CV-related mortality (p=0.064, from a likelihood ratio test). 
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Figure 18: Adjusted relative hazard of CV-related mortality by quintiles of 
baseline blood pressure components 
 
Note, p-values are from global likelihood ratio tests across quintile groups.  Estimates are from 
models adjusted for pre-specified baseline risk factors.  
 
Although patterns of relative hazard of stroke-related mortality across quintile 
groups of blood pressure components appeared to follow a similar pattern to that 
with CV-related mortality, there was weak evidence of an association for each 
component of blood pressure (see Figure 19).  This is likely a result of the relatively 
low number of stroke deaths, a total of 263.  While estimated adjusted HRs between 
quintile groups were not too dissimilar to those estimated for CV-related mortality, 
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overall statistical evidence for associations between each blood pressure 
component and stroke-related mortality was lacking.       
Figure 19: Adjusted relative hazard of stroke-related mortality by quintiles of 
baseline blood pressure components 
 
Note, p-values are from global likelihood ratio tests across quintile groups.  Estimates are from 
models adjusted for pre-specified baseline risk factors.  
 
There was strong evidence that both SBP and PP were associated with CHD-related 
mortality (p<0.001 and p<0.001, respectively, see Figure 20). The proportion of 
deaths from CHD ranged from under 5% in the lowest PP quintile group to over 11% 
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in the highest quintile group, an estimated adjusted HR of 1.91 (95% CI: 1.45-2.51).  
DBP and MAP showed somewhat weak evidence of a relationship with CHD-related 
mortality (p=0.047 and p=0.010, respectively, see Figure 20). 
The number and percentage of deaths across quintile groups for each component 
of blood pressure are presented in Table 16, along with adjusted HR estimates from 
single-component models.  
Figure 20: Adjusted relative hazard of CHD-related mortality by quintiles of 
baseline blood pressure components 
 
Note, p-values are from global likelihood ratio tests across quintile groups.  Estimates are from 
models adjusted for pre-specified baseline risk factors. 
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Table 16: Adjusted HRs (95% CI) for baseline blood pressure component quintile groups from single component models  









Events, n (%) 





Adjusted HR  
(95% CI)* 
P-value Events, n (%) 





Adjusted HR (95% 
CI)* 
P-value 
SBP                
 1 (ref) 121-<147 1789 680 (38.01) - p<0.001 216 (12.07) - p<0.001 101 (5.65) - p<0.001 37 (2.07) - p=0.069 
 2 147-<155 1662 693 (41.70) 0.96 (0.86-1.07)   201 (12.09) 0.87 (0.72-1.06)   96 (5.78) 0.91 (0.69-1.21)   42 (2.53) 1.06 (0.68-1.65)   
 3 155-<165 1874 879 (46.91) 1.06 (0.96-1.17)   336 (17.93) 1.29 (1.08-1.53)   167 (8.91) 1.40 (1.09-1.80)   63 (3.36) 1.39 (0.92-2.09)   
 4 165-<176 1541 770 (49.97) 1.10 (0.99-1.22)   269 (17.46) 1.22 (1.02-1.47)   126 (8.18) 1.27 (0.98-1.66)   47 (3.05) 1.20 (0.78-1.86)   
 5 176-<252 1714 1018 (59.39) 1.25 (1.14-1.39)   380 (22.17) 1.49 (1.25-1.77)   173 (10.09) 1.54 (1.19-1.98)   74 (4.32) 1.56 (1.04-2.34)   
DBP                
 1 57-<85 1929 1167 (60.50) 1.20 (1.10-1.32)   405 (21.00) 1.21 (1.03-1.42)   200 (10.37) 1.41 (1.12-1.79)   78 (4.04) 1.14 (0.78-1.65)   
 2 85-<90 1554 764 (49.16) 1.08 (0.98-1.19)   266 (17.12) 1.10 (0.92-1.30)   126 (8.11) 1.17 (0.91-1.50)   46 (2.96) 1.01 (0.67-1.53)   
 3 (ref) 90-<95 1913 765 (39.99) - p=0.001 260 (13.59) - p=0.064 119 (6.22) - p=0.047 46 (2.40) - p=0.450 
 4 95-<101 1653 722 (43.68) 1.09 (0.98-1.21)   243 (14.70) 1.08 (0.91-1.29)   114 (6.90) 1.10 (0.85-1.42)   49 (2.96) 1.25 (0.84-1.87)   
 5 101-<139 1531 622 (40.63) 1.17 (1.05-1.30)   228 (14.89) 1.26 (1.05-1.50)   104 (6.79) 1.22 (0.94-1.59)   44 (2.87) 1.41 (0.93-2.13)   
PP                
 1 (ref) 16-<57 1791 548 (30.60) - p<0.001 180 (10.05) - p<0.001 84 (4.69) - p<0.001 27 (1.51) - p=0.237 
 2 57-<65 1773 703 (39.65) 1.08 (0.97-1.21)   220 (12.41) 1.03 (0.85-1.26)   96 (5.41) 1.01 (0.75-1.35)   43 (2.43) 1.29 (0.80-2.09)   
 3 65-<73 1686 773 (45.85) 1.13 (1.01-1.27)   272 (16.13) 1.23 (1.01-1.49)   135 (8.01) 1.42 (1.08-1.88)   56 (3.32) 1.50 (0.94-2.39)   
 4 73-<83 1651 925 (56.03) 1.29 (1.16-1.44)   316 (19.14) 1.37 (1.13-1.65)   156 (9.45) 1.62 (1.23-2.13)   59 (3.57) 1.45 (0.91-2.33)   
 5 83-<163 1679 1091 (64.98) 1.41 (1.26-1.58)   414 (24.66) 1.66 (1.37-2.00)   192 (11.44) 1.91 (1.45-2.51)   78 (4.65) 1.68 (1.05-2.66)   
MAP                
 1 88-<107 1822 936 (51.37) 1.12 (1.02-1.24)   327 (17.95) 1.19 (1.00-1.41)   161 (8.84) 1.28 (1.00-1.64)   62 (3.40) 1.13 (0.76-1.67)   
 2 107-<112 1777 784 (44.12) 1.02 (0.93-1.13)   250 (14.07) 0.99 (0.83-1.19)   112 (6.30) 0.94 (0.72-1.22)   48 (2.70) 1.04 (0.69-1.58)   
 3 (ref) 112-<117 1601 702 (43.85) - p=0.001 229 (14.30) - p<0.001 108 (6.75) - p=0.010 42 (2.62) - p=0.086 
 4 117-<124 1767 807 (45.67) 1.10 (0.99-1.21)   287 (16.24) 1.20 (1.01-1.43)   144 (8.15) 1.28 (0.99-1.64)   46 (2.60) 1.04 (0.69-1.58)   
 5 124-<175 1613 811 (50.28) 1.21 (1.09-1.34)   309 (19.16) 1.41 (1.19-1.67)   138 (8.56) 1.34 (1.04-1.73)   65 (4.03) 1.60 (1.08-2.36)   
* adjusted for pre-specified baseline risk factors: age, sex, ethnicity, age subject left full-time education, body mass index, total cholesterol, presence of type 
II diabetes, and smoking history. 
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3.4.4 Relationship between combinations of baseline blood pressure 
components with CV-related mortality 
Two models were fitted, each containing a pair of blood pressure components, the 
first SBP and DBP, and the second PP and MAP, with both models also adjusted for 
pre-specified baseline risk factors.  From the model containing SBP and DBP 
together, the highest quintile group of SBP (176 mmHg and over) and lowest 
quintile group of DBP (<85 mmHg) were associated with increased CV-related 
mortality risk.  From the model with PP and MAP, the highest 3 quintile groups of PP 
(65 mmHg and over) were associated with increased CV-related mortality, and 
weaker evidence for increased risk associated with both low and high MAP.   
There was strong evidence that both SBP and DBP were independently associated 
with CV-related mortality, from the model containing both components (p<0.001 
and p=0.004, respectively, see Figure 21).   
When SBP was modelled together with DBP, the relationship between SBP and CV-
related mortality was more extreme compared to the singular component model.  In 
other words, at a fixed level of DBP the increase in CV-related mortality risk 
associated with increasing SBP, which implies increasing PP, was higher in 
magnitude compared to when SBP was modelled alone.  Compared to the lowest 
quintile of SBP, the hazard ratio for the highest quintile group of SBP increased from 
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1.49 (95% CI: 1.25, 1.77, p<0.001) when modelled without DBP adjustment to 1.64 
(95% CI: 1.36, 1.98, p<0.001) with DBP adjustment.  From the same dual-
component model, once adjusted for SBP, the increased risk associated with high 
DBP was lessened compared to when unadjusted for SBP, while the relative risk 
associated with low DBP was more marked.  Relative to the middle quintile, the HR 
in the highest quintile group of DBP reduced from 1.26 (95% CI: 1.05, 1.50, 
p=0.012) when unadjusted for SBP to 1.05 (95% CI: 0.87, 1.26, p=0.617 when 
adjusted.  Conversely, the HR in the lowest quintile group of DBP increased from 
1.21 (95% CI: 1.03, 1.42, p=0.021) to 1.33 (95% CI: 1.13, 1.56, p=0.001).  It 
seemed that, once adjusted for SBP the increased risk associated with higher DBP 
levels was captured by SBP, and so higher DBP levels were no longer very predictive 
of increased risk, while lower levels of DBP were more strongly associated with 
increased risk.  Once adjusted for SBP, lower DBP at baseline could be capturing 
both increased risk associated with diastolic hypotension, as well as increased risk 
associated with a wide PP, particularly in this context where a low DBP implies a 
high SBP at baseline due to the trial inclusion criteria.    
There was strong evidence that PP was independently associated with CV-related 
mortality, from a model containing both PP and MAP (p<0.001), but the estimated 
HR comparing the highest quintile to the lowest slightly reduced slightly from 1.66 
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(95% CI: 1.37, 2.00, p<0.001) when unadjusted for MAP to 1.58 (95% CI: 1.29, 1.92, 
p<0.001) once adjusted (see Figure 21).   
Once adjusted for PP, the overall relationship between MAP and CV-related 
mortality had diminished to leave only borderline evidence (p=0.022) of an overall 
association.  Relative to the middle quintile, the HR in the highest quintile group of 
MAP reduced from 1.41 (95% CI: 1.19, 1.67, p<0.001) when unadjusted for PP to 
1.25 (95% CI: 1.06, 1.23, p=0.010) when adjusted, however the HR in the lowest 
quintile group of MAP slightly increased after adjustment for PP from 1.19 (95% CI: 
1.00, 1.41, p=0.049) to 1.25 (95% CI: 1.05, 1.50, p=0.012), after adjustment.   
PP might be partially capturing increased risk as a result of elevated blood pressure 
levels, as well as that associated with wider PP.  However, it is likely PP is not 
capturing it all, and MAP was still giving a hint of the increased risk associated with 
low blood pressure levels, probably coming specifically from low DBP levels.    
Estimates from paired-component models are presented in Table 17.Table 16: 
Adjusted HRs (95% CI) for baseline blood pressure component quintile groups 
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Figure 21: Adjusted relative hazard plots of CV-related mortality by blood 
pressure quintile groups when adjusted for a second blood pressure 
component 
 
Note: SBP and DBP are modelled together, and PP and MAP are modelled together. 
 
 
Note, p-values are from global likelihood ratio tests across quintile groups.  Estimates are from 
models adjusted for pre-specified baseline risk factors. 
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Table 17: Adjusted HRs (95% CI) for baseline blood pressure component quintile groups from paired component 
models 









Events, n (%) 
Adjusted HR (95% 
CI)* 
P-value Events, n (%) 
Adjusted HR (95% 
CI)* 






Adjusted HR (95% 
CI)* 
P-value 
SBP                
 1 (ref) 121-<147 1789 680 (38.01) - p<0.001 216 (12.07) - p<0.001 101 (5.65) - p<0.001 37 (2.07) - p=0.252 
 2 147-<155 1662 693 (41.70) 0.97 (0.87-1.07)   201 (12.09) 0.88 (0.73-1.07)   96 (5.78) 0.93 (0.71-1.24)   42 (2.53) 1.05 (0.67-1.64)   
 3 155-<165 1874 879 (46.91) 1.09 (0.99-1.21)   336 (17.93) 1.34 (1.12-1.59)   167 (8.91) 1.50 (1.17-1.93)   63 (3.36) 1.38 (0.92-2.09)   
 4 165-<176 1541 770 (49.97) 1.16 (1.04-1.29)   269 (17.46) 1.31 (1.08-1.58)   126 (8.18) 1.43 (1.09-1.88)   47 (3.05) 1.19 (0.76-1.86)   
 5 176-<252 1714 1018 (59.39) 1.36 (1.21-1.51)   380 (22.17) 1.64 (1.36-1.98)   173 (10.09) 1.86 (1.41-2.44)   74 (4.32) 1.52 (0.98-2.36)   
DBP                
 1 57-<85 1929 1167 (60.50) 1.27 (1.16-1.40)   405 (21.00) 1.33 (1.13-1.56)   200 (10.37) 1.58 (1.24-2.00)   78 (4.04) 1.21 (0.83-1.77)   
 2 85-<90 1554 764 (49.16) 1.10 (1.00-1.22)   266 (17.12) 1.13 (0.95-1.34)   126 (8.11) 1.21 (0.94-1.55)   46 (2.96) 1.03 (0.68-1.56)   
 3 (ref) 90-<95 1913 765 (39.99) - p<0.001 260 (13.59) - p=0.004 119 (6.22) - p<0.001 46 (2.40) - p=0.743 
 4 95-<101 1653 722 (43.68) 1.04 (0.94-1.15)   243 (14.70) 1.00 (0.84-1.20)   114 (6.90) 1.01 (0.78-1.31)   49 (2.96) 1.19 (0.79-1.78)   
 5 101-<139 1531 622 (40.63) 1.04 (0.93-1.17)   228 (14.89) 1.05 (0.87-1.26)   104 (6.79) 0.99 (0.75-1.30)   44 (2.87) 1.25 (0.81-1.92)   
PP                
 1 (ref) 16-<57 1791 548 (30.60) - p<0.001 180 (10.05) - p<0.001 84 (4.69) - p<0.001 27 (1.51) - p=0.670 
 2 57-<65 1773 703 (39.65) 1.07 (0.95-1.20)   220 (12.41) 1.01 (0.83-1.23)   96 (5.41) 0.98 (0.73-1.31)   43 (2.43) 1.27 (0.78-2.06)   
 3 65-<73 1686 773 (45.85) 1.12 (1.00-1.25)   272 (16.13) 1.18 (0.98-1.44)   135 (8.01) 1.37 (1.03-1.81)   56 (3.32) 1.46 (0.91-2.33)   
 4 73-<83 1651 925 (56.03) 1.28 (1.15-1.43)   316 (19.14) 1.33 (1.10-1.61)   156 (9.45) 1.60 (1.21-2.12)   59 (3.57) 1.37 (0.85-2.21)   
 5 83-<163 1679 1091 (64.98) 1.40 (1.25-1.58)   414 (24.66) 1.58 (1.29-1.92)   192 (11.44) 1.90 (1.42-2.55)   78 (4.65) 1.48 (0.91-2.40)   
MAP                
 1 88-<107 1822 936 (51.37) 1.16 (1.05-1.28)   327 (17.95) 1.25 (1.06-1.49)   161 (8.84) 1.38 (1.08-1.77)   62 (3.40) 1.13 (0.76-1.69)   
 2 107-<112 1777 784 (44.12) 1.06 (0.95-1.17)   250 (14.07) 1.04 (0.87-1.24)   112 (6.30) 1.00 (0.77-1.31)   48 (2.70) 1.07 (0.71-1.63)   
 3 (ref) 112-<117 1601 702 (43.85) - p=0.036 229 (14.30) - p=0.022 108 (6.75) - p=0.049 42 (2.62) - p=0.213 
 4 117-<124 1767 807 (45.67) 1.06 (0.96-1.18)   287 (16.24) 1.15 (0.96-1.37)   144 (8.15) 1.20 (0.93-1.54)   46 (2.60) 1.01 (0.66-1.54)   
 5 124-<175 1613 811 (50.28) 1.11 (1.00-1.23)   309 (19.16) 1.25 (1.05-1.50)   138 (8.56) 1.14 (0.88-1.48)   65 (4.03) 1.51 (1.01-2.26)   
* adjusted for pre-specified known baseline risk factors: age, sex, ethnicity, age subject left full-time education, body mass index, total cholesterol, 
presence of type II diabetes, and smoking history. 
Note, estimates for SBP and DBP are from a model containing both components, and estimates for PP and MAP are from a model containing both 
components. 
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3.4.5 Relationship between baseline blood pressure components with CV-
related mortality with components modelled as continuous variables 
Components of blood pressure were modelled continuously, each with restricted 
cubic spline transformations with 3 knots (at the 10th, 50th, and 90th percentiles) 
in order to allow curvature in their association with CV-related mortality.  For each 
of the four blood pressure components, there was strong evidence of an association 
with risk in models containing only single components (p<0.001 for each).   For 
DBP and MAP, there was evidence of a non-monotonic relationship with risk 
(p<0.001 & p=0.005, respectively), but no evidence against linearity for SBP or PP.  
Figure 22 presents plots of relative hazard, showing the relationships between each 
component of blood pressure with CV-related mortality.  The relative hazards and 
95% CIs for each blood pressure component shown on the plots are in relation to 
the reference levels indicated on each plot.  
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Figure 22: Adjusted relative hazard plots of CV-related mortality from models 
containing single components of baseline blood pressure  
 
Note, for each blood pressure component, HRs and 95% CIs are shown in relation to reference level, 
labelled as “(ref)” on the plots.  Blood pressure components are modelled with restricted cubic spline 
transformations.  P-values are from global likelihood ratio tests comparing models with and without 
the blood pressure component present.  
 
3.4.6 Relationship between baseline blood pressure components with CV-
related mortality in subgroups of age 
Relationships between components of blood pressure with CV-related mortality 
were stronger in younger subjects, and attenuated with increasing age for all 
components of blood pressure (see Figure 23 & Figure 24).  
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There was still some evidence for a relationship between both SBP and DBP with risk 
in the oldest age-group, those 70 years and older (p=0.049 & p=0.037, 
respectively, from global likelihood ratio tests).   
In those 70 years and over, the increased risk associated with lower levels of DBP 
appeared more extreme than the increased risk associated with higher levels of DBP 
(see Figure 23).  
There was still strong evidence of a relationship between PP and CV-related 
mortality at all ages including those 70 years and over (p=0.002).  While for MAP, 
there was very little evidence of a relationship with risk in those 70-80 years 
(p=0.305, see Figure 24). 
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Figure 23: Adjusted relative hazard plots of CV-related mortality from models 
containing SBP and DBP as single components of baseline blood pressure over 
3 age categories 
 
Note, for each blood pressure component, HRs and 95% CIs are shown in relation to reference level, 
labelled as “(ref)” on the plots.  Blood pressure components are modelled with restricted cubic spline 
transformations, with interactions with age group.  P-values are from global likelihood ratio tests 
comparing models with and without the blood pressure component present.  
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Figure 24: Adjusted relative hazard plots of CV-related mortality from models 
containing PP and MAP as single components of baseline blood pressure over 3 
age categories 
 
Note, for each blood pressure component, HRs and 95% CIs are shown in relation to reference level, 
labelled as “(ref)” on the plots.  Blood pressure components are modelled with restricted cubic spline 
transformations, with interactions with age group.  P-values are from global likelihood ratio tests 
comparing models with and without the blood pressure component present.  
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It appeared that PP was the strongest predictor of CV-related mortality in older 
subjects.  To help visualise this, Figure 25 presents a plot of adjusted HRs 
comparing quintiles of SBP and PP, in the subgroup of those 70 years and older.  In 
comparison with the lowest quintile, the adjusted HR for the highest quintile for PP 
was substantially higher, almost double the relative increase in hazard, than for SBP 
(HR=1.63 [95% CI: 1.14-2.32], p=0.007, & HR=1.34 [1.01-1.78], p=0.041, 
respectively).  
Figure 25: Plot of adjusted HRs (95% CI) comparing quintiles of SBP and PP, in 
those 70 years and older 
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Since there was no evidence against linearity for both baseline SBP and PP relating 
to risk, modelling each component in a linear fashion the HR for a one SD increase 
in PP was, again, substantially higher than for SBP in those 70 years and older.  
There was a relative increase in hazard of 20% per SD increase for PP (95% CI: 11%-
29%, p<0.001) and 12% for SBP (95% CI: 4%-20%, p=0.004).  At lower ages, there 
was less of a difference between SBP and PP (see Figure 26).   
Figure 26: Plot of adjusted HRs (95% CI) comparing CV-related mortality per SD 




Although relationships between blood pressure components and CV-related 
mortality risk attenuate with age when hazard rate is compared on the relative 
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scale, this was not the case on the absolute scale.  Absolute differences in CV-
mortality rates were very similar over different ages, for each of the components of 
blood pressure.  Analysis of CV-mortality rate was undertaken using Poisson 
survival models containing single blood pressure components modelled as quintile 
categories with an interaction with age and adjusted for other pre-specified 
baseline risk factors.  From these models, the estimated adjusted absolute 
differences between blood pressure component quintile groups were calculated for 
those < 70 years of age and for those 70 years and older.  For SBP, the absolute 
increase in rate between the lowest and highest quintile groups was estimated as 
5.62 events per 1000 person-years (95% CI: 3.52-7.72) in those under 70 years, 
and 6.58 events per 1000 person-years (95% CI: 0.67-12.49) in those 70+ years.  
For PP the absolute increase in rate between the lowest and highest quintile groups 
was also similar between age-groups, an estimated: 7.52 events per 1000 person-
years (95% CI: 5.20-9.83) in those under 70 years, and 9.65 events per 1000 
person-years (95% CI: 3.20-16.10) in those 70+ years.  For both SBP and PP, the 
estimated absolute differences were marginally higher in those 70 years and over, 
but with no statistical evidence for the differences.  
Figure 27 and Figure 28 present plots of adjusted relative hazard over the same 
three age groups, from models containing pairs of blood pressure components (SBP 
with DBP, and PP with MAP) each modelled continuously with restricted cubic spline 
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transformations.  As seen in the previous section when modelling components in 
quintile groups, the relationship of SBP with CV-related mortality risk, when 
adjusted for DBP, becomes more extreme.  Also, the relationship between DBP and 
risk, once adjusted for SBP, becomes more extreme for the lower values of DBP but 
less so for higher DBP values.  In the oldest age category, 70-80 years, there seems 
to no longer be any independent increase of risk associated with higher values of 
DBP at all.  Once again, the relationships with risk were stronger in those younger 
(on a relative scale), and attenuate with increasing age, however, for both SBP and 
DBP there was stronger evidence of an association in each age group, including the 
oldest group, 70-80 years (p=0.001 & p<0.001, respectively).  
When adjusted for MAP, there remained strong evidence of an association between 
PP and CV-related mortality risk in each age group, although again the relationship 
become weaker with increasing age.  Once adjusted for PP, there was poor evidence 
of an association between MAP and risk, in each age category (see Figure 28).  
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Figure 27: Adjusted relative hazard plots of CV-related mortality from models 
containing pairs of baseline blood pressure components, SBP adjusted for DBP 
and DBP adjusted for SBP over 3 age groups 
 
Note, for each blood pressure component, HRs and 95% CIs are shown in relation to reference level, 
labelled as “(ref)” on the plots.  Blood pressure components are modelled with restricted cubic spline 
transformations, with interactions with age group.  P-values are from global likelihood ratio tests 
comparing models with and without the blood pressure component present.  
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Figure 28: Adjusted relative hazard plots of CV-related mortality from models 
containing pairs of baseline blood pressure components, PP adjusted for MAP 
and MAP adjusted for PP over 3 age groups 
 
Note, for each blood pressure component, HRs and 95% CIs are shown in relation to reference level, 
labelled as “(ref)” on the plots.  Blood pressure components are modelled with restricted cubic spline 
transformations, with interactions with age group.  P-values are from global likelihood ratio tests 
comparing models with and without the blood pressure component present.  
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3.4.7 Comparing models containing different components of blood pressure 
modelled as continuous variables 
A number of models were constructed containing difference single components of 
blood pressure, pairs of components, with and without allowing interactions 
between components with age.  These models contain blood pressure components 
modelled continuously with restricted cubic splines as previously described, as well 
as being adjusted for pre-specified baseline risk factors. Age is also modelled 
continuously with the same spline transformations.  A comparison of models is 
presented in Table 18.   
For models containing single blood pressure components, goodness-of-fit was best 
in models containing SBP or PP, with slightly better fit statistics for PP models based 
on log likelihood and R2, and slightly better discrimination based on C-statistic. The 
model with MAP alone showed the poorest fit and had the lowest discrimination 
compared to other single blood pressure component models. This was the case 
comparing single blood pressure component models both with and without an 
interaction with age.   
For each component of blood pressure modelled singularly, there was somewhat 
borderline evidence of an interaction with age.  
The best models with pairs of blood pressure components contained SBP and DBP, 
or PP and DBP.  Whether allowing interactions with age or not, in both cases each 
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component of blood pressure in the paired models showed strong evidence of 
association with CV-related mortality while adjusted for the other component in the 
model.  When MAP was modelled with PP, there was poor evidence for an 
independent association between MAP and risk, whether allowing interactions with 
age or not (p=0.234 & p=0.088, respectively).    
Paired component models that contained both PP and SBP performed the worst, very 
closely to models with both PP and MAP. Once adjusted for PP, there was no longer 
evidence that SBP was independently associated with CV-related mortality whether 
allowing interactions with age or not (p=0.525 & p=0.788, respectively), however, 
evidence for the relationship between PP and risk was still strong (p=0.008 & 
p=0.003, respectively).   
There was no evidence for an interaction between SBP and DBP (p=0.441).  
However, there was evidence of an interaction between PP and MAP (p=0.005).  
When MAP was lower, the relationship between PP and risk was stronger.  
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Table 18: Comparison of models containing different components of baseline blood pressure (N=8580)  
Blood pressure 
in model 








1st  2nd Interaction with BP 
measures in model 






No BP        -11730.43 23488.85 0.2725 0.7038 
SBP   < 0.001  0.175    -11712.52 23457.05 0.2818 0.7101 
DBP   < 0.001  < 0.001    -11720.90 23473.79 0.2765 0.7081 
PP   < 0.001  0.251    -11706.80 23445.60 0.2868 0.7113 
MAP   < 0.001  0.005    -11721.40 23474.79 0.2762 0.7074 
SBP  DBP  < 0.001 < 0.001 0.087 < 0.001   -11699.86 23435.72 0.2872 0.7145 
PP  DBP  < 0.001 0.002 0.292 < 0.001   -11700.77 23437.53 0.2873 0.7141 
PP  MAP  < 0.001 0.088 0.196 0.030   -11704.37 23444.75 0.2867 0.7123 
PP  SBP  0.003 0.788 0.610 0.572   -11706.56 23449.12 0.2868 0.7115 
SBP  Age < 0.001  0.906  0.055  -11707.89 23455.78 0.2821 0.7111 
DBP  Age < 0.001  < 0.001  0.072  -11716.60 23473.20 0.2777 0.7087 
PP  Age < 0.001  0.673  0.040  -11701.79 23443.57 0.2860 0.7127 
MAP  Age < 0.001  0.017  0.073  -11717.11 23474.22 0.2773 0.7085 
SBP  DBP Age < 0.001 < 0.001 0.738 0.001 0.224 0.159 -11693.65 23439.31 0.2886 0.7155 
PP  DBP Age < 0.001 0.010 0.625 0.002 0.088 0.279 -11693.41 23438.82 0.2878 0.7158 
PP  MAP Age < 0.001 0.234 0.579 0.110 0.243 0.385 -11697.76 23447.52 0.2869 0.7141 
PP  SBP Age 0.008 0.525 0.231 0.373 0.306 0.345 -11699.21 23450.42 0.2871 0.7135 
Note: each model is adjusted for a-priori covariates.  Each blood pressure component, and age, is modelled as continuous using restricted cubic 
splines with 3 knots (knot positions at the 10th, 50th, and 90th percentiles).  
Note: R2 measure is based on Royston & Sauerbrei (2004)'s D measure of discrimination.  
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3.4.8 Blood pressure measures collected at the 1-year ASCOT trial visit 
Analyses were repeated using measurements of blood pressure components 
captured at the 1-year ASCOT trial visit, when mean blood pressure levels had 
fallen following the initiation of antihypertensive trial treatments.   
In this approach, follow-up began from the time of the 1-year visit for each subject.  
8030 (93.6%) out of the 8580 ASCOT legacy subjects had a 1-year scheduled visit at 
which blood pressure measurements were recorded.  Out of the 550 patients 
without a 1-year visit, 70 had died prior to the visit, one had been withdrawn from 
the study, and the remaining 479 subjects missed the 1-year visit.   
Mean age of subjects at the 1-year visit was 65.1 years (SD: 8.1), and 6541 (81.5%) 
subjects were male. 
Mean SBP and DBP at 1-year were 141.18 mmHg (SD: 16.30) and 81.66 mmHg (SD: 
9.31), a mean decrease from baseline of 20.53 mmHg (SD: 19.31) and 10.49 mmHg 
(SD: 10.32), respectively.  Hence mean PP was 59.52 mmHg (SD: 14.19) at 1-year, a 
decrease of 10.04 mmHg (SD: 14.07) from baseline.   
The correlation between SBP and DBP was slightly higher than with the baseline 
readings (overall r=0.497), likely due to truncated blood pressure measures at 
baseline as a result of the exclusion criteria.  PP was again highly positively 
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correlated with SBP (overall r=0.822), while the negative correlation between PP and 
DBP was less than that at baseline (overall r=-0.085).    
Table 19: Pair-wise correlations between blood pressure component 
measurements collected at the 1-year ASCOT trial visit, by subgroups of age 
 Correlation (p-value) between pairs of BP measurements 
Age group (years) SBP & DBP SBP & PP PP & DBP PP & MAP 
40 - <50 (n=443) 0.728 (p<0.001) 0.787 (p<0.001) 0.150 (p=0.002) 0.118 (p=0.015) 
50 - <60 (n=2162) 0.603 (p<0.001) 0.827 (p<0.001) 0.051 (p=0.022) 0.141 (p<0.001) 
60 - <70 (n=3737) 0.574 (p<0.001) 0.842 (p<0.001) 0.041 (p=0.015) 0.119 (p<0.001) 
70 - 80 (n=2238) 0.531 (p<0.001)  0.838 (p<0.001) -0.018 (p=0.406) 0.083 (p<0.001) 
 
As with baseline measures, there was strong evidence that each component of 
blood pressure was associated with CV-related mortality, and relationships were 
stronger with CV-related mortality than for all-cause (see Figure 29).     
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Figure 29: Adjusted relative hazard plots of CV-related mortality from models 
containing single components of blood pressure measured at 1 year 
 
Note, for each blood pressure component, HRs and 95% CIs are shown in relation to reference level, 
labelled as “(ref)” on the plots.  Blood pressure components are modelled with restricted cubic spline 
transformations.  P-values are from global likelihood ratio tests comparing models with and without 
the blood pressure component present.  
 
There was stronger evidence for a lack in linearity between SBP measured at 1-year 
with CV-related mortality (p<0.001) from single component models.  SBP showed a 
slight J-shape association which began to look slightly more similar to the shape of 
relationship that DBP had with risk, although to a lesser extent.  There also 
appeared to be a slight suggestion of curvature in the relationship between PP and 
risk, with there being less association at lower levels of PP, and an increase in risk 
when PP is higher than around 70 mmHg.  
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Relationships between all components of blood pressure taken at 1-year with risk 
became attenuated with increasing age.  PP seemed to have the strongest 
relationship with risk in the oldest age group, as with the baseline blood pressure 
measures.   
Table 20 presents details from a variety of models using components of blood 
pressure collected at the 1-year visit modelled as continuous variables with 
restricted cubic spline transformations as previously described.  In general, the best 
models were consistent with those using baseline blood pressure measurements.  
Model goodness-of-fit was best in single blood pressure component models 
containing SBP or PP, and models with MAP alone showed the poorest performance.  
The best performing models containing pairs of blood pressure components 
contained SBP and DBP, or PP and DBP.  
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Table 20: Comparison of models containing difference single BP measures at 1-year visit (N=8030) 
Blood pressure 
in model 








1st  2nd Interaction with BP 
measures in model 






No BP        -10345.32 20718.63 0.2764 0.4143 
SBP   < 0.001  < 0.001    -10324.86 20681.72 0.2851 0.4280 
DBP   < 0.001  < 0.001    -10334.36 20700.72 0.2863 0.4226 
PP   < 0.001  0.043    -10318.85 20669.71 0.2922 0.4320 
MAP   0.002  0.013    -10339.22 20710.45 0.2789 0.4202 
SBP  DBP  < 0.001 < 0.001 0.014 0.003   -10309.82 20655.65 0.2990 0.4370 
PP  DBP  < 0.001 < 0.001 0.044 < 0.001   -10310.82 20657.63 0.2998 0.4375 
PP  MAP  < 0.001 0.047 0.054 0.043   -10315.80 20667.59 0.2934 0.4347 
PP  SBP  < 0.001 0.007 0.681 0.005   -10314.11 20664.22 0.2947 0.4337 
SBP  Age < 0.001  < 0.001  0.004  -10317.31 20674.61 0.2915 0.4304 
DBP  Age < 0.001  < 0.001  0.320  -10332.01 20704.03 0.2851 0.4235 
PP  Age < 0.001  0.004  < 0.001  -10307.15 20654.30 0.2990 0.4350 
MAP  Age 0.007  0.066  0.247  -10336.52 20713.04 0.2798 0.4218 
SBP  DBP Age < 0.001 < 0.001 0.073 0.036 0.004 0.121 -10300.60 20653.20 0.3037 0.4388 
PP  DBP Age < 0.001 0.005 0.006 < 0.001 < 0.001 0.516 -10297.80 20647.60 0.3063 0.4406 
PP  MAP Age < 0.001 0.182 0.006 0.203 < 0.001 0.466 -10302.73 20657.45 0.3011 0.4384 
PP  SBP Age < 0.001 0.410 0.666 0.292 0.380 0.968 -10304.09 20660.18 0.3016 0.4366 
Note: each model is adjusted for a-priori covariates.  Each blood pressure component, and age, is modelled as continuous using restricted cubic splines with 3 
knots (knot positions at the 10th, 50th, and 90th percentiles).  
Note: R2 measure is based on Royston & Sauerbrei (2004)'s D measure of discrimination.  
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This trial-based cohort study of 8580 hypertensive subjects aimed to compare the 
ability of components of blood pressure collected at baseline to predict mortality, 
with a focus on mortality from CV-related causes specifically, and to assess how 
associations depend on age.  The main focus was the comparison between SBP and 
PP in their predictive value, while also considering the importance of DBP and MAP.  
The single components of blood pressure that undoubtedly had the strongest 
prognostic power for mortality, and specifically CV-related mortality were SBP and 
PP, but PP was the stronger predictor in older subjects.  
It has long been accepted that blood pressure increases with age.  Blood vessel 
function deteriorates with age, and vessels can become stiffer and less compliant 
leading to hypertension.  However, the understanding of how to define 
hypertension, particularly in the elderly, has changed over time.  Specifically, 
isolated systolic hypertension is known to be the most prevalent type of 
hypertension in older people 104–106.  Previous studies, such as the Framingham 
study, have demonstrated that SBP shows a continued steady increase over the age 
of 30, and that DBP begins to decrease after the age of 60.  The Framingham study 
found a mixed pattern for DBP, showing an increase with age below the age of 60, 
followed by a steady decline thereafter 107.   In this study there was both a vastly 
higher SBP as well as a strikingly lower DBP in older subjects.  As a result, there was 
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a steep gradient of increase in PP with increasing age as a result in part of isolated 
elevated SBP, but also due to this vastly lower DBP in older subjects.      
SBP was found to be similar between the sexes across all age-groups, while females 
had a slightly lower DBP and hence wider PP compared to males.  Many studies have 
shown that healthy males tend to have higher blood pressure, both systolic and 
diastolic, compared to healthy females 108–110.  The lack of difference in SBP between 
the sexes seen at baseline may be a consequence of the restriction of the trial entry 
criteria.   
The age at which subjects left full-time education was used to attempt to act as a 
proxy for level of socio-economic status (SES).  While SBP decreased with the 
assumed higher education level, perhaps rather unexpectedly DBP increased, and 
hence PP was lower in those with higher education levels.  SES has been shown to  
be associated with blood pressure, and this has been demonstrated through the 
level of education, with lower levels of education, more socio-economically 
deprived areas being associated with higher blood pressure 111.   
It is well-known that increased BMI is associated with increased blood pressure.  In 
this cohort, due to the lack of increased SBP while DBP was increased in those with 
higher BMI, there was evidence of lower PP in those at higher BMIs.  There have 
been other studies that have also seen this negative correlation with PP and BMI, 
with wider PP being reported in in the lean 112,113.  It has been suggested that this 
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backs up findings from reports that suggest an increased risk among lean 
compared to obese subjects who have isolated hypertension.    
As is expected, those with higher lipid levels tended to have higher DBP and SBP.  
There is good evidence in the literature of the interrelation between blood pressure 
and blood lipid levels 114.  
Each of the four components of blood pressure, diastolic, systolic, pulsatile and 
mean pressure, were strongly associated with all-cause mortality, and to a greater 
extent with CV-related mortality.  For each component there was some evidence 
that their association had a dependence on age.  SBP and PP were the strongest 
predictors of CV-related mortality, and MAP was the weakest.  PP appeared to be 
the slightly better predictor of CV-related mortality compared to SBP, particularly in 
older subjects.    
Having a high PP is known to be predominantly a consequence of increased 
stiffness of the artery walls, particularly in older people. Arterial stiffness is closely 
associated with biological aging and the build-up of atherosclerotic plaques in the 
arterial walls.  This can lead to reduced arterial compliance (volume of blood 
increase per amount of pressure increase)115.  As well as acting as a marker for 
arterial stiffness as a result of atherosclerosis and deterioration of the blood vessel 
walls, raised PP itself is said to be a cause of vascular damage, which in turn can 
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increase the risk of atherosclerosis, and other vascular and cardiac damage 116.  In 
young people, high PP is often more related to an increase in stroke volume 117. 
While there was a lack of evidence against linearity for baseline measures of SBP and 
PP, DBP had a J-shape relationship with CV-related mortality with high levels, and 
more acutely at low levels, being associated with increased risk, as is very well 
documented 118,119.  It followed that MAP also had a somewhat lessened J-shape 
relationship with risk as a result be being formed from a combination of DBP and 
SBP.   However, as subjects were hypertensive at baseline, one might not expect to 
see increased risk associated with lower DBP levels as these lower levels are still 
considered higher than ranges normally associated with hypotension in the general 
population.   Research usually points to increased risk when DBP levels are around 
70 mmHg or lower 120, whereas, risk seemed to be elevated in those with baseline 
DBP from around 90 mmHg and lower.  A possible reason for this observed increase 
risk at lower baseline DBP values could be that having lower DBP at baseline was 
associated with having even lower DBP after treatment and hence a result of 
subsequent hypotension.  Alternatively, it may be because lower levels of DBP at 
baseline indicate a higher baseline SBP and hence higher PP, due to the inclusion 
criteria constraints.  Subjects recruited to the ASCOT trial needed to have baseline 
SBP ≥160 or DBP ≥100 if not currently being treated for hypertension, or an SBP 
≥140 or DBP ≥90 if currently being treated.  As a result, the distribution of baseline 
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blood pressure was restricted, and subjects with lower DBP, i.e. lower than 100 
mmHg if untreated or 90 mmHg if treated, would have had a high SBP of ≥160 or 
≥140, respectively.   This constraint could be the cause of the negative correlation 
between baseline DBP and PP, which was not apparent in the 1-year blood pressure 
measures.   
In addition, correlations between SBP and DBP were substantially lower than have 
been found in some other studies.  For example, Kannel et al. found correlation 
coefficients to be over 0.60 in all age categories, and as much as 0.79 in those 
below 50 years in their study of 6539 individuals between 20 and 79 years from the 
Framingham study 83. The reason for the weaker correlation between baseline SBP 
and DBP in the ASCOT legacy cohort, could also be a result of the inclusion criteria.  
Baseline PP appeared to have the clearest monotonic relationship with CV-related 
mortality risk.  However, there was slight evidence of a lack of linearity between 
both SBP and PP with CV-mortality risk when using the blood pressure measures 
collected at the 1-year visit.  This is likely due to blood pressure measures being 
elevated at baseline, with SBP having to be 140 mmHg or above, and hence those 
low SBP levels associated with increased risk were not observed, this of course 
being a hypertensive patient group.  At 1-year when mean blood pressure had 
decreased, low levels of SBP could well be representing subject frailty or other 
morbidities associated with low blood pressures, particularly in older subjects.   
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There was evidence that the relationship between each blood pressure component 
with CV-related mortality (on a relative scale) was dependent on age.  As the age of 
subjects increased, relationships between components of blood pressure and risk 
attenuated.   
As single components, baseline SBP and DBP presented weak, borderline evidence 
of a relationship with CV-related mortality in the oldest age group 70-80 years.   
Previous research suggests that with increasing age, SBP becomes more important 
and DBP becomes less so 80,83. It appeared that associations weakened with age for 
both components in a similar way in this population.  For DBP, this association 
seemed to come mostly from the increased risk associated with lower levels rather 
than higher levels in the older age group.    
While associations attenuated with increasing age on the relative scale, this was not 
the case on the absolute scale.  Absolute differences in rates of CV-related 
mortality over levels of blood pressure components were similar across age groups.  
Hence, as risk increased with age but absolute risk differences associated with 
blood pressure remained similar, this resulted in a reduction of relative effect with 
increasing age of subjects.     
Both SBP and DBP were independently associated with CV-related mortality.  Once 
adjusted for each other both SBP and DBP remained fairly strongly associated with 
risk in older subjects.  In fact, across all age-groups, when adjusting DBP, the 
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relationship between SBP and CV-related mortality become slightly stronger than 
when unadjusted for DBP.  When adjusting for SBP, the relationship between DBP 
and CV-related mortality also changed slightly in that elevated risk was only seen in 
those with low DBP and to a slightly greater degree compared to analysis not 
adjusted for SBP, and no increased risk associated with higher DBP.   
Consistent with previous studies, in general, models containing SBP performed 
better than models with DBP 81.  However, the fact that DBP remained important in 
joint models with SBP conflicted with some studies that found DBP to not be an 
independent risk factor once adjusted for SBP, particularly in older patients.  Kannel 
et al. found that when both SBP and DBP were in the same model, that DBP become 
less important with age and SBP more important in relation to CHD risk, with DBP 
being more important in under 50s and SBP more important in over 60s. This was 
not observed in this study, although there were few patients under 50, and none 
under 40, while in the Kannel study the age ranged from 28 to 62 79.  This was 
perhaps also due again to the restricted ranges of SBP and DBP at baseline as a 
result of inclusion criteria (as previously discussed).     
In many previous studies that compared the predictive abilities of blood pressure 
components, comparisons were made between models with components modelled 
as linear variables.  Hence, relationships with risk were assumed linear and 
comparisons between their ability to predict were often made on the basis of 
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comparing their estimated change in risk per unit increases in blood pressure 
component, or per standardised increase such as SD or SE 79,83,92,96. However, in 
many cases the relationships with risk are not linear, especially with DBP, and hence 
this approach is often inappropriate.  By allowing relationships between blood 
pressure components with risk to be non-linear through the use of restricted cubic 
spline transformations, non-linear relationships could be captured and models 
containing different blood pressure components could be compared without the, 
often invalid, assumption linearity.  In previous research, perhaps this is why the 
independent association between DBP and risk seemed to diminish once adjusted 
for SBP.   
Baseline PP maintained a strong relationship with CV-related mortality, even in the 
oldest age group when modelled as a single blood pressure component.  This 
supports other studies that have found PP to be a better predictor of CV events in 
older subjects compared to SBP 76.  While both elevated SBP and PP have been 
shown to be more powerful than DBP in predicting risk in older people, it is thought 
that this increased risk is predominantly coming from the increased PP due to the 
increase in SBP and decrease in DBP with age.  Staessen et al. conducted a meta-
analysis combining results from a number of large clinical trials which showed the 
increased risk of CV complications associated with a wider PP 121.    
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There was strong evidence of a relationship between MAP and risk in younger 
subjects, but not in those 70 years and older.  Once PP and MAP were modelled 
together, there was a slight decrease in magnitude of independent association 
between PP and risk, but more so between MAP and risk.   After adjustment for MAP 
there remained strong evidence of an association between PP and risk in all age 
groups, but after adjustment for PP, there was little evidence for an independent 
association between MAP and risk in any age group.  
MAP was the poorest predictor of CV-related mortality risk out of all of the blood 
pressure components.  This is in-keeping with much of the previous research, for 
example with the conclusions from the meta-analysis conducted by Gasowski et al. 
which found, after adjustment for PP and other known risk factors, that mean 
pressure was not associated with the risk of fatal events 90.  MAP may not be well 
capturing the important elements of DBP or SBP.   However, there is conflicting 
research, for example, Palaniappan et al. found that SBP and MAP were the 
strongest predictors of CV-related mortality risk in both in men and women who 
were over 60 years old from the Dubbo study, compared to PP and DBP 92.   Dyer et 
al also found MAP more strongly associated with CVD risk compared to PP 97.  
When modelled as single blood pressure components, models containing PP 
seemed to perform slightly better in terms of discrimination and model goodness-
of-fit compared to models with SBP.  The addition of DBP to either SBP or PP in 
Chapter 3: Comparison of prognostic performance between components of blood pressure for cardiovascular 
mortality using baseline measurements 
180 
 
dual-component models seemed to add value beyond the single predicator.  A 
model with the combination of SBP and DBP was slightly stronger in prediction 
compared to PP alone.  A reason for this could be that when SBP and DBP are 
modelled together, they can collectively give insightful information about increased 
risk associated with both high and low levels of blood pressure as well as the 
increased risk associated with a wider PP.  PP alone might be capturing part of the 
increased risk associated with high and also low blood pressure, but not as 
completely as SBP and DBP.   
One might expect the relationship between SBP and risk to be dependent on DBP, 
and vice-versa.  For example, it might be expected that the increased risk 
associated with low DBP might be more extreme at higher levels of SBP, as we might 
expect additional risk captured from a wider PP in that scenario.  However, there 
was no evidence for such an interaction.  However, there was evidence for an 
interaction between MAP and PP.  The increased risk associated with a wider PP was 
greater when MAP was lower.  Further, when adjusting for baseline PP, evidence for 
the increased risk associated with lower levels of DBP remained (although slightly 
attenuated).  This might suggest that the increased risk associated with low DBP 
levels was not entirely indicating the increased risk associated with wider PP, but 
might also be representing increased risk associated with diastolic hypotension.  
Hence, while PP might be capturing slightly more of the risk than SBP alone, i.e. 
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increased risk from elevated blood pressure as well as from wider PP, PP alone may 
not be completely capturing the increased risk from lower DBP. 
In dual component models, there was little difference between models containing 
SBP and DBP to models containing PP and DBP.  This is expected as once a model 
contains both SBP and DBP, it has equivalent information to a model containing PP 
and DBP, with slight differences depending on how the blood pressure components 
are modelled.  The combination of PP with MAP was inferior to SBP and DBP. This 
might be because MAP does not fully capture all of the informative information 
from either DBP or SBP.   
Overall, results from the analysis of the 1-year blood pressure data analysis were 
consistent with the baseline data.  Similar relationship patterns were observed for 
both.  However, in general each blood pressure component seemed to have a 
slightly stronger association with CV-related mortality, when using the blood 
pressure measurements from the 1-year visit compared to baseline measurements.  
This slight increase in strength of association might be because baseline values are 
not representing the true underlying blood pressure for these patients as well as 
the 1-year measures.  This might also be due to the inclusion criteria for the trial in 
the recruitment of hypertensive subjects resulting in a more constrained 
distribution of baseline blood pressure.  After treatment initiation blood pressure 
measures had a wider and more unconstrained distribution and hence may be able 
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to predict risk and discriminate between those at higher and lower risk better.  
Differences in post-baseline blood pressure measures might be highlighting how 
well subjects are able to have their blood pressure controlled, emphasising those 
with resistant hypertension, those with chronic hypertension, and identifying those 
with more fundamental vascular damage, for example.   
This research supports existing evidence that PP is as good as or better than other 
blood pressure components in the prediction of CV-related mortality, especially at 
older ages.   There is evidence from clinical trials that some agents, particularly 
ACE-inhibitors, can directly affect arterial stiffness and other elements of vascular 
dysfunction that may be best identified by PP 122.  While most clinical trials in 
hypertension have outcomes that target the reduction of SBP and DBP, in some 
cases a reduction in PP may be a better marker of success in order to be able to 
assess the impact of therapies in targeting vascular dysfunction that directly affect 
PP.  Although there is now much evidence to support the important role of PP as a 
marker for CV events, more investigation is needed through clinical studies to 
evaluate optimum PP targets to help with the formation of clinical guidelines for PP 
for the management of blood pressure and treatment of hypertension. 
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 Background & aims 
4.1.1 Background 
Blood pressure is a naturally highly variable parameter.  A single blood pressure 
measurement or even a collection of measurements from a single occasion can be 
very limited in what they convey about some someone’s underlying blood pressure.  
Blood pressure can vary both in the short-term from moment-to-moment as a 
direct result of daily activities and environmental factors and it can change more 
fundamentally over the long-term.  Biological variations in blood pressure are 
known to be the result of complex interactions between external environmental and 
behavioural factors with internal CV-related mechanisms 123. Many mechanisms 
behind variation in blood pressure are known but there are still many that are not 
fully understood.    
As well as being naturally highly variable, the measurement of blood pressure is 
highly prone to measurement error 124.   The high degree of true natural variability 
in blood pressure from moment to moment throughout the day as well as more 
fundamental changes over time makes blood pressure a complex factor to 
understand and to clinically monitor.  The addition of the high degree of 
measurement error that blood pressure is subject to creates a challenge in the 
assessment of risk and blood pressure management.  Hence, a single measurement 
in time is of limited use when trying to understand an individual’s long-term risk.  
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Utilisation of multiple blood pressure readings over time can greatly improve 
accuracy in the estimation of a true underlying blood pressure level.   
The concept of a “true underlying” blood pressure represents a level at which 
someone is considered to have when at rest at a particular time.  It is most often 
represented by some kind of mean value over several measurements in time, e.g. 
across multiple clinical visits.  A common approach to help reduce blood pressure 
measurement error at a particular clinical visit is to take repeat measurements.  
Clinicians also use various techniques to relax a patient as much as possible in 
order to help a patient’s blood pressure fall as close to resting as possible.  Patients 
will often be asked to sit and relax for a number of minutes before blood pressure 
measures are taken.  Often initial blood pressure measurements are discarded and 
subsequent readings used in an attempt to remove early potentially elevated 
measures before the subject is closer to being at a state of complete rest. 
Measurement error can cause a reduction in estimated association between the 
object being measured and the outcome, a phenomenon known as regression 
dilution bias 125,126.  Methods for correcting for such a bias have been proposed 
when it is not possible to collect multiple measurements from all participants within 
a study 127.  Through the averaging of a set of multiple measurements, each 
carrying some uncertainty, overall uncertainty can be reduced.  As the number of 
measurements increases, the level of precision can increase.  By relating repeated 
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blood pressure measurements to risk of CV mortality, rather than using a single 
measurement, the increased precision gained can reduce regression dilution bias 
128.  This works for multiple measurements that are taken on the same occasion, as 
well as for measurements taken on separate occasions over a longer period of time.  
Repeated measures over longer periods of time can help build a more accurate 
picture of true underlying blood pressure over that period 129.  
The importance of blood pressure level as a risk factor for CVD and mortality has 
long been established and accepted.  In the past blood pressure variability was 
often dismissed and simply seen as a challenging factor in the measurement of 
blood pressure level.  There has more recently been increasing evidence that 
greater measurement-to-measurement short-term and clinical visit-to-visit long-
term variability in blood pressure is associated with increased risk of CVD outcomes 
and mortality, over that of mean level 130–133.  There has been other evidence to 
suggest that blood pressure variability is also a risk factor for other morbidities 
such as dementia and chronic kidney disease 134,135. A systematic review and meta-
analysis conducted by Stevens et al. and published in 2016 concluded that long-
term blood pressure variability was found to be associated with CV and mortality 
outcomes, over and above the effect of mean blood pressure 136.   Since 2018, 
variability in SBP was included in the QRISK risk model (version 3), an algorithm that 
calculates a person’s risk of developing CHD or stroke within 10 years 137.  The 
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QRISK3 model uses the standard deviation (SD) of SBP (from at least 2 
measurements) to represent blood pressure variability, along-side SBP mean level 
and other important risk factors in the model.  Blood pressure variability is being 
seen not just as a nuisance to overcome in the measurement of blood pressure 
level, but an important part of a blood pressure profile that needs to be considered.  
If the variability in blood pressure can improve CVD prediction and indeed mortality 
prediction over that of usual level alone, it should be incorporated in patient care.  
There may also be other aspects of a blood pressure profile that might be 
informative of individuals’ risk and useful in the management of blood pressure.  
For example, it may be important to understand how blood pressure is 
fundamentally changing over time, or to understand periodic peaks in blood 
pressure.    
Some guidelines for the management of hypertension do focus on what is 
considered a patient’s “usual” blood pressure, most commonly defined as the mean 
over multiple visits.  But despite the importance of repeated blood pressure 
measurements, the most common approaches to blood pressure management and 
the treatment of hypertension remain based on responses to measurements taken 
on one occasion.  Modern approaches to blood pressure management should 
include considering current blood pressure levels in the context of historic blood 
pressure profiles.  
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
188 
 
Using repeated blood pressure measurements recorded for patients during the 
course of the ASCOT trial, this study enabled the assessment of blood pressure 
profiles and how they relate to CV-related mortality in this hypertensive ASCOT 
legacy cohort.  
4.1.2 Aims 
The aim of this chapter was to use blood pressure data collected repeatedly during 
the ASCOT trial to investigate relationships between visit-to-visit recurrent blood 
pressure measurements with CV-related mortality risk.   
The first focus in this chapter was on exploring factors that influence blood 
pressure level and the variability in blood pressure measures from visit-to-visit.   
The chapter begins by describing how blood pressure level and variability change 
over time in this ASCOT legacy cohort.  An assessment of how subject 
characteristics relate to blood pressure level and variability was then undertaken.  
Furthermore, blood pressure variation over the calendar year was explored and an 
assessment of which factors influence seasonal variation in blood pressure was 
carried out.  
The second main aim was to investigate the relationship between usual blood 
pressure levels and risk of CV-related mortality, and assess the independent 
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association of visit-to-visit blood pressure variability over that of blood pressure 
level.  
The association between blood pressure level and CV-related mortality was initially 
assessed using the arithmetic mean of historic blood pressure measures to 
represent blood pressure level.  The association between blood pressure variability 
and risk over and above that of mean level was then assessed using the standard 
deviation (SD) of historic blood pressure measures to represent blood pressure 
variability.  
An investigation into how the number of historical blood pressure measures used in 
the estimation of blood pressure level and variability impacted the prediction of risk 
was undertaken.  In addition, as assessment as to whether there was a difference in 
predictive ability between earlier or later blood pressure measures (older or more 
recent) was made. 
Following analyses with the mean and SD used to represent blood pressure level 
and variability, respectively, alternative approaches of representation of blood 
pressure level and blood pressure variability were assessed as to their relationship 
with risk, in order to investigate how other expressions of these factors of repeated 
blood pressure measures relate to risk.  In addition, other attributes of blood 
pressure profiles were assessed.  
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Building upon the findings in Chapter 3, the emphasis in this chapter was on the 
systolic and pulsatile components of blood pressure, since these were shown to be 
the strongest predictors of CV-related mortality.  The objective to compare the 
predictive ability of PP and SBP was extended in this chapter with the use of 
repeated visit-to-visit blood pressure measurements following antihypertensive 
trial treatment initiation.  The comparison between SBP and PP was made in relation 
to both blood pressure level and the variability in measurement of each blood 
pressure component, as well as other attributes of the blood pressure profiles. 
The final part of this chapter aimed to develop a clinically useful predictive risk 
model for CV-related mortality, incorporating a representation of both blood 
pressure level and blood pressure variability, along with other key risk factors for 
the prediction of CV-related mortality. 
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 Blood pressure during the trial in ASCOT legacy subjects 
4.2.1 Blood pressure measurements collected over the trial 
During the trial period which spanned a median of 5.5 years, blood pressure 
measurements were recorded at both scheduled and unscheduled visits.  The 
intended visit schedule was at baseline (screening), 6 weeks, 3 months, 6 months, 
and then at 6 monthly intervals thereafter until trial end.   
All ASCOT legacy patients had blood pressure measured at baseline.  150 patients 
(1%) had no post-baseline measurement, leaving 8470 with at least one post-
baseline.   The median time of last blood pressure visit out of those who had at 
least one measurement post-baseline was 5.3 years (IQR: 4.9-5.9, max: 7.1). 
The distribution of visit times over the trial for ASCOT legacy patients is shown in 
the histogram below (Figure 30), split by those scheduled and unscheduled.  69% of 
all visits were scheduled.  The unscheduled visits occurred for a variety of reasons: 
sometimes due to a patient having missed a scheduled visit; or because of a clinical 
visit for an unrelated reason, routine or otherwise.   
The overall mean SBP at scheduled visits was lower than at unscheduled visits (when 
excluding blood pressure collected at randomisation), 139.42 vs. 141.60 mmHg, 
respectively.  However, since average blood pressure was declining over time and a 
higher proportion of unscheduled visits occurred earlier on compared to scheduled, 
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
192 
 
once adjusted for time from randomisation to reduce confounding by time, the 
difference reduced substantially and scheduled visits were associated with only a 
slightly lower SBP of 0.39 mmHg compared to unscheduled visits (95% CI: 0.24, 
0.55, p<0.001, from a linear mixed model with random components for time of 
visit and subject).   
Figure 30: Distribution of patient visits at which a blood pressure reading was 
recorded 
 
4.2.2 Changes in blood pressure during the ASCOT trial 
For the 8580 ASCOT legacy subjects, there was an initial steep decrease in blood 
pressure in the first 6 months after randomisation, following initiation of blood 
pressure-lowering trial treatment. As well as being a response to anti-hypertensive 
trial treatment, this initial decrease is also likely to be in part a consequence of 
being in a clinical trial context, as well as some regression to the mean as ASCOT 
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patients were recruited on the basis of having high blood pressure when measured 
at screening.  After the first 6-month period, the steep decline in blood pressure 
reduced, but there remained a slight continued decrease in blood pressure over the 
remainder of the trial (see Figure 31).  This pattern was similar for both SBP and 
DBP.  For PP, following a similar steep early decline, there did not appear to be 
further decline PP after about year 3, while SBP and DBP continues to decline 
thereafter slightly.   
Those allocated to amlodipine-based treatment had lower SBP and DBP following 
the baseline visit, compared to those allocated to atenolol-based treatment.  There 
remained approximately a 2mmHg difference between treatment groups in both SBP 
and DBP throughout the whole of trial follow-up.   
There appeared to be an initial difference in PP within the first year following 
baseline measurements, with those in the amlodipine-based group having lower PP.  
In the atenolol-based group, the initial decrease in SBP was proportionately less 
than the amlodipine-based group in relation to the initial decrease in DBP.  This led 
to the initial difference in PP between groups, which later diminished once the 
difference in SBP and DBP between groups became similar after 1 year.  
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Figure 31: Mean profiles (with 95% CI bars) of blood pressure components 
across trial visits (scheduled only), by BPLA treatment allocation 
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 Broad analysis approach and descriptive statistics  
4.3.1 General approach to analysis 
A 5-year period defined from 6-months post-randomisation to the ASCOT trial 
until 5.5-years was used as the observation period from which repeated blood 
pressure measurements were utilised for analysis.  5.5 years was the median 
within-trial time for this population and so was thought an acceptable length in 
which to make use of the majority of measures, while maximising the survival 
follow-up time thereafter. The time of 5.5-years post randomisation represented a 
landmark time-point, which defined the origin for exposure time in survival 
analyses.  Blood pressure measurements from the 6-month period after 
randomisation were excluded in order to remove the initial steep decline in blood 
pressure following initiation of trial treatment (see Figure 32).   
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Figure 32: Fictional SBP profile collected during the trial, blood pressure 
observation period and landmark time  
 
Measurements of blood pressure from both scheduled and unscheduled visits were 
used in this analysis, and patients were included if they had at least 3 visits at which 
blood pressure was measured.   
An initial exploration into how subject characteristics relate to blood pressure level 
and blood pressure variability was conducted.  In addition, the change in blood 
pressure over seasons of the year and the influence of factors on seasonal 
variability were assessed. 
The next step was to assess the relationship between both blood pressure level and 
blood pressure variability with the risk of CV-related mortality.  The general 
approach to this analysis was to adopt a 2-stage method: the first stage consisting 
of estimation of blood pressure level and variability for each subject; and the 
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
197 
 
second stage involving relating these estimated within-subject measures to the 
survival process. This was a landmark analysis where repeated blood pressure 
measurements were utilised during the defined time period to estimate blood 
pressure level and variability.  These estimates were then related to the survival 
process, beginning from the defined landmark time. Hence this analysis was 
conditional on subjects still being at risk at the landmark time, i.e. conditional on 
surviving until the landmark time and still being in follow-up.  
4.3.2 Blood pressure during the 5-year observation period 
By the specified landmark time, 5.5-years post-baseline, 7407 (86.3%) patients 
were alive and in observation.  681 patients had died prior and 492 patients had 
either been lost to follow-up or left the trial without giving consent for further 
follow-up.   
Out of those 7407 patients still in follow-up, 7092 had at least three blood 
pressure measurements within the 5-year observation period and hence were 
included in analyses. 
The median (IQR) number of visits at which blood pressure measures were taken 
was 13 (11-17), that’s 9 (9-10) scheduled and 4 (2-7) unscheduled visits.  93.1% of 
subjects had at least one unscheduled visit during the observation period.  
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The overall mean across subjects for SBP and PP was 137.11 mmHg and 58.34 
mmHg, respectively.  Distributions of individuals’ mean blood pressures are 
presented as histograms in Figure 33.  The spread of PP mean relative to overall 
mean was larger than for SBP.  The SD was 18.6% of the mean value (10.86 mmHg) 
for PP and 9.0% of the mean value (10.39 mmHg) for SBP. The wider distribution of 
PP mean values compared to SBP (and also DBP) seems logical as a consequence of 
its calculation from both DBP and SBP. 
Distributions of the within-subject SD for PP and SBP are presented as histograms in 
Figure 34.  The mean of the SDs was slightly higher for SBP at 11.77 mmHg than PP 
at 8.06 mmHg.  For each component of blood pressure, the SD appeared slightly 
right-skewed from a normal distribution, expected to a degree as SDs are bound on 
the left-side by zero.  SDs equal to zero can occur when all blood pressure 
measurements for a subject are the same.  This was the case for one subject in 
relation to PP, but no subject had zero SD for SBP.     
Within-subject SD was highly correlated with within-subject mean level for both PP 
and SBP.  Figure 35 shows a plot of the relationship between the SD and mean level 
for each component of blood pressure.  As mean blood pressure increases the SD 
increases.  While this relationship appears to be fairly linear for PP, this relationship 
appears to have some curvature for SBP (test for linearity gives p<0.001), with the 
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gradient becoming steeper at higher SBP mean levels.  The increase in variability in 
SBP measurements was not quite growing proportionately to the overall mean level. 
Figure 33: Distributions of mean blood pressure presented as histograms for 
each component of blood pressure 
 
Figure 34: Distributions of blood pressure standard deviation presented as 
histograms for each component of blood pressure 
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Figure 35: Relationship between standard deviation (95% CI) and mean blood 
pressure level 
 
In the 7092 subjects included in analysis, mean SBP over the defined 5-year period 
of observation was lower in the amlodipine-based group (136.27 mmHg, SD=9.90) 
compared to the atenolol-based group (137.98 mmHg, SD=10.80), a difference of 
1.71 mmHg (95% CI: 1.23-2.19, p<0.001).  This difference was considered small 
from a clinically important perspective, and one that trial investigators suspected 
was not enough alone to account for the differences in outcomes between the 
treatment arms 138.  There was no difference in mean PP between the anti-
hypertensive treatment arms (0.03 mmHg lower in the amlodipine-based arm, 
p=0.903).   
There was a more striking difference between BPLA treatment groups in relation to 
blood pressure variability.  The variability of both PP and SBP was substantially less 
in the amlodipine-based arm compared to that in the atenolol-based arm. The SD 
for SBP was 10.79 mmHg (SD=4.40) in the amlodipine-based arm and 12.78 mmHg 
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(SD=4.83) in the atenolol-based arm.  Once adjusted for the mean level, the 
difference in SD was estimated at 1.69 mmHg lower in the amlodipine-based group 
(95% CI: 1.49-1.88, p<0.001).   For PP the SD was estimated to be 1.06 mmHg 
lower in the amlodipine-based group (95% CI: 0.94-1.19, p<0.001) after 
adjustment for mean level.    
 Factors that influence blood pressure level and its variability 
following antihypertension treatment initiation  
4.4.1 Background 
Hypertension has long been understood to be both a disease and an important risk 
factor for other morbidities and death.  It has been well established that there are 
many risk factors that increase the probability of developing hypertension.  Genetic 
studies have suggested that certain individuals can have a susceptibility for 
hypertension, and when coupled with environmental risk factors can lead to 
increased risk of development.  Certain risk factors have long been identified for 
high blood pressure, including age, obesity, having an inactive lifestyle, as well as 
dietary factors like high alcohol intake, smoking, and a high sodium intake 139–141.  
Much research has focused on identifying genetic risk factors separate to 
environmental influences on blood pressure in order to improve the prediction of 
hypertension and improve patient care and assist with early intervention to help 
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reduce risk of hypertension-related morbidity and mortality in those identified as 
high risk 142.    
Factors that influence variability in blood pressure have been explored and 
documented to a lesser extent than blood pressure level.  With the growing 
realisation that variability as well as blood pressure level is an important risk factor 
for CV diseases, it is important to understand which factors influence variability, 
and which influences are associated with worse outcomes.  
Clinical visit-to-visit variability in blood pressure in hypertensive subjects may be a 
result of poor blood pressure management as well as non-adherence to 
antihypertensive medication.  Efforts to improve patient adherence have been an 
important research focus in recent years 143–147.  
Blood pressure is known to vary in response to environmental changes, such as 
when there are changes in climate across the seasons 148–151.  This can occur for a 
number of reasons which include both direct effects from environmental changes 
such as changes in temperature, exposure to ultra-violet radiation, and other 
changes that people might be exposed to across the seasons, as well as indirect 
effects through comorbidities associated with different seasons 152.   
The variation in blood pressure over the seasons has large implications for the 
management of blood pressure and hypertension.  Some research has highlighted 
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factors that influence seasonal changes in blood pressure, such as age 153.  
However, there has been relatively little research conducted to identify the extent to 
which patient-related characteristics influence seasonal variations in blood 
pressure.  
4.4.2 Predictors of blood pressure level  
4.4.2.1 Methods 
Within-subject blood pressure level was represented by the arithmetic mean of each 
subject’s blood pressure profile during the defined 5-year observation period (from 
6 months to 5.5-years post-randomisation).  Between-subject mean blood pressure 
was calculated across different categories of baseline characteristics.  Multivariable 
linear regression was conducted in order to assess the relationship between 
baseline characteristics and within-subject blood pressure level.  Mean differences 
in blood pressure level between categories, both unadjusted and adjusted, were 
estimated.  These analyses were conducted for both SBP and PP.  
4.4.2.2 Results 
Mean within-subject SBP and PP mean levels during the defined 5-year observation 
period over categories of baseline characteristics are presented in Table 21. 
Mean level of SBP was markedly higher with increasing age of subjects: an 
estimated 4.1 mmHg higher in those 75 years and over compared to those under 
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60, from an adjusted model (p<0.001).  An even more striking difference was 
observed for PP between age-groups: an estimated 12.5 mmHg higher in those 75 
years and over compared to those under 60 years (p<0.001).  A similar pattern was 
seen with baseline measurements of blood pressure shown in Chapter 3, although 
differences were larger for baseline measurements with those 75 or more years of 
age having 11.8 mmHg and 18.3 mmHg higher baseline SBP and PP compared to 
those under 60 years, respectively.  
While there was little difference in SBP between the sexes, males had a lower PP 
than women, with an adjusted estimated 1.6 mmHg lower (p<0.001), a smaller 
difference compared to baseline blood pressure with males having an adjusted 3.4 
mmHg lower baseline PP compared to women (p<0.001).  
Those of Asian ethnicity had the lowest mean SBP and PP compared to other 
ethnicities.  After adjustment mean SBP was estimated to be 1.9 mmHg lower in 
those of Asian ethnicity compared to those of White ethnicity (p=0.009).  Those of 
Black ethnicity had an estimated 1.3 mmHg higher SBP compared to those of White 
ethnicity (p=0.023).  Those of White ethnicity had the highest mean PP, but after 
adjustment there was little difference between the different ethnic groups.   
While there was no evidence of a difference in SBP between BMI groups, there was a 
trend towards decreased PP with higher BMI (p<0.001), as seen with baseline PP 
measurements.  Those with diabetes mellitus at baseline had an estimated 3.3 
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mmHg higher PP compared to those without (p<0.001), while there was no 
difference in SBP in adjusted models.  
There was strong evidence of a trend of decreasing blood pressure with increasing 
age at which subjects left full-time education, both for SBP and PP (p<0.001 for 
both).  There was no evidence of a difference in blood pressure between non-
smokers compared to ex- or current smokers.  There was a trend of increasing 
blood pressure with increasing average weekly units of alcohol consumed for both 
SBP and PP.  Those who reported drinking 28 units or more per week had estimated 
adjusted increased SBP and PP of 1.9 mmHg and 1.4 mmHg, respectively, compared 
to those who reported no intake (p<0.001 for both). 
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Table 21: Level of blood pressure based on within-subject arithmetic mean during 5-year observation period, by categories 
of baseline characteristics, with unadjusted and adjusted mean differences  
   Systolic blood pressure Pulse pressure 












P-value** Mean (SD) 











40-59 2255 135.7 (9.8) ref   ref   53.2 (9.4) ref   ref   
60-64 1576 136.3 (9.7) 0.6 (-0.1, 1.2)   0.6 (-0.1, 1.2)   56.9 (9.6) 3.7 (3.0, 4.3)   3.4 (2.7, 4.0)   
65-69 1568 137.6 (10.8) 1.9 (1.2, 2.6)   1.8 (1.1, 2.6)   60.4 (10.1) 7.2 (6.6, 7.8)   6.7 (6.0, 7.3)   
70-74 1111 138.9 (11.1) 3.2 (2.4, 3.9)   3.0 (2.2, 3.9)   63.6 (10.8) 10.4 (9.7, 11.2)   9.6 (8.8, 10.4)   
75+ 582 139.9 (10.9) 4.2 (3.2, 5.1) p<0.001 4.1 (3.0, 5.1) p<0.001 66.6 (10.6) 13.4 (12.5, 14.3) p<0.001 12.5 (11.5, 13.5) p<0.001 
Sex 
Female 1335 136.7 (11.7) ref   ref   60.6 (11.6) ref   ref   




White  6328 137.2 (10.3) ref   ref   58.6 (10.8) ref   ref   
Asian (east/south) 218 133.6 (12.4) -3.6 (-5.0, -2.2)   -1.9 (-3.4, -0.5)   55.1 (11.8) -3.5 (-4.9, -2.0)   -0.7 (-2.0, 0.7)   
Black 397 137.5 (10.8) 0.2 (-0.8, 1.3)   1.3 (0.2, 2.3)   56.7 (10.6) -1.8 (-2.9, -0.7)   -0.4 (-1.4, 0.7)   





12-14 1999 138.6 (11.0) ref   ref   62.6 (11.0) ref   ref   
15-16 3562 136.9 (10.1) -1.6 (-2.2, -1.0)   -0.1 (-0.8, 0.5)   57.2 (10.4) -5.4 (-6.0, -4.8)   -0.6 (-1.3, -0.0)   
17-18 811 135.5 (10.2) -3.0 (-3.8, -2.2)   -1.8 (-2.7, -0.9)   55.7 (10.2) -6.9 (-7.7, -6.0)   -2.8 (-3.7, -2.0)   
19+ 716 135.7 (9.6) -2.8 (-3.7, -1.9) p<0.001 -1.4 (-2.4, -0.5) p<0.001 55.0 (9.9) -7.6 (-8.5, -6.7) p<0.001 -2.7 (-3.6, -1.8) p<0.001 
BMI (kgm-2) 
<25 1283 136.9 (10.5) ref   ref   59.5 (11.0) ref   ref   
25- <30 3325 137.4 (10.3) 0.5 (-0.1, 1.2)   0.6 (-0.1, 1.2)   58.7 (11.1) -0.7 (-1.4, -0.0)   -0.5 (-1.1, 0.1)   
30- <35 1819 136.7 (10.3) -0.2 (-0.9, 0.6)   0.2 (-0.5, 0.9)   57.1 (10.4) -2.4 (-3.2, -1.6)   -1.4 (-2.1, -0.7)   
≥35 665 137.0 (10.9) 0.1 (-0.9, 1.1) p=0.089 0.9 (-0.0, 1.9) p=0.158 57.5 (10.4) -2.0 (-3.0, -0.9) p<0.001 -0.7 (-1.7, 0.2) p<0.001 
Smoking status 
within 1 year 
Non-smoker 2346 137.1 (10.6) ref   ref   58.1 (10.6) ref   ref   
Current/ex 4746 137.1 (10.3) 0.0 (-0.5, 0.5) p=0.987 -0.4 (-0.9, 0.1) p=0.116 58.4 (11.0) 0.3 (-0.2, 0.9) p=0.215 0.4 (-0.1, 0.9) p=0.118 
Average weekly 
units of alcohol 
consumed 
No intake 1773 136.9 (11.2) ref   ref   59.3 (11.3) ref   ref   
Intake 1 - <14 3021 136.7 (10.2) -0.2 (-0.8, 0.4)   -0.1 (-0.8, 0.5)   58.1 (10.8) -1.2 (-1.9, -0.6)   -0.4 (-1.0, 0.2)   
Intake 14 - < 28 1378 137.5 (9.7) 0.6 (-0.1, 1.3)   0.8 (0.1, 1.6)   57.8 (10.6) -1.5 (-2.3, -0.8)   0.1 (-0.6, 0.9)   
Intake 28+ 920 138.3 (10.0) 1.4 (0.6, 2.2) p<0.001 1.9 (1.0, 2.8) p<0.001 58.0 (10.5) -1.3 (-2.2, -0.4) p<0.001 1.4 (0.6, 2.2) p<0.001 
Diabetes 
mellitus 
No 5119 137.2 (10.0) ref   ref   57.4 (10.6) ref   ref   
Yes 1973 136.8 (11.3) -0.5 (-1.0, 0.1) p=0.100 -0.3 (-0.8, 0.3) p=0.359 60.6 (11.3) 3.2 (2.6, 3.8) p<0.001 3.3 (2.7, 3.8) p<0.001 
* adjusted for all other baseline risk factors in the table in multivariable linear regression models.  Subjects with missing values for “age left education” were 
included in multivariable models, grouped into missing categories when missing.    
** P-values from likelihood ratio tests. 
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4.4.3 Predictors of blood pressure variability  
4.4.3.1 Methods 
The variability in blood pressure was expressed on a subject-by-subject basis as 
the standard deviation which was calculated on measures collected during the 
defined 5-year observation period (from 6 months to 5.5-years post-
randomisation).  Mean variability (mean of within-subject SD) was calculated across 
different categories of baseline characteristics.  Crude and adjusted mean 
differences between categories were estimated using linear regression models.  
These analyses were conducted for both SBP and PP.  
Adjusted models controlled for other important baseline risk factors.  When 
estimating adjusted differences in blood pressure level (as presented in the 
previous section), models were not adjusted for blood pressure variability.  This is 
because on average blood pressure variability increases with increasing mean level.  
Hence to adjust for variability when interested in blood pressure level would 
attribute some of the effect of blood pressure level to the corresponding level of 
variability, and reduce the estimated association between blood pressure level and 
risk in a way that we do not want.  Conversely, when studying blood pressure 
variability, the part of increased blood pressure variability that is purely a 
consequence of increased blood pressure level is not of interest and the part of 
variability that is independent of the mean is of interest.  Hence, when estimating 
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adjusted differences in blood pressure variability, blood pressure level was adjusted 
for in models.  
4.4.3.2 Results 
Mean within-subject SDs of SBP and PP during the defined 5-year observation 
period over categories of baseline characteristics are presented in Table 22. 
The SD in SBP was strikingly different across categories of age, getting progressively 
larger with increasing age of subjects, even after adjustment for mean level.   Those 
75 years and over had 1.8 mmHg greater SD compared to those under 60 
(p<0.001).  While there was strong evidence of increasing PP SD with increasing 
age, in adjusted models the differences were reduced, with those 75 years and 
older having 0.5 mmHg higher PP SD compared to those under 60 years (p<0.001).  
There was also a difference in the SD of SBP and PP between males and females, 
which remained after adjustment with males having 1.5 mmHg lower SBP SD 
(p<0.001) and 0.9 mmHg lower PP SD (p<0.001).    
From adjusted models, those of White ethnicity had slightly lower SBP SD compared 
to other ethnic backgrounds, but there was no evidence of a difference in PP SD.  
Although the SD of SBP seemed to decline as age the subject left full-time 
education increased, after adjustment there was no evidence of a difference, and 
neither was there for PP SD.  
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Although there was little difference in PP SD between BMI groups, after adjustment 
strong evidence for a small trend in increasing SD with increasing BMI level was 
revealed (p<0.001).  There was no evidence of a difference in SBP SD across BMI 
groups.  
Those who were diabetic at baseline had higher SBP SD compared to non-diabetics 
(p<0.001), as well as marginally higher PP SD (p=0.009).  As obesity can contribute 
to the onset of diabetes and hence may be on the causal pathway, an adjusted 
model was built without adjustment for BMI.  However, there was little change and 
the adjusted estimated differences in the SD of both SBP and PP were consistent 
with or without adjustment for BMI.    
Those who were current smokers or ex-smokers within a year from randomisation 
had slightly higher SD for both SBP and PP compared to non-smokers (p<0.001 for 
both) after adjustment.   
There were small differences in blood pressure variability across different levels of 
alcohol consumption.  The group that had the lowest variability in both SBP and PP 
was those who reported alcohol consumption of between1 and 14 units per week.  
It appeared that there was a trend of increasing variability with increasing alcohol 
intake, but the group with no intake did not have the lowest variability.  This 
pattern was the same for both SBP and PP.   
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Table 22: Variability of blood pressure based on within-subject standard deviation during 5-year observation 
period, by categories of baseline characteristics, with unadjusted and adjusted mean differences 
   Systolic blood pressure Pulse pressure 
Risk factor Risk factor group 
No. 
subjects 
(N=7092) Mean (SD) 








value** Mean (SD) 












40-59 2255 10.8 (4.3) ref   ref   7.1 (2.7) ref   ref   
60-64 1576 11.5 (4.5) 0.7 (0.4, 1.0)   0.5 (0.2, 0.8)   7.8 (2.9) 0.7 (0.5, 0.9)   0.2 (-0.0, 0.4)   
65-69 1568 12.1 (4.8) 1.3 (1.0, 1.6)   0.9 (0.6, 1.2)   8.4 (3.3) 1.3 (1.1, 1.5)   0.3 (0.1, 0.5)   
70-74 1111 12.8 (5.0) 1.9 (1.6, 2.3)   1.3 (1.0, 1.7)   9.0 (3.6) 1.9 (1.7, 2.1)   0.5 (0.2, 0.7)   
75+ 582 13.4 (5.2) 2.5 (2.1, 3.0) p<0.001 1.8 (1.3, 2.2) p<0.001 9.4 (3.5) 2.3 (2.0, 2.6) p<0.001 0.5 (0.2, 0.8) p<0.001 
Sex 
Female 1335 12.9 (5.2) ref   ref   9.1 (3.7) ref   ref   




White 6328 11.7 (4.7) ref   ref   8.1 (3.2) ref   ref   
Asian (east/south) 218 11.2 (4.3) -0.5 (-1.1, 0.1)   0.6 (-0.0, 1.2)   7.4 (3.0) -0.6 (-1.1, -0.2)   -0.0 (-0.4, 0.4)   
Black 397 12.3 (4.9) 0.6 (0.1, 1.1)   0.6 (0.1, 1.0)   8.0 (3.6) -0.1 (-0.4, 0.3)   0.2 (-0.1, 0.5)   





12-14 1999 12.5 (5.0) ref   ref   8.8 (3.4) ref   ref   
15-16 3562 11.6 (4.6) -1.0 (-1.2, -0.7)   -0.0 (-0.3, 0.3)   7.8 (3.1) -1.0 (-1.2, -0.8)   0.0 (-0.2, 0.2)   
17-18 811 11.2 (4.6) -1.3 (-1.7, -0.9)   -0.2 (-0.6, 0.2)   7.7 (3.2) -1.1 (-1.4, -0.9)   0.1 (-0.2, 0.3)   
19+ 716 11.3 (4.3) -1.2 (-1.7, -0.8) p<0.001 -0.1 (-0.4, 0.3) p=0.091 7.5 (2.8) -1.3 (-1.5, -1.0) p<0.001 0.1 (-0.2, 0.4) p=0.173 
BMI (kgm-2) 
<25 1283 11.9 (4.9) ref   ref   8.1 (3.3) ref   ref   
25- <30 3325 11.7 (4.7) -0.2 (-0.5, 0.1)   -0.2 (-0.4, 0.1)   8.0 (3.3) -0.1 (-0.3, 0.1)   0.1 (-0.1, 0.2)   
30- <35 1819 11.8 (4.6) -0.1 (-0.4, 0.3)   0.1 (-0.2, 0.4)   8.1 (3.0) -0.1 (-0.3, 0.2)   0.3 (0.1, 0.5)   
≥35 665 11.8 (4.7) -0.0 (-0.5, 0.4) p=0.676 0.0 (-0.4, 0.4) p=0.148 8.2 (3.1) 0.1 (-0.2, 0.4) p=0.322 0.4 (0.1, 0.7) p<0.001 
Smoking status 
within 1 year 
Non-smoker 2346 11.6 (4.7) ref   ref   8.0 (3.2) ref   ref   
Current/ex 4746 11.8 (4.7) 0.2 (-0.0, 0.4) p=0.108 0.4 (0.2, 0.6) p<0.001 8.1 (3.2) 0.2 (-0.0, 0.3) p=0.064 0.2 (0.1, 0.4) p=0.001 
Average weekly 
units of alcohol 
consumed 
No intake 1773 12.3 (4.9) ref   ref   8.5 (3.3) ref   ref   
Intake 1 - <14 3021 11.5 (4.7) -0.7 (-1.0, -0.5)   -0.3 (-0.6, -0.1)   7.9 (3.2) -0.5 (-0.7, -0.4)   -0.2 (-0.3, 0.0)   
Intake 14 - < 28 1378 11.6 (4.5) -0.7 (-1.0, -0.4)   -0.2 (-0.5, 0.2)   7.9 (3.0) -0.6 (-0.8, -0.4)   0.0 (-0.2, 0.2)   
Intake 28+ 920 11.9 (4.6) -0.4 (-0.8, -0.0) p<0.001 0.2 (-0.2, 0.6) p=0.005 7.9 (3.1) -0.5 (-0.8, -0.3) p<0.001 0.1 (-0.2, 0.3) p=0.056 
Diabetes 
mellitus 
No 5119 11.6 (4.7) ref   ref   7.8 (3.1) ref   ref   
Yes 1973 12.3 (4.8) 0.8 (0.5, 1.0) p<0.001 0.7 (0.4, 0.9) p<0.001 8.6 (3.4) 0.8 (0.6, 0.9) p<0.001 0.2 (0.0, 0.4) p=0.009 
* adjusted for all other baseline risk factors in the table, as well as for mean level, in multivariable linear regression models.  Subjects with missing 
values for “age left education” were included in multivariable models, grouped into missing categories when missing.    
** P-values from likelihood ratio tests. 
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4.4.4 Seasonal variability in blood pressure  
4.4.4.1 Methods 
Using blood pressure measurements from subjects that had at least three blood 
pressure measurements within the defined 5-year observation period, the variation 
in blood pressure over seasons of the year was investigated.   Linear mixed models 
with random components for time and subject were used to estimate mean blood 
pressure level in each month of the calendar year, allowing correlation between 
within-subject measures to differ from between-subject correlation.  Mean blood 
pressure was estimated in each month of the year overall, and then in subgroups of 
baseline age, sex, and BPLA trial treatment allocation by adding interaction terms to 
the model.   
Adjusted models were developed to estimate mean blood pressure differences 
between summer time and winter time.  Summer was defined from 21 June to 22 
September, and Winter time was defined from 21 December to 19 March, to reflect 
the seasons in the northern hemisphere. The models were adjusted for predefined 
baseline risk factors, and the time since randomisation (since blood pressure was 
on average also declining slightly over time year-to-year post baseline).   
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Adjusted mean differences between the coldest and warmest months were also 
calculated in each subgroup, from inclusion of an interaction term between a factor 
and time of year.  Interactions were tested statistically.    
Baseline blood pressure measurements were excluded in these analyses.  This was 
because baseline measures were substantially higher, on average, compared to the 
usual level over the course of the trial, and the time of year that patients were 
randomised was not spread out equally and likely to not be at random.  In addition, 
the first 6 months of blood pressure measures were excluded from analysis as the 
mean blood pressure decreased rapidly at first following initiation into the trial and 
beginning trial treatment.  After 6 months, mean blood pressure levels continued to 
decline but to a lesser extent and in more of a linear fashion.  Hence, making an 
adjustment for time since randomisation when using post 6-month measurement 
was considered acceptable.   
In order to explore geographical differences in seasonal variability, analyses were 
conducted on repeated blood pressure measures from the Scandinavian countries 
that participated in the ASCOT trial and compared to the ASCOT legacy UK subjects.  
Blood pressure measurements as recorded at scheduled and unscheduled visits 
from the same 5-year observation time-period as defined for UK subjects were 
used.  Models were run with both UK patients and Scandinavian patients in the 
same model with an interaction between the two geographical regions.  




The 7092 UK ASCOT legacy subjects and a further 9795 subjects from Scandinavian 
counties were included in these analyses. Figure 36 presents mean SBP and PP 
levels over calendar time between 1999 and 2005, separately for the two 
geographical regions.  The varying levels of SBP clearly follow a seasonal pattern 
with highs during the colder winter months and lows during the warmer summer 
months.  Blood pressure levels were consistently higher in Scandinavian countries 
compared to the UK for both SBP and PP.  However, the pattern in seasonal blood 
pressure change appears visually to be slightly less pronounced in Scandinavian 
countries compared the UK.  Behind changes in blood pressure level over the 
seasons, there is a general overall decline which is steeper between 1999 and about 
2002, before further overall reduction slows thereafter.  The patterns for PP were 
similar to that of SBP.  
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Figure 36: Plots of mean SBP & PP (95% CI) over calendar time from 1999 to 
beginning of 2005 
 
 
Note: estimates are from a linear mixed model with random components for calendar time and 
subject.  Months are grouped into pairs, starting with January & February 1999, and so on.  




Overall, the estimated adjusted mean difference in SBP and PP between the winter 
and summer periods was 2.63 mmHg and 1.58 mmHg, respectively.  
There was strong evidence for a seasonal effect at all ages, with both SBP and PP 
being lower in summer months compared to winter in each age group.  However, 
the difference was markedly larger in older subjects compared to younger, with 
strong evidence for this interaction for both SBP and PP (p<0.001 in both cases).   
Figure 38 illustrates the difference in magnitude of change in blood pressure over 
the months of the year between the age groups.  For those <55 years of age, the 
estimated mean SBP was 1.74 mmHg lower in summer than in winter (p<0.001), 
and PP was 1.12 mmHg lower (p<0.001).  Whilst in the oldest age group, those 75 
years and older, SBP was 3.67 mmHg lower in summer compared to winter 
(p<0.001), and PP was 2.34 mmHg lower (p<0.001).     
The change in mean blood pressure between seasons was similar for females and 
males, with females having a very slightly higher mean increase in both SBP and PP 
in summer compared to men (interaction p-values 0.204 & 0.014, respectively).   
Figure 37 shows mean blood pressure levels by individual months of the year, 
separately for UK and Scandinavian countries.  Overall, mean SBP was a lot higher in 
Scandinavian countries compared to the UK: 142.85 mmHg compared to 137.13 
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mmHg, respectively.  Mean PP was also higher in Scandinavian countries compared 
to the UK, but the difference was not as striking: 59.89 mmHg compared to 58.35 
mmHg, respectively.  Trial entry criteria was the same for both geographical 
regions, but baseline SBP was higher in those from Scandinavia compared to the UK: 
mean SBP was 165.68 mmHg and 161.36 mmHg, respectively.  However, there was 
little difference in PP at baseline: mean PP was 68.94 mmHg for Scandinavian 
subjects and 69.18 mmHg in UK subjects.  These differences in blood pressure 
between geographical regions could not be explained by differences in ethnic 
background.  For both regions, SBP and PP was lowest in the 3 summer months: 
June to August.  The magnitude in change blood pressure was larger in UK subjects 
compared to Scandinavian subjects.   
From adjusted models there was a fairly striking difference in the magnitude of 
change in SBP and PP between geographical regions, with strong evidence of 
interactions (p<0.001 in for both components of blood pressure).   Mean SBP was 
estimated to have risen by 3.43 mmHg in the UK and 1.76 mmHg in Scandinavian 
countries in the summer compared to winter, and PP by 1.96 mmHg in the UK and 
1.17 mmHg in Scandinavian countries.   
There was some evidence for interactions between blood pressure levels and which 
allocated BPLA trial treatment group subjects were assigned to, although the actual 
differences were small.  Those assigned to amlodipine-based treatment had a 
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slightly larger estimated adjusted increase in both SBP and PP in the summer season 
(interaction p-values 0.022 & 0.008, respectively).   
Table 23 presents adjusted blood pressure differences between summer and winter 
time by subgroups, and Figure 39 presents a forest plot of differences by subgroup.
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Figure 37: Mean SBP (95% CI) by month of the year, by age at baseline and geographical region 
 Categorical plots by month of the year  Continuous plots using sinusoidal function 
  
  
Note: estimates are from a linear mixed model with random components for time of the year and subject, with a fixed component interaction between time of 
the year and geographical region
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Figure 38: Mean SBP (95% CI) by month of the year, by age at baseline 
 Categorical plots by month of the year  Continuous plots using sinusoidal function  
  
  
Note: estimates are from a linear mixed model with random components for time of the year and subject, with a fixed component interaction between time of 
the year and age-group) 
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Table 23: Mean difference in blood pressure (95% CI, mmHg) between Summer and Winter time, overall and by 
subgroups  















40-<55 2783  1.74 (1.30-2.17)  
<0.001 
1.12 (0.82-1.42)  
<0.001 
55-<65 7171  2.28 (2.01-2.55)  1.31 (1.12-1.50)  
65-<75 5649  3.24 (2.94-3.54)  1.96 (1.75-2.17)  
75+ 1284 3.67 (3.04-4.30)  2.34 (1.91-2.78)  
Sex 
Female 3965  2.90 (2.52-3.27)  
0.204 
1.95 (1.69-2.21)  
0.014 
Male 12922 2.55 (2.35-2.75)  1.48 (1.34-1.61)  
Region 
UK (ASCOT Legacy) 7092 3.43 (3.19-3.68)  
<0.001 
1.96 (1.79-2.13)  
<0.001 
Scandinavia 9795  1.76 (1.51-2.01)  1.17 (1.00-1.35)  
BPLA treatment 
allocation 
Atenolol-based 8384  2.44 (2.20-2.69)  
0.022 
1.43 (1.26-1.60)  
0.008 
Amlodipine-based 8503  2.81 (2.56-3.06)  1.74 (1.57-1.91)  
Overall 16887 2.63 (2.45-2.80) <0.001  1.58 (1.46-1.70) <0.001  
Note: estimates are from linear mixed models with random components for time of year group and subject, adjusted for pre-specified baseline risk 
factors.  Interaction p-value for age groups is from a test for trend (linear).  
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Figure 39: Forest plot of mean change in blood pressure (95% CI, mmHg) in summer compared to winter time 
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4.4.5 Conclusions and Discussion 
It is well documented that SBP increases with age, and that DBP decreases with age 
and hence a resultant large increase in pulsatile pressure with increasing age 95,104.  
The mechanism behind a wider PP with increasing age is thought to be largely a 
consequence of arterial stiffness that increases with age, as mentioned in the 
previous chapter.  In these data there was a striking increase in PP mean with 
increasing age, an average increase of over 12 mmHg in PP for those 75 years or 
older compared to those under 60 years.  
The largest differences in blood pressure variability were seen across age-groups 
and between the sexes.  The SD of SBP was higher in older subjects and to a lesser 
extent the trend was similar with PP variability.  This was independent of the mean 
values.  This may be in part due to the increased seasonal variation over the year 
that we see in older subjects, highlighting an increased frailty and vulnerability in 
those more elderly.  Some studies have found visit-to-visit variability in blood 
pressure to attenuate with increasing age, particularly the variability of DBP 154,155, 
while others have found no association between SBP variability and age 156.   
While there was only a very slight increase in SBP in males compared to females, 
males had a much larger increased DBP compared to females.  Hence males had 
lower mean PP than females.  This was also the case comparing baseline PP 
measurements (see Chapter 3) where males had a higher baseline DBP compared to 
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females, but with little difference in SBP men had a lower baseline PP compared to 
females.  The majority of studies that compared males to females reported both 
higher SBP and PP in men compared to women of the same age 109.  Some studies, 
however, have found that although pulse pressure tends to be higher in males 
compared to females in younger people, females may have a steeper increase in PP 
with increasing age compared to men which may explain why PP may be higher in 
older women compared to men of the same age 157.   
Males had lower variability in both SBP and PP compared to females.  This was 
somewhat evident in the seasonal changes in blood pressure, with females having a 
slightly larger increase in SBP and PP in winter compared to summer.   This is 
contrary to some other studies where males have often been shown to have a 
higher variability for both SBP and DBP 158. 
Those who left full-time education at a younger age, a possible proxy for socio-
economic status, had higher SBP and PP level, compared to those who left full-time 
education later on in life.  This trend may be indicating poorer health for those who 
left education at a younger age, possibly resulting from higher levels of deprivation.  
Many other studies have reported higher blood pressure in those from lower socio-
economic backgrounds, particularly in women 159.  It is thought that wealthier 
communities have lower blood pressures as a result of benefitting from improved 
health awareness, better diet and better access to anti-hypertensive medications.  
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After adjustment, there was no independent association between blood pressure 
variability and the age that subjects left full-time education.   
There was a suggestion of a slight decrease in mean PP with increasing BMI.  While 
SBP was higher in those with larger BMI, there was a relatively larger difference in 
DBP.  There is clear evidence in the literature of the increased risk of hypertension 
associated with obesity 160–163.  However, studies have also shown that PP appeared 
to be higher in the lean compared to the overweight, increasing again in the obese 
112,164,165.  In this study we also see the highest PP in the lean, those with a BMI less 
than 25 kg/m2, while the lowest PP was seen in those with BMI from 30 to <35 
kg/m2.  PP was then lower in those 35 kg/m2 or higher.  It has been suggested that 
this higher PP seen in leaner subjects might help explain some of the increase in CV 
risk that has been seen in many studies in those who are lean compared to those 
overweight.   
There was a very slight increase in the variability of PP with increasing BMI.  BMI has 
been identified as a risk factor for increased variability in blood pressure in other 
studies 166–169. 
While smoking is a well-known high-risk factor for CVD, it is not completely clear 
how it relates to blood pressure levels in the long-term.  It is known that blood 
pressure can increase at the point of smoking as a result of acute vasoconstriction 
due to the nicotine content.  However, there is some conflicting evidence from 
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different studies about the longer-term effects, with some studies reporting lower 
blood pressure in smokers compared to non-smokers 170–172.  While in this study, 
there was no difference observed in SBP or PP mean level between those reported to 
be non-smokers and those reporting to be current or ex-smokers within one year 
prior to randomisation, there was a slight increase in the variability of both SBP and 
PP in those who were either current or ex-smokers.  This increased variability could 
potentially be due to the acute spikes in blood pressure at the point of smoking in 
those who continued to smoke during the trial.  Studies have suggested that 
continuous smoking does not lead to increased short-term variability in blood 
pressure, but it is the temporary cessation of smoking that can lead to immediate 
short-term variability, particularly affecting morning blood pressure levels following 
overnight cessation 173. 
As has been shown in other studies, in general those reporting increased alcohol 
consumption had higher SBP and PP.  What is often unclear is the make-up of the 
group who report no alcohol consumption, as this group may represent a mixture 
of those who have always consumed little or no alcohol as well as those who have 
given up alcohol as a consequence of a morbidity, being at high risk of morbidities, 
or even because of excessive alcohol consumption in the past.  The largest 
difference in blood pressure level was seen in those who reported consuming 28 
units of alcohol or more per week.  It is well known that drinking high levels of 
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
226 
 
alcohol in one sitting can cause an acute increase in blood pressure, and sustained 
high levels of alcohol consumption over time can cause longer-term increases in 
blood pressure. There was some weak evidence of a light increase in the SD of both 
SBP and PP as the amount of alcohol consumed increased 159,174–176.   The highest 
variability in both SBP and PP was seen in those who reported no alcohol intake, 
with little difference between other categories.  After adjustment it appeared that 
those reporting no intake or the highest intake had the highest variability in blood 
pressure.  An increase in blood pressure variability with increasing amount of 
alcohol consumed is plausible, considering the acute effects of alcohol on blood 
pressure.  However, increased blood pressure variability in those who reported no 
alcohol intake could be a result of the potential mixed group making up this group.  
Diabetes and blood pressure share some underlying causes and have been shown 
to be linked in a number of ways.  It has been shown that over time, diabetes can 
damage the walls of small vessels and lead to endothelial dysfunction 177–179.  There 
was no difference in mean SBP between those with or without diabetes at baseline, 
but a fairly large mean difference in PP, with diabetic subjects having an adjusted 
mean PP 3.3 mmHg higher than non-diabetic subjects. This is consistent with many 
findings that PP may be the better predictor of new-onset diabetes and morbidities 
associated with diabetes as a result of increased arterial stiffness associated with 
diabetes 180–182.  
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Blood pressure level was strongly correlated with the time of the year.  Blood 
pressure is known to vary over the seasons of the year, particularly in response to 
changes in temperature, exposure to UV light, and due to comorbidities associated 
with different seasons 183.  Some have speculated that changes in blood pressure in 
response to the seasons reflects seasonal variations in other risk factors 152. In 
addition, studies have suggested a direct effect from environmental temperature, 
giving rise to evidence that it is was a strong risk factor for daily blood pressure, 
particularly in older subjects 184.  Cold temperatures can cause vessels to narrow 
and hence increase blood pressure.   
Other studies have also shown that the change in blood pressure level over the 
seasons is greater in older subjects 153.   
There are other changes in behaviours and habits that occur between seasons which 
may also contribute to blood pressure changes, such as reduced physical activity in 
the colder months. 
The number of daylight hours has been shown to positively correlate with blood 
pressure level, independently of environmental temperature 148.   Differences 
between geographical regions might be explained by differing weather conditions.  
Overall, blood pressure was higher in Scandinavian countries compared to the UK.  
Scandinavian countries have a colder climate than the UK and have more extreme 
changes in their daylight hours across the year.  Scandinavian countries tend to 
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have a slightly earlier summer compared to the UK, in that the warmer weather 
tends to be shifted a little earlier.  It appears this is somewhat reflected in the blood 
pressure levels as there is a hint of this with a slightly earlier drop in blood pressure 
in Scandinavian countries.   
Despite having higher blood pressures in general, quite strikingly Scandinavian 
countries had less variability over the seasons compared to the UK.  This is despite 
countries further north having more extreme variation in number of daylight hours 
over the year compared to countries further south in the northern hemisphere. For 
example, Sweden’s daylight hours vary from close to 6 in the winter, to over 17 in 
the summer, while the UK varies between around 8 to 16.5 daylight hours.  It is 
plausible that the variation in vasodilation and hence blood pressure due to 
exposure to colder temperature depends on the underlying temperate.  For 
example, it could be that when overall annual temperatures are colder, such as in 
Scandinavian countries as compared to the UK, the same level of temperature 
variation may have less impact on blood pressure change.  Reduced variability in 
blood pressure in Scandinavian countries could also be a result of differing medical 
care, possible improvements in blood pressure control or better compliance to 
medication compared to the UK.  
Blood pressure levels seemed to vary slightly more between summer and winter in 
those allocated to amlodipine-based treatment, compared to those allocated to 
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atenolol-based treatment.  This might be a little surprising since overall the 
variability in blood pressure was lower in the amlodipine-based arm.   However, 
these differences in blood pressure change between treatment arms were relatively 
small.  This suggests that the lower variability observed in the amlodipine-based 
arm was not linked to impacts on variability associated with seasonality.    
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 Relating blood pressure level and variability to cardiovascular-
related mortality 
4.5.1 Background 
Following investigation into factors that influence blood pressure level and 
variability, an exploration of how these elements relate to CV-related mortality was 
undertaken.  
Firstly, using the arithmetic mean to represent average blood pressure level and the 
SD to represent variability in blood pressure, the relationship between both these 
characteristics of blood pressure were assessed as to their relationship with risk.   
Next, an assessment was made to see how the number of blood pressure measures 
used in the calculation of within-person blood pressure mean and SD impacts on 
the estimate of association that these measures had with risk.  Single blood 
pressure measurements are prone to measurement error both from the equipment 
used to measure and in the inaccuracy in capturing resting blood pressure level.  In 
addition, natural biological fluctuations in blood pressure levels both in the short-
term and over longer periods means that capturing a “usual level” is improved with 
the inclusion of a higher number of measures. So, the inclusion of a higher number 
of measures would likely help to reduce measurement error, and better represent 
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usual underlying blood pressure for a subject, hence potentially strengthening the 
estimated relationship with risk.   
It might seem somewhat intuitive to think that more recent measures may be more 
predictive of future risk compared to more historic measurements, that measures 
further in the past might not be as correlated with future risk as more current 
readings.  For the clinical management of blood pressure, the focus of course would 
be mainly on recent and current blood pressure measurement in order to target 
keeping blood pressure controlled at the current time.  However, there may be 
important insight into being aware of more historic blood pressure when assessing 
patient risk which may also impact patient treatment and care.  It is uncertain which 
blood pressure measurements historically can be most predictive of long-term 
outcomes.  It may be that blood pressure is more predictive when considered in 
relation to specific situations or events.  For example, how much blood pressure 
varies when under stress of changing seasons, or how responsive blood pressure 
levels are to antihypertensive treatment.   
Blood pressure data from the ASCOT legacy cohort allowed the investigation into 
which measurements might be the strongest predictors of risk, assessing baseline 
measurements prior to antihypertensive treatment initiation, assessing early blood 
pressure measurements once subjects had begun treatment and were first 
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responding to treatment, and assessing later measurements when subjects’ blood 
pressure had more time to be controlled.   
The next research question considered was whether risk prediction could be 
improved with alternative representations of blood pressure level and variability 
beyond the representation of these characteristics by the arithmetic mean and SD. 
While the mean and SD are the most commonly used measures to represent these 
characteristics, there may be other measures that could provide better 
discrimination in risk prediction.  In this section a number of alternative measures 
were explored. 
The majority of previous research analysing blood pressure variability has focused 
on the spread around a mean value (e.g. the standard deviation [SD] or coefficient 
of variation [SD/mean]) 136,185.  However, if blood pressure is systematically 
changing with time (for example with increasing age) then this trend won’t be 
captured by the simple measurement of spread around the mean.  Some patterns or 
trends in blood pressure over time might be useful to describe as they may be 
informative in the prediction of risk, over their influence when caught up in a single 
measure of variability around a mean value.  Some researchers have studied 
variability in the context of the residual spread around a linear gradient over time, 
but little seems to be known about how more complex elements of a BP profile 
might help inform on CV mortality-related risk.  
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In the final part of this chapter, the measures of blood pressure level and variability 
that are considered the best are used to create a simple useful clinical model, in 
which both blood pressure level and variability are represented most appropriately, 
alongside other important risk factors.  
4.5.2 Mean blood pressure and standard deviation  
4.5.2.1 Methods 
Using the 5-year time-period as previously defined, from 6 months to 5.5-years 
post randomisation, blood pressure measurements were used to calculate the 
arithmetic mean and SD for each subject, used to represent the blood pressure level 
and variability, respectively.  The relationship between both blood pressure mean 
and SD with CV-related morbidity was explored using adjusted Cox Proportional 
Hazards models in conditional survival analyses beginning from the landmark time-
point of 5.5 years.   
In order to make HRs comparable between different components of blood pressure, 
each component was standardised, i.e. divided by the between subject SD of the 
component, before being modelled.  Hence, the units of the standardised 
components were no longer mmHg but standardised z-scores.  Therefore, 
estimated HRs represented the relative change in hazard per z-score increase.  HRs 
per z-score increase for both within subject mean level and SD were estimated.  
This was done for both SBP and PP.   
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The assumption of linearity in the relationship between risk factor and outcome was 
assessed for blood pressure mean and SD by comparing a model assuming linearity 
to a model where the characteristics of blood pressure were transformed using 
restricted cubic spline transformations, with 3 knots at the 10th, 50th and 90th 
percentiles, where the assumption of linearity was relaxed allowing curvature.  An 
adjusted model containing the blood pressure characteristic of interest modelled as 
a linear variable was compared to an adjusted model containing the blood pressure 
characteristic of interest modelled with a restricted cubic spline transformation 
using a likelihood ratio test, in order to assess the validity of linearity.  
Model fit and discrimination were compared using AIC and the C-statistic from the 
models where the linearity assumption was relaxed. 
All adjusted models were adjusted for the pre-specified baseline risk factors: age; 
sex; BMI; SBP; total cholesterol; smoking status; diabetes status; the age at which 
the subject left full-time education; and ethnicity.   
4.5.2.2 Results 
There was strong evidence that both within-subject SBP mean and PP mean were 
associated with CV-related mortality.  A z-score increase in SBP mean (representing 
a 10.39mmHg increase) was associated with an estimated increase in relative 
hazard of 23% after adjustment (p<0.001, see Table 24).  The effect was stronger 
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for PP, with a z-score increase in PP mean (representing 10.86mmHg) associated 
with an increase in relative hazard estimated at 33% after adjustment (p<0.001).   
Furthermore, as with baseline blood pressure measures explored in Chapter 3, 
there was some, although weak evidence for an interaction between mean blood 
pressure and age (p=0.072 for SBP and p=0.045 for PP).  The relative hazard for a 
z-score increase in mean blood pressure was larger in younger subjects and 
diminished with age for both mean SBP and PP.  For those under the age of 60, the 
HR for a z-score increase in PP was 1.51 (95% CI: 1.31-1.76), while the HR was 1.34 
(95% CI: 1.18-1.52) for SBP.  In the oldest age group, those 70 years and older, the 
HR for a z-score increase in PP was 1.27 (95% CI: 1.15-1.39), while the HR was 
again lower at 1.16 (95% CI: 1.06-1.26) for SBP.   
For both SBP and PP there was weak evidence for a lack of linearity in the 
relationship between mean level and risk (p=0.022 for SBP and p=0.130 for PP).  
When comparing the highest mean blood pressure decile group to the lowest 
quintile group for both SBP and PP, the relative hazard was larger for mean PP at 
2.36 (95% CI: 1.85-3.02) compared to SBP at 1.85 (95% CI: 1.50-2.28, see Figure 
41).  When modelling both means continuously with restricted cubic spline 
transformations to relax the assumption of linearity and allow for curvature, 
discrimination was slightly better from the adjusted model involving PP compared 
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to the adjusted model containing SBP, a C-statistic of 0.732 compared to 0.729, 
respectively (see Table 25).   
There was strong evidence of an association between the SD and risk for both SBP 
and PP, independent of the mean value.  For SD there was also only weak evidence 
for a lack of linearity for both SBP and PP (p=0.175 and p=0.055, respectively).  The 
estimated adjusted HRs for a z-score increase in SD for SBP (representing 
4.72mmHg) and PP (representing 3.22mmHg) was very similar: 1.26 (95% CI: 1.18-
1.34) for SBP; and 1.25 (95% CI: 1.17-1.33) for PP.  In addition, comparing the 
highest decile of SD to the lowest quintile, the HR was slightly larger for SBP 
compared to PP: 2.53 (95% CI: 1.96-3.26) for SBP; and 2.33 (1.82-3.00) for PP.  
Models containing both SD and mean level (along with other pre-specified risk 
factors) discriminated slightly better when using PP (C-statistic 0.741) compared to 
using SBP (C-statistic 0.737).  Relative hazards for each characterisation of blood 
pressure, and for both SBP and PP are plotted in order to visualise the shape of the 
relationships where restricted cubic spline transformations have been used, see 
Figure 40.  
There was fairly strong evidence for interactions between blood pressure SD and 
age (p=0.002 for SBP and p=0.002 for PP).  As was the case with mean level, the 
relative hazard for a z-score increase in the SD of BP was larger in younger subjects 
and attenuated with age for both the SD of SBP and PP.  For those under the age of 
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60, the HR for a z-score increase in the SD of SBP was 1.56 (95% CI: 1.36-1.80), 
slightly larger than for the SD of PP at 1.49 (95% CI: 1.32-1.67).  For the oldest age 
group, those 70 years and older, the HR for a z-score increase in the SD of SBP was 
1.21 (95% CI: 1.11-1.31), slightly smaller than for the SD of PP at 1.23 (95% CI: 
1.14-1.33, see Figure 42).   
While there was no evidence for an interaction between blood pressure mean and 
SD when using SBP (p-value for interaction p=0.303), there was evidence that the 
relationship between the SD of PP with risk was dependent on mean level (p-value 
for interaction p=0.008).  In particular, the relationship (on the relative scale) 
between the SD of PP and risk attenuated with higher PP mean level (see Figure 43).  
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Table 24: Hazard ratios (95% CIs) of CV-related mortality per z-score increase in components of blood pressure level, from 
Cox proportional hazards models 
Characteristic of BP, mmHg From Cox models assuming linear association 
Mean  Z-score Unadjusted HR 
(95% CI) 
p-value Adjusted HR (95% 
CI)* 
p-value 
       
Systolic       
Arithmetic mean  137.11  10.39 1.33 (1.26-1.40) <0.001 1.23 (1.16-1.30) <0.001 
Standard deviation  11.77  4.72 1.45 (1.38-1.53) <0.001 1.26 (1.18-1.34) <0.001 
       
Pulse Pressure       
Arithmetic mean  58.34  10.86 1.68 (1.59-1.77) <0.001 1.33 (1.25-1.42) <0.001 
Standard deviation  8.06  3.22 1.49 (1.43-1.56) <0.001 1.25 (1.18-1.33) <0.001 
*Adjusted for pre-specified baseline risk factors.  For SD, mean level was additionally adjusted for.  
 
Table 25: Comparison of models containing estimates of blood pressure mean and SD with restricted cubic spline 
transformations, from Cox proportional hazards models with CV-related mortality outcome 
Characteristic of BP, mmHg From Cox models with restricted cubic splines 
Effect p-value Linearity p-value AIC C-statistic 
     
Systolic     
Arithmetic mean  <0.001 0.022 17374.71 0.729 
Standard deviation of the mean  <0.001 0.175 17327.90 0.737 
     
Pulse Pressure     
Arithmetic mean  <0.001 0.130 17351.37 0.732 
Standard deviation of the mean  <0.001 0.055 17303.43 0.741 
Each characteristic of BP was modelled using restricted cubic spline transformations with 3 knots (at 10th, 50th, and 
90th percentiles), and adjusted for pre-specified baseline risk factors. For SD, mean level was additionally adjusted for. 
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Figure 40: Plots of adjusted HRs (95% CI) for CV-related mortality for mean and SD modelled with restricted cubic spline 
transformations for SBP and PP, from Cox Proportional Hazards models 
Systolic blood pressure  Pulse Pressure  
Mean level  Mean level 
 
 
SD  SD 
  




Figure 41: Plots of adjusted HRs (95% CI) for CV-related mortality for mean and SD, over intervals of SBP & PP 
 
Note: Q1-Q4 represent quintiles of the data from the lowest quintile to the 4th quintile, respectively.  D9 and D10 represent the top 2 deciles of the data. 
Adjusted HRs for each interval are in relation to the lowest quintile of the data, adjusted for pre-specified risk factors.  
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Figure 42: Adjusted HRs (95% CIs) for mean blood pressure and the SD, by subgroups of age 
Mean blood pressure The SD of blood pressure 
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Figure 43: Adjusted HRs (95% CIs) for the SD of blood pressure, by subgroups 
of blood pressure mean level  
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4.5.3 Assessing how the number of measurements used in the calculation of 
blood pressure level and variability impacts their association with 
cardiovascular-related mortality 
4.5.3.1 Methods 
An investigation was undertaken into how the number of visits that were used in the 
calculation of blood pressure level and variability impacts the association between 
these risk characteristics of blood pressure with CV-related mortality.  The purpose 
was to assess the incremental gain in strength of association with increasing 
numbers of visits used.   
Using only scheduled 6-monthly trial visits spanning 5 years from the 6-month visit 
to the 5.5-year visit (i.e. excluding unscheduled visits), blood pressure level and 
variability were calculated for each individual using blood pressure from a varying 
number of visits.  The arithmetic mean was used to represent blood pressure levels 
and the number of visits used ranged from a single visit to 11 scheduled visits.  The 
SD was used to represent the variability in blood pressure measures across visits, 
and the number of visits used ranged from a minimum of two up to 11.  These 
scheduled visits were all approximately 6 months apart (although there was some 
slight variation).   
A landmark time was defined as the date of the last visit (i.e. date of the 5.5-year 
visit), which formed the beginning of exposure time for the conditional survival 
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analyses.  Subjects were included in this analysis if they had data at all 11 
scheduled visits within this period.  The approach was to consider the landmark 
time as a representation of a clinical visit, with the aim to assess the incremental 
benefit of looking back further and further at previous blood pressure visits, on the 
strength of relationship between both blood pressure level and variability with risk.  
For blood pressure level a single measure was considered as the blood pressure 
level at that final visit at 5.5 years.  As mentioned previously, blood pressure from a 
single visit usually represents the mean of the last two of three repeated 
measurements.  Using two blood pressure visits then took the mean of the last two 
consecutive visits, and so on, until all scheduled visits were included going back in 
time to the 6-month visit.  The same approach was used for calculating the 
variability, but starting with a minimum of the last two visits on which to calculate 
the standard deviation.  Further to this, for both mean level and the SD of blood 
pressure, after all 11 visits were utilised, all other unscheduled visits between the 
6-month and 5.5-year visits were also included along with the 11 scheduled visits 
in the calculations, to see if these additional measures would have any further 
impact.  
Cox PH models were used to estimate HRs per increase in z-score of blood pressure 
mean and SD, using subject-by-subject means and SDs calculated using blood 
pressure measures from the varying numbers of visits.  
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Adjusted models each model adjusted for pre-specified risk factors.  In addition, 
when modelling the exposure of variability, models were adjusted for blood 
pressure level in order to control for the increased risk associated with increased 
blood pressure level, while models were not adjusted for SD when blood pressure 
level was exposure, as previously discussed. 
4.5.3.2 Results 
Out of the 8580 subjects in the ASCOT legacy cohort, there were 3814 subjects 
included in analyses who had blood pressure measurements recorded at all 11 
scheduled trial visits from 6 months to 5.5 years.  The median number of additional 
unscheduled visits within the time-period of observation for this sub-cohort was 
four, ranging from one to 34. 
There was a striking increase in strength of association between blood pressure 
level and CV-related mortality with increasing numbers of visits used. The 
estimated increased risk per z-score of SBP level went from 9.31% when using 
blood pressure from only the last blood pressure visit, to 16.82% when using mean 
blood pressure across all 11 scheduled visits.  It did not appear that the increase in 
strength of association had reached a peak with the use of all 11 visits, with 
additional increase to 19.62% when all available unscheduled visits were also 
included.   
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A similar pattern was observed with PP level, however, the association between PP 
level and CV-related mortality was stronger at every incremental number of visits 
used.  The estimated increased risk per z-score of PP level went from 16.74% when 
using blood pressure only from the last blood pressure visit, to 23.90% when using 
mean blood pressure from all 11 visits.  Again, the increase in strength of 
association did not seem to have hit a limit, and there was a slightly further 
increase to 25.56% when also using unscheduled visits. 
A different pattern was observed with the variability of SBP as there seemed to be a 
peak in magnitude of association with risk from the use of the last six visits.  
Thereafter, the amplification in magnitude of association with further incorporation 
of additional blood pressure data diminished (see Figure 44).  The estimated 
increase in risk per z-score of SBP variability went from 11.35% when using only the 
last two blood pressure visits, to 27.82% when using the last six visits, and did not 
increase any higher thereafter.   
For the variability in PP, there was some additional increase in magnitude of 
association past the use of the last 6 visits, but the incremental gain was 
decelerating.  The estimated increased risk per z-score of PP variability went from 
4.74% when using only the last two blood pressure visits, to 30.93% when using all 
11 visits, but did not increase with inclusion of the unscheduled visits (see Table 
26).   
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Table 26: Model coefficients (SEs) and percentage increase in risk per Z-score increase in blood pressure mean and 
SD using differing numbers of visits, for the outcome of CV mortality 












Mean  SD used in 
Z-score 




score increase  
Systolic blood 
pressure 
         
1 Single visit 132.43 14.59 0.089 (0.043) 9.31     
2 6 months 132.74 12.29 0.095 (0.043) 9.95 8.28 7.46 0.107 (0.040) 11.35 
3  1 year 132.66 11.25 0.089 (0.044) 9.30 9.14 6.23 0.151 (0.041) 16.28 
4 1.5 years 132.93 10.75 0.102 (0.043) 10.69 9.65 5.73 0.196 (0.040) 21.62 
5  2 years 133.02 10.34 0.120 (0.043) 12.73 9.89 5.28 0.226 (0.041) 25.30 
6  2.5 years 133.26 10.00 0.124 (0.043) 13.16 10.16 5.12 0.245 (0.041) 27.82 
7 3 years 133.46 9.70 0.131 (0.042) 13.98 10.36 4.91 0.228 (0.042) 25.59 
8  3.5 years 133.92 9.60 0.133 (0.042) 14.19 10.63 4.85 0.220 (0.043) 24.60 
9  4 years 134.36 9.42 0.145 (0.042) 15.57 10.90 4.76 0.239 (0.043) 26.95 
10  4.5 years 134.95 9.31 0.143 (0.042) 15.35 11.26 4.75 0.224 (0.043) 25.13 
11  5 years 135.73 9.29 0.155 (0.042) 16.82 11.73 4.81 0.241 (0.043) 27.19 
11 plus  5 years 136.37 9.29 0.179 (0.043) 19.62 11.85 4.52 0.231 (0.046) 25.94 
Pulse pressure          
1 Single visit 57.05 12.90 0.152 (0.045) 16.47     
2 6 months 56.78 11.72 0.180 (0.047) 19.74 5.84 5.17 0.047 (0.041) 4.76 
3  1 year 56.78 11.14 0.175 (0.047) 19.15 6.49 4.26 0.131 (0.040) 13.96 
4 1.5 years 56.63 10.89 0.176 (0.047) 19.28 6.83 3.94 0.184 (0.041) 20.19 
5  2 years 56.65 10.67 0.189 (0.047) 20.80 7.00 3.60 0.193 (0.042) 21.30 
6  2.5 years 56.58 10.50 0.188 (0.047) 20.67 7.17 3.47 0.225 (0.042) 25.26 
7 3 years 56.63 10.37 0.195 (0.047) 21.50 7.27 3.33 0.229 (0.043) 25.72 
8  3.5 years 56.72 10.36 0.197 (0.047) 21.78 7.42 3.27 0.233 (0.043) 26.18 
9  4 years 56.90 10.30 0.205 (0.047) 22.79 7.57 3.22 0.255 (0.043) 28.99 
10  4.5 years 57.08 10.29 0.204 (0.047) 22.68 7.74 3.22 0.248 (0.043) 28.14 
11  5 years 57.37 10.35 0.214 (0.047) 23.90 7.93 3.22 0.270 (0.043) 30.93 
11 plus  5 years 57.82 10.46 0.228 (0.047) 25.56 8.02 2.98 0.263 (0.046) 30.13 
*Adjusted for pre-specified baseline risk factors.  For SD of the mean, mean level was additionally adjusted for.  
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Figure 44: Hazard ratios (95% CI) for CV-related mortality per z-score increase 
in blood pressure level and variability using differing numbers of scheduled BP 
visits 
Systolic blood pressure Pulse pressure 
Mean  
  
Standard deviation  
  
 
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
249 
 
4.5.4 Comparing the association of recent blood pressure measures to historic 
measures with cardiovascular-related mortality  
4.5.4.1 Methods 
As in the previous section, ASCOT legacy subjects who had blood pressure 
measures taken at all 11 scheduled visits from the 6-month visit to the 5.5-year 
visit were included in this analysis.  
Firstly, blood pressure from each of the 11 single scheduled visits was used to 
separately estimate the relationship between blood pressure level and CV-related 
mortality.  In addition to the 11 post-treatment visits, the blood pressure from 
baseline (pre-treatment) was also assessed for comparison to individual post-
treatment initiation visits (note that baseline, pre-treatment blood pressure 
measures are not used in any other analyses in this chapter).  Blood pressure from 
each visit was used in separate adjusted Cox proportional hazards models, adjusted 
for pre-specified baseline risk factors.  Estimated adjusted HRs per SD increase (z-
score) in blood pressure when using measures from each of the 11 visits and the 
baseline visit were compared as to their magnitude, and presented graphically.   
Secondly, each individual’s blood pressure mean and SD was calculated only on 
blood pressure from the first 5 visits (i.e. from the 6-month visit to the 2.5-year 
visit), and then separately only on blood pressure measured from the last 5 visits 
(i.e. the 3.5-year visit to the 5.5-year visit, baseline).  Both calculated blood 
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pressure means were put into the same adjusted Cox proportional hazards model, 
and both calculations of the SD of blood pressure were put into another adjusted 
Cox proportional hazards model.  Each model was again adjusted for pre-specified 
baseline risk factors, and when estimating the effect of the SD of blood pressure, 
both blood pressure means were adjusted for in those models.  These analyses 
were repeated for SBP and PP. 
4.5.4.2 Results 
Using individual scheduled visits from 3814 subjects that had blood pressure from 
each scheduled visit from the 6-month to the 5.5-year visit, HRs per z-score 
increase in SBP ranged from around 1.05 to 1.16.  There were a number of single 
visits from which the association between SBP measures with risk was fairly week at 
the 5% level.  There appeared to be a suggestion that SBP from earlier visits tended 
to have a slightly stronger relationship with risk (see Figure 45).  Overall, the 
associations between PP levels with risk were higher than for SBP, with HRs ranging 
from around 1.13 to 1.21 per z-score increase in PP.  For PP from each individual 
visit, there was strong evidence of an association with risk.  As with SBP, there 
appeared to be a slight hint that PP level from earlier visits tended to have a slightly 
stronger relationship with risk, in these conditional survival analyses.   
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It is worth noting that the pre-treatment (baseline) measurements were not the 
strongest predictors of risk in this sub-cohort surviving until 5.5 years post 
randomisation, compared to blood pressure from other single clinical visits.     
When blood pressure mean from early and late sets of visits were modelled 
together, for both SBP and PP, the mean calculated from the earlier visits had a 
stronger association with risk compared to mean calculated from the later visits 
when both means were present in one model.  For SBP, the adjusted HR was 1.15 
(95% CI: 1.04-1.27) for the mean from earlier visits and 1.03 (95% CI:0.93-1.15) for 
the mean from later visits.  For PP, the adjusted HR was 1.20 (1.05-1.38) for the 
mean from earlier visits and 1.05 (0.91-1.21) for the mean from later visits.   
The opposite was found for the SD, with SD calculated on the later five visits being 
more strongly associated with risk compared to SD calculated on the earlier five 
visits when both calculated SDs were present in one model.  This was the case for 
both SBP and PP (see Table 27 and Figure 46Figure 44).  
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Figure 45: Hazard ratios (95% CI) for CV-related mortality per z-score increase 
in blood pressure from single scheduled visits 
Systolic blood pressure Pulse pressure 
  
 
Table 27: Adjusted HRs (95% CI) per z-score increase in mean blood pressure 
and SD from early and late visits, for SBP and PP 
 Level (mean) Variability (standard deviation) 
Visits 
included  
Mean (SD) Adjusted HR 
(95% CI)* 
p-value Mean (SD) Adjusted HR 
(95% CI)* 
p-value 
       
SBP       
First 5  137.56 (10.96) 1.15 (1.04-1.27) 0.005 10.73 (5.57) 1.05 (0.96-1.15) 0.251 
Last 5 133.02 (10.34) 1.03 (0.93-1.15) 0.519 9.89 (5.28) 1.23 (1.13-1.34) <0.001 
       
PP       
First 5  57.99 (11.22) 1.20 (1.05-1.38) 0.009 7.40 (3.80) 1.09 (1.00-1.19) 0.052 
Last 5 56.65 (10.67) 1.05 (0.91-1.21) 0.530 7.00 (3.60) 1.19 (1.09-1.29) <0.001 
*Adjusted for pre-specified baseline risk factors.  For SD of the mean, mean level (from both periods) 
was additionally adjusted for.  
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Figure 46: Forest plot of adjusted HRs (95% CI) per z-score increase in mean 
blood pressure and SD from early and late visits, for SBP and PP 
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4.5.5 Consideration of alternative representation of blood pressure level and 
variability  
4.5.5.1 Introduction 
While the arithmetic mean and SD are the most commonly used representations of 
usual blood pressure level and variability, there are many other possible measures 
that might be of prognostic value.  In this section alterative measures of blood 
pressure level and variability are considered.  Assessments are made as to their 
relationship with CV-related mortality and their predictive ability.  The purpose of 
this analysis is to investigate whether alternative measures to represent blood 
pressure level and variability can improve prediction over that of the arithmetic 
mean and SD.   
Alternative representations of variability were considered, those that are less 
correlated with mean level than SD, variation independent of linear trend, and other 
representations of variation in blood pressure.  
In addition, other aspects that characterise blood pressure profiles such as 
maximum (peak) blood pressure and rate of change in blood pressure over time 
were investigated.  
  




Using the 5-year time-period previously defined, blood pressure measurements 
collected at scheduled and unscheduled visits were used to estimate various 
representations of subjects’ blood pressure level and variability.  These estimates 
for each subject were then each explored as to their relationship with CV-related 
morbidity, in survival analyses beginning from the landmark time-point of 5.5-
years post-randomisation.  Cox PH models were used, and adjusted models 
included pre-specified risk factors.   
4.5.5.2.1 Estimating characteristics of blood pressure level on a subject-by-subject 
basis 
In most research, blood pressure levels and variability have been estimated on a 
subject-by-subject basis, i.e. an estimate is calculated on individuals’ data alone.    
While usual blood pressure is most often taken to be the arithmetic mean, there are 
alternative approaches to characterising blood pressure level.  The arithmetic mean 
does not account for the timings that each blood pressure measurement was taken.  
Hence, a “time-dependent mean” uses the area under a blood pressure-time graph 
to estimate a level which accounts for the timing of measurements (assuming 
linearity of blood pressure level between any 2 consecutive visits).  The time-
dependent mean was calculated using the trapezoidal rule with the formula: 











In addition to an estimate of usual blood pressure level, the overall rate of change 
was considered.  Ordinary least squares regression was used on each individual’s 
set of blood pressure measurements in order to calculate the gradient over time as 
well as an estimate of the blood pressure level at the mid-point over the 5-year 
observation period. 
Blood pressure level from the single visit where the highest blood pressure level 
was recorded in the observation period was also investigated, representing the 
maximum or peak blood pressure.  In order to try to capture a slightly more stable 
maximum blood pressure, the mean of the two visits at which blood pressure was 
highest was also evaluated. 
4.5.5.2.2 Estimating characteristics of blood pressure level involving all individuals 
using random effects 
Measures that are estimated on a person-by-person basis are prone to 
considerable measurement error, which can lead to regression dilution bias 
between the estimated association between blood pressure measures and mortality 
risk.  As previously discussed and investigated in this chapter, the use of repeated 
blood pressure measures can improve accuracy in estimating attributes of blood 
pressure and hence reduce regression dilution bias.   
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In addition to utilising repeated individual blood pressure measurements, to help 
reduce regression dilution bias, mixed effects models have been proposed, which 
allow the borrowing of information across individuals 186.  This in turn can lead to 
less error in the estimation of the true value of the blood pressure characteristic for 
a particular individual, and hence can lead to reduced bias in the estimation of 
association with CV-related mortality risk. 
A linear mixed effects model with a random component for each subject was used 
to estimate within-individual mean level over the observation period.  A second 
mixed effects model with a random component for each subject and a random 
component for time (in order to allow each subject to have their own level and 
gradient over time) and a fixed effect of time was used to model the trajectory of 
slope (gradient) for each individual, along with predicted blood pressure level at the 
mid-point during the 5-year observation period.  These estimates from mixed 
effects models are referred to as best linear unbiased predictions (BLUPs).  
4.5.5.2.3 Estimating characteristics of blood pressure variability  
The first alternative representation of blood pressure variability to be assessed was 
the coefficient of variation (COV).  The COV is defined as the SD divided by the 
mean value.  Hence, as this measure of variability has been scaled by the magnitude 
of the mean the strength of correlation with mean level is reduced.  The COV is a 
proportion, the magnitude of the SD compared to the mean.  
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Because the COV can still be slightly correlated with mean level, the variation 
independent of the mean (VIM) was also calculated for each subject.  The VIM is 




The value of p for SBP and PP was determined through curve fitting, i.e. an iterative 
process to find the value of p at which the correlation between mean level and VIM 
is closest to zero (to 3 DPs). 
The variability independent of linear trend was next considered.  This was 
calculated by fitting a linear relationship between blood pressure measurements 
and time using OLS regression on each individual’s blood pressure profile over the 
5-year observation period.  The root mean square error (RMSE) was calculated as 
the square root of the sum of squared differences from each observed blood 
pressure measure (𝑦𝑖) and the predicted (ŷ𝑖), divided by the number of blood 
pressure measures used in the calculation minus two: 
𝑅𝑀𝑆𝐸 =  √
(ŷ𝑖 − 𝑦𝑖)
2
(𝑛 − 2)⁄  
Next, the mean absolute difference in blood pressure between all chronologically 
consecutive blood pressure visits was investigated.  This is known as the average 
real variability (ARV).  This measure of variability considers the order in which the 
blood pressure measurements across visits were taken.   
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Lastly, the range was considered, i.e. the difference between the highest blood 
pressure from a single visit and the lowest blood pressure from a single visit.  This 
approach utilised only the maximum and minimum blood pressure visits only and 
discarded all other data.   
4.5.5.2.4 Relating blood pressure level, variability, and other attributes to 
cardiovascular-related mortality 
Each type of representation of subjects’ blood pressure level, variability, or other 
attribute was related to CV-related mortality using Cox PH survival models.  
Exposure time began from the landmark time of 5.5-years post-randomisation.  
Estimates of each individual’s blood pressure level, variability, and other attributes 
were standardised (converted to a z-score by subtracting the overall between-
subject mean and dividing by the between-subject SD of that particular measure).  
Crude and adjusted HRs for CV-related mortality were estimated representing the 
relative difference in hazard per z-score increase in each representation of blood 
pressure level, variability, and other attributes, assuming linearity.   
Adjusted models were adjusted for the aforementioned pre-specified risk factors.  
As with SD and mean level, models assessing blood pressure level were not 
adjusted for a component of variability.  However, models assessing blood pressure 
variability were adjusted for a measure of blood pressure level in order to estimate 
the effect of blood pressure variability independent of blood pressure level.   
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Analyses involving rate of change in blood pressure over time were always executed 
in conjunction with blood pressure level, represented as the predicted blood 
pressure level at the mid-point of the 5-year observation period.  The mid-point 
was chosen in an attempt to have a level of blood pressure which was likely to be 
the least correlated with the slope, as opposed to the predicted blood pressure level 
at either the beginning or end of the period.  
The assumption of linearity was assessed for each measure of blood pressure level, 
variability, and other attributes by comparing a model assuming linearity to a model 
with a restricted cubic spline transformation where the assumption of linearity was 
relaxed (as described in previous sections).  Model fit and discrimination were 
compared between models using AIC and the C-statistic from the models where the 
linearity assumption was relaxed.  
Once again, these analyses were repeated both for SBP and PP. 




4.5.5.3.1 Relating alternative representations of blood pressure level to 
cardiovascular-related mortality 
In order to visualise some subject blood pressure profiles, Figure 47 presents the 
SBP readings over the 5-year observation period for three ASCOT legacy subjects, 
illustrating how measures of blood pressure level can vary depending on the shape 
of the profile.  Subject A has an arithmetic mean SBP, SD, and gradient, all very 
close to the overall cohort between subject mean values (138.65 mmHg, 11.96 
mmHg, and -1.62 mmHg, respectively).  For this subject both the arithmetic and 
time-dependent mean were similar.  The measures have lot of variability early on, 
for example the first three measurements within 6-months of each other vary from 
125 mmHg to 173 mmHg.  The maximum value of 173 mmHg seems to be a bit of 
an extreme outlier in this case. 
Subject B has a gradient which is very close to zero (-0.26 mmHg per year), but has 
fairly high variability in SBP with a SD of 20.17 mmHg.  The arithmetic and time-
dependent mean were also very similar for this subject.    
Subject C has a very steep decreasing gradient over time (-22.85 mmHg per year).  
This extreme downward trend has a fairly convincing tight set of blood pressure 
measurements around it.  For this subject the earlier values were close to the 
maximum level, and similarly the latest values were close to the minimum value.  
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The time-dependent mean was lower than the arithmetic mean for this subject as it 
appeared the decline in SBP was slightly steeper initially before becoming less steep 
towards the end of the period and hence the time-dependent mean was pulled 
lower than the arithmetic mean.   
In each scenario it might be that the most important indicator of CV-mortality risk 
could be different.  In some cases, the means may be most important, for Subject A 
and Subject B for example.  While for Subject C, because they have such a steep 
decreasing SBP, possibly the maximum or first value might be important as they 
may more closely represent how high the subject’s blood pressure levels were early 
on.   For subject A, the maximum value looks to be quite an extreme outlier, and so 
might may not represent the true peak, but might be a result of measurement error 
or indeed an important true fluctuation in blood pressure.  Hence in that case, the 
mean of the two highest blood pressure measures may represent a truer maximum 
value.  
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
263 
 
Figure 47: Plots of SBP profiles over time in 3 selected ASCOT Trial subjects, highlighting different characteristics 
of BP level and gradient 
Subject A Subject B Subject C 
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The arithmetic mean was highly correlated with the time-dependent mean (r=0.979 
and r=0.991, for SBP and PP, respectively).  The time-dependent mean had a very 
similar distribution to the arithmetic, but with slightly lower overall between-
subject mean for both SBP and PP.  The magnitude of the HRs per z-score were 
slightly lower with the time-dependent mean compared to the arithmetic (for SBP: 
HR=1.23 for arithmetic and 1.20 for time-dependent; and for PP: HR=1.33 for 
arithmetic and 1.31 for time-dependent, see Table 28).   
Similarly, to the arithmetic mean, for SBP there was some evidence of a non-linear 
relationship between the time-dependent mean and hazard of CV-related mortality 
(p=0.022).  There was less evidence of non-linearity for the PP time-dependent 
mean (p=0.068). 
From models with RCS transformations, model fit and discrimination were very 
similar between the time-dependent and arithmetic means, but marginally better 
for the arithmetic mean for both SBP and PP (see Table 29).  
The BLUP estimates for mean level were highly correlated with the arithmetic mean 
calculated on a subject-by-subject basis: r=0.996 and r=0.999, for SBP and PP, 
respectively, and had almost identical mean values.  However, BLUP mean 
distributions were narrower than the arithmetic mean distributions for both SBP and 
PP.  The SDs were 8.89 mmHg vs. 10.39 and 10.25 mmHg vs. 10.86 mmHg, 
comparing the BLUP mean to subject-by-subject arithmetic means for SBP and PP, 
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respectively.  When calculating a mean on a subject-by-subject basis, there is more 
possibility for error and for extreme mean values to be estimated, particularly if a 
subject has few blood pressure measurements, while this is reduced in the 
estimates of BLUP means since they are estimated considering the distribution of 
means over all subjects assuming means are normally distributed between subjects. 
The range for the SBP arithmetic means was 107.45-216.00 mmHg and 111.16-
190.58 mmHg for the BLUP means.  The subject with the high arithmetic mean of 
216 mmHg had blood pressure measurements from only four visits over the 5 years 
which were all within a 3-month period.  Therefore, it is likely that this high 
estimate of SBP level might be somewhat inflated.   
While estimates from mixed models led to BLUP blood pressure means that were 
more normally distributed compared to the subject-by-subject arithmetic means, 
ultimately there appeared to be no gain in predictive ability, the strength of 
relationship with CV-related mortality was no stronger.   
Blood pressure from a single visit when blood pressure was highest over the 5-year 
period of observation (maximum blood pressure) had a slightly stronger association 
with CV-related mortality than each of the estimated mean level characteristics, for 
both SBP and PP.  The HR was 1.26 for SBP and 1.37 for PP per z-score increase in 
maximum blood pressure value.  The mean of the highest blood pressure measures 
from two visits during the observation period was also as strong a predictor as 
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maximum level, but made little improvement over the maximum single measure.  
There was no evidence against linearity for maximum blood pressure level for SBP 
or PP.  Using maximum blood pressure, the fit and discrimination of models was 
slightly better than for any other representation of blood pressure level.   
The patterns of magnitude of relationship between the different representations of 
blood pressure level with risk were consistent between SBP and PP.  However, for 
each representation of blood pressure level the estimated HR was consistently 
larger for PP than it was for SBP, per z-score increase in the component measure.  
For each representation of blood pressure level, model fit and discrimination were 
also superior with PP when modelled with RCS transformation to relax the 
assumption of linearity (see Table 29).  
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Table 28: Hazard ratios (95% CI) of CV-related mortality per z-score increase in components of blood pressure level, 
from Cox proportional hazards models 
Characteristic of blood 
pressure profile, mmHg 
 





Unadjusted HR (95% CI) p-value Adjusted HR (95% CI)* p-value 
        
Systolic blood pressure        
Arithmetic mean  137.11  10.39 1 1.33 (1.26-1.40) <0.001 1.23 (1.16-1.30) <0.001 
Time-dependent mean 135.68  10.21 0.979 1.28 (1.22-1.35) <0.001 1.20 (1.14-1.27) <0.001 
Maximum value 158.98  17.25 0.807 1.42 (1.34-1.50) <0.001 1.26 (1.19-1.33) <0.001 
Mean of max 2 values  155.38  15.84 0.850 1.43 (1.36-1.51) <0.001 1.27 (1.20-1.35) <0.001 
Mean level (BLUP) 137.13 8.89 0.996 1.33 (1.26-1.40) <0.001 1.23 (1.16-1.30) <0.001 
        
Pulse pressure        
Arithmetic mean 58.34  10.86 1 1.68 (1.59-1.77) <0.001 1.33 (1.25-1.42) <0.001 
Time-dependent mean 57.53  10.64 0.991 1.64 (1.56-1.73) <0.001 1.31 (1.23-1.40) <0.001 
Maximum value 73.28  15.36 0.899 1.70 (1.62-1.80) <0.001 1.37 (1.29-1.46) <0.001 
Mean of max 2 values  70.79  14.45 0.928 1.72 (1.63-1.81) <0.001 1.37 (1.29-1.46) <0.001 
Mean level (BLUP) 58.35 10.25 0.999 1.68 (1.60-1.78) <0.001 1.33 (1.25-1.42) <0.001 
* Adjusted for pre-specified baseline risk factors  
BLUP: best linear unbiased prediction (estimated from mixed effects model). 
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Table 29: Comparison of models containing different representations of blood pressure level with restricted cubic 
spline transformations, from Cox proportional hazards models with CV-related mortality outcome 
Characteristic of blood pressure profile, 
mmHg 
From Cox models with restricted cubic splines 
Effect p-value Linearity p-value AIC C-statistic 
     
Systolic blood pressure      
Arithmetic mean  <0.001 0.022 17374.71 0.729 
Time-dependent mean <0.001 0.022 17383.92 0.727 
Maximum value <0.001 0.524 17365.28 0.731 
Mean of max 2 values  <0.001 0.244 17361.22 0.732 
Mean level (BLUP) <0.001 0.022  17376.26 0.729 
     
Pulse pressure      
Arithmetic mean <0.001 0.130 17351.37 0.732 
Time-dependent mean <0.001 0.068 17357.48 0.731 
Maximum value <0.001 0.573 17335.49 0.735 
Mean of max 2 values  <0.001 0.735 17336.99 0.735 
Mean level (BLUP) <0.001 0.150 17353.01 0.731 
Each characteristic of blood pressure profile was modelled using restricted cubic spline transformations with 3 knots (at 
10th, 50th, and 90th percentiles), and adjusted for pre-specified baseline risk factors.  
BLUP: Best linear unbiased prediction (estimated from mixed effects model). 
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The mean rate of change in SBP per year was -1.70 mmHg and in PP was -0.47 
mmHg.   After adjustment for blood pressure at the mid-point in the 5-year 
observation period and pre-specified baseline risk factors, the HR per increase in z-
score in gradient was similar for SBP and PP: 0.79 (p<0.001) and 0.78 (p<0.001), 
respectively.  This means that risk was estimated to be lower when the gradient was 
higher, after adjustment.  In this context, when denoting to an “higher” gradient, 
this refers to the numeric value of the gradient being higher, not necessarily the 
steepness of the slope.     
Once adjusted for the gradient (and other pre-specified risk factors), the blood 
pressure level estimated at the mid-point in the 5-year observation period had a HR 
per increase in z-score of 1.32 (p<0.001) and 1.41 (p<0.001) for SBP and PP, 
respectively.  As was seen with other measures of blood pressure level, PP had the 
stronger relationship with risk (see Table 30).  For both SBP and PP, after 
adjustment, the blood pressure level at the mid-point calculated from OLS 
regression on a subject-by-subject basis had a larger HR per z-score than any 
other representation of blood pressure level, for both SBP and PP.   
Blood pressure level at the mid-point and gradient were highly correlated.  A higher 
blood pressure level was associated with a higher gradient (r=0.707 for SBP and 
r=0.625 for PP).  Gradient had a weak relationship with CV-related mortality when 
unadjusted, but was confounded by blood pressure level since lower gradient 
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indicated a lower blood pressure level on average.  Once adjusted for blood 
pressure level, there was evidence for a relationship between the gradient and CV 
mortality, with no evidence against linearity for the measures calculated by OLS on a 
subject-by-subject basis.  There was no evidence of an interaction between blood 
pressure level and gradient estimated by OLS regression for either SBP or PP 
(interaction tests p=0.976 for SBP and p=0.823 for PP).  
Calculating gradients on a subject-by-subject basis was problematic, however, 
because this led to many very extreme gradient values calculated.  The distribution 
of gradients had extremely long tails and ranged from -87.47 to 214.11 mmHg per 
year for SBP, with a kurtosis of 420.60.  Hence, the z-score that was calculated for 
the gradient was very large and as a result the estimated HR for an increase in 
gradient per z-score is hard to interpret and compare to other characteristics of 
blood pressure since the distributions were so widely spread.  Similarly, the 
distribution of blood pressure level at the mid-point was heavily kurtosed and 
ranged from, the impossible, -46.77 mmHg to, the implausible, 780.82 mmHg for 
SBP (kurtosis was 539.98).  Extreme estimates of blood pressure gradient and blood 
pressure level are also highly influential, and so these results are likely unreliable 
and misleading.  
As expected, BLUP blood pressure level at mid-point and blood pressure gradient 
were much more normally distributed than those calculated from OLS on a subject-
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by-subject basis, since that is the assumption made about these characteristics in 
the random effects models with random components for subject and time.  
Estimates were less extreme and more realistic.  For SBP the level at the mid-point 
ranged from 95.36 mmHg to 215.73 mmHg, with a kurtosis of 5.60, still a little 
wider than a perfect normal distribution of 3, but much closer.  For BLUP gradient 
the distribution ranged from -11.38 to 5.43 mmHg per year (kurtosis was 5.58) for 
SBP.   
After adjustment for BLUP blood pressure level at the mid-point in the 5-year 
observation period and pre-specified baseline risk factors, the HR per increase in z-
score in BLUP gradient was similar when using SBP and PP, and for both the 
estimated effect was reduced compared to using these characteristics calculated on 
a subject-by-subject basis: 0.93 (p<0.001) and 0.95 (p=0.091), respectively.  Still a 
hint of an association between gradient and risk estimated, with higher risk in those 
with lower value gradient.   
Once adjusted for BLUP blood pressure gradient (and other pre-specified risk 
factors), the BLUP blood pressure at the mid-point in the 5-year observation period 
had a HR per increase in z-score of 1.24 (p<0.001) and 1.34 (p<0.001) for SBP and 
PP, respectively.  These HRs were very similar in magnitude to those estimated when 
using the arithmetic mean.   
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There was, however, more evidence for lack of linearity of gradient with the BLUP 
measures (see Table 31).  For both SBP and PP, the lack of linearity was such that at 
higher value gradients, the relationship between gradient and risk attenuated.  
When assessing only gradients that were above zero (positive increasing blood 
pressure trend), there was no evidence of an effect for both SBP and PP.  It seemed 
that the relationship of decreased risk per increase in blood pressure gradient was 
stronger the more negative the blood pressure gradients.  
There was also some evidence for interactions between BLUP estimates of blood 
pressure gradient and blood pressure level, when modelled with RCS 
transformations to allow for curvature (interaction test p=0.043 for SBP, and 
p=0.038 for PP).  For example, to illustrate, for higher blood pressure levels the 
association of decreased risk with increasing blood pressure gradient became 
weaker.  At higher blood pressure levels, for example above 140 mmHg for SBP 
and, there was no longer evidence for a relationship between gradient and risk.  
For both SBP and PP, there was some slight improvement in discrimination and 
model fit when using the BLUP blood pressure level and gradient compared to the 
models containing the arithmetic mean calculated on a subject-by-subject basis, 
and to the models containing the BLUP mean estimates (see Table 31).     
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
273 
 
Table 30: Hazard ratios (95% CI) of CV-related mortality per z-score increase in component of blood pressure level & 
gradient, from Cox proportional hazards models 
Characteristic of BP profile, 
mmHg 
  From Cox models assuming linear association  




p-value Adjusted HR (95% 
CI)* 
p-value Adjusted HR (95% 
CI)** 
p-value 
Systolic blood pressure (mmHg)         
BP level at mid-point 135.57 17.04 1.07 (1.04-1.10) <0.001 1.46 (1.36-1.56) <0.001 1.32 (1.22-1.42) <0.001 
Gradient (change per year) -1.70 6.22 0.92 (0.86-0.99) 0.018 0.70 (0.65-0.76) <0.001 0.79 (0.73-0.85) <0.001 
BLUP BP level at mid-point 136.59 9.09 1.31 (1.24-1.39) <0.001 1.37 (1.29-1.45) <0.001 1.24 (1.17-1.32) <0.001 
BLUP gradient (change per year) -1.90 1.26 0.97 (0.91-1.03) 0.337 0.87 (0.82-0.93) <0.001 0.93 (0.88-0.99) <0.001 
Pulse pressure (mmHg)         
BP level at mid-point 57.80 15.08 1.22 (1.10-1.14) <0.001 1.84 (1.73-1.96) <0.001 1.41 (1.30-1.52) <0.001 
Gradient (change per year) -0.47 4.64 0.96 (0.89-1.03) 0.275 0.62 (0.59-0.66) <0.001 0.78 (0.73-0.84) <0.001 
BLUP BP level at mid-point 58.14 10.31 1.68 (1.59-1.77) <0.001 1.70 (1.61-1.80) <0.001 1.34 (1.26-1.43) <0.001 
BLUP gradient (change per year) -0.57 1.00 1.01 (0.95-1.08) 0.743 0.92 (0.87-0.97) 0.003 0.95 (0.90-1.01) 0.091 
* Adjusted for the other blood pressure profile characteristic. 
** Adjusted for pre-specified baseline risk factors, and the other blood pressure profile characteristic. 
BLUP: best linear unbiased prediction (estimated from mixed effects model). 
 
  
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
274 
 
Table 31: Comparison of models containing estimates of blood pressure level and rate of change with restricted 
cubic spline transformations, from Cox proportional hazards models with CV-related mortality outcome 
Characteristic of blood pressure 
profile, mmHg 






Systolic blood pressure (mmHg)     
BP level at mid-point <0.001 0.764 17380.36 0.728 
Gradient (change per year) <0.001 0.430   
BLUP BP level at mid-point <0.001 0.044 17368.35 0.731 
BLUP gradient (change per year) <0.001 0.002   
Pulse pressure (mmHg)     
BP level at mid-point <0.001 0.979 17354.22 0.732 
Gradient (change per year) <0.001 0.151   
BLUP BP level at mid-point <0.001 0.156 17342.01 0.734 
BLUP gradient (change per year) <0.001 <0.001   
Each characteristic of blood pressure profile was modelled using restricted cubic spline transformations with 3 knots (at 10th, 
50th, and 90th percentiles), and adjusted for pre-specified baseline risk factors and the other blood pressure profile 
characteristic. 
BLUP: best linear unbiased prediction (estimated from mixed effects model). 
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4.5.5.3.2 Relating alternative representations of blood pressure variability to 
cardiovascular-related mortality 
Figure 48 presents SBP profiles for the same three subjects presented previously in 
Figure 47.  The plots illustrate how these measures of blood pressure variability can 
differ depending on the shape of the profile.  Subject A had an SD and RMSE fairly 
close to the overall mean values (11.96 mmHg, and 12.04 mmHg, respectively).   
In comparison to Subject B and Subject C, the range for Subject A was wider in 
comparison to the other measures, as the range for Subject A was influenced by the 
maximum point which appeared to be somewhat of an outlier.  The SD and RMSE 
are less influenced by single outliers as the number of observations increases.   
Because of the steep negative gradient for Subject C (-22.85 mmHg per year) the SD 
was close to double that of RMSE (39.51 mmHg and 19.56 mmHg, respectively).  In 
addition, the ARV was small for Subject C since the changes in blood pressure from 
one visit to the next were not so extreme because they followed an overall decline 
over time, as opposed Subject B who had large fluctuations with little overall trend.  
In contrast, Subject B had almost identical SD and RMSE, since their slope was close 
to zero. 
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Figure 48: Plots of SBP profiles over time in 3 selected ASCOT Trial subjects, highlighting different characteristics 
of blood pressure variability  
Subject A Subject B Subject C 
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As with SD, which showed strong evidence of an association with CV-related 
mortality independent of the mean, each alternative representation of blood 
pressure variability also had strong evidence of an association independent of mean 
level (or independent of blood pressure level at mid-point and slope for RMSE).   
While each alternative representation of variability of SBP had a similar strength of 
association with CV-related mortality (a similar magnitude of HR per z-score 
increase), none had higher than with SD. This pattern was similar for PP, except that 
the COV and VIM of PP had very slightly larger HRs compared to the SD (both had 
HR=1.26 compared to HR=1.25, respectively, see Table 32).  
As expected the COV was less correlated with the mean compared to SD for both 
SBP and PP, however, while the correlation went from 0.407 for the SD of SBP down 
to 0.216 for the COV of SBP with mean SBP level, for PP the correlation went from 
0.498 for the SD down to almost zero, r=0.025, for the COV of PP with mean PP 
level.  Hence, the VIM for PP was very similar to the COV, with the power p 
estimated at 1.046 (to three DPs).  While the power p for SBP was estimated to be 
2.025 (to three DPs).   
The ARV had the weakest association with CV-related mortality risk, with the 
smallest HRs of 1.18 for SBP and 1.17 for PP.  There was little evidence against 
linearity for any representations of blood pressure variability except for ARV 
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(p=0.016 for both SBP and PP), as well as some weak evidence against linearity for 
the SD of PP (as previously mentioned, p=0.055).   
For both SBP and PP, model fit and discrimination were very slightly better for 
adjusted models containing SD, COV, or VIM compared to other representations of 
blood pressure variability, all of which were adjusted for mean level except for RMSE 
which was adjusted for blood pressure level at the mid-point and gradient (from 
models where linearity assumption was relaxed, see Table 33).  Even an adjusted 
model including RMSE, blood pressure level at mid-point, and gradient, did not 
improve prediction over that of an adjusted model with mean level and SD (or 
COV/VIM), all adjusted for the same pre-specified risk factors.  
While PP was the stronger predictor of CV-related mortality compared to SBP when 
it came to each representation of blood pressure level, maximum blood pressure, or 
slope, there was little difference between SBP and PP in the magnitude of 
relationship between each representation of blood pressure variability and CV-
related mortality.  However, adjusted models with both a representation of blood 
pressure level and blood pressure variability (and slope in the case of RMSE) had 
better goodness-of-fit and discrimination when using the PP component of blood 
pressure compared to SBP (see Table 33).    
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Unadjusted HR  
(95% CI) 
p-value Adjusted HR  
(95% CI)* 
p-value Adjusted HR  
(95% CI)** 
p-value 
Systolic          
SD (mmHg) 11.77  4.72 1 1.45 (1.38-1.53) <0.001 1.36 (1.28-1.44) <0.001 1.26 (1.18-1.34) <0.001 
COV (x102) 8.53 3.17 0.977 1.42 (1.35-1.50) <0.001 1.35 (1.28-1.43) <0.001 1.25 (1.18-1.33) <0.001 
VIM (x104) 5.50 2.00 0.901 1.36 (1.28-1.43) <0.001 1.36 (1.28-1.44) <0.001 1.26 (1.19-1.33) <0.001 
RMSE (mmHg) 11.03  4.44 0.923 1.41 (1.34-1.48) <0.001 1.32 (1.25-1.40) <0.001 1.23 (1.16-1.31) <0.001 
ARV (mmHg) 11.81  4.93 0.826 1.35 (1.29-1.41) <0.001 1.26 (1.20-1.33) <0.001 1.18 (1.12-1.25) <0.001 
Range (mmHg) 40.90  17.66 0.926 1.42 (1.35-1.50) <0.001 1.33 (1.25-1.41) <0.001 1.21 (1.14-1.29) <0.001 
Pulse Pressure          
SD (mmHg) 8.06  3.22 1 1.49 (1.43-1.56) <0.001 1.26 (1.19-1.33) <0.001 1.25 (1.18-1.33) <0.001 
COV (x102) 13.80  4.66 0.862 1.29 (1.22-1.36) <0.001 1.27 (1.21-1.34) <0.001 1.26 (1.19-1.33) <0.001 
VIM (x102) 11.45 3.86 0.849 1.28 (1.21-1.35) <0.001 1.27 (1.21-1.34) <0.001 1.26 (1.19-1.34) <0.001 
RMSE (mmHg) 7.70  3.09 0.934 1.36 (1.31-1.41) <0.001 1.21 (1.15-1.27) <0.001 1.21 (1.14-1.27) <0.001 
ARV (mmHg) 8.39  3.46 0.847 1.31 (1.27-1.35) <0.001 1.17 (1.11-1.22) <0.001 1.17 (1.11-1.24) <0.001 
Range (mmHg) 28.04  12.06 0.921 1.51 (1.44-1.59) <0.001 1.25 (1.43-1.61) <0.001 1.21 (1.14-1.28) <0.001 
* Adjusted for: mean level for SD, COV, VIM, ARV, and range; and for gradient and intercept for RMSE. 
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Table 33: Comparison of models containing characteristics of blood pressure variability modelled with RCS, from 
Cox PH models 









     
Systolic blood pressure     
SD (mmHg) <0.001 0.175 17327.90 0.737 
COV (x102) <0.001 0.538 17326.01 0.737 
VIM (x104) <0.001 0.901 17323.88 0.737 
RMSE (mmHg) <0.001 0.813 17338.53 0.736 
ARV (mmHg) <0.001 0.016 17343.75 0.734 
Range (mmHg) <0.001 0.682 17340.57 0.736 
     
Pulse pressure     
SD (mmHg) <0.001 0.055 17303.43 0.741 
COV (x102) <0.001 0.483 17295.55 0.742 
VIM (x104) <0.001 0.438 17295.01 0.742 
RMSE (mmHg) <0.001 0.288 17318.23 0.739 
ARV (mmHg) <0.001 0.016 17320.03 0.738 
Range (mmHg) <0.001 0.164 17318.29 0.740 
Each characteristic of blood pressure variability was modelled using restricted cubic spline transformations with 3 knots (at 10th, 50th, and 90th 
percentiles), and adjusted for pre-specified baseline risk factors, and adjusted for: mean level for SD, COV, VIM, ARV, and range; for gradient and 
level at mid-point for RMSE. 
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4.5.6 The joint impact of blood pressure level and variability on CV-related 
mortality and development of a clinically useful risk prediction model  
4.5.6.1 Introduction 
The approach so far has been to assess the relationship between blood pressure 
level and CV-related mortality over a 5-year period of observation, and to assess 
the relationship between blood pressure variability and CV-related mortality that is 
independent of blood pressure level.  The next stage in this section was to evaluate 
how blood pressure level and variability could best be used together to predict CV-
related mortality, and hence, how they could be used practically for patient 
assessment of risk in a clinical setting, aiding patient management and risk 
reduction.   
Since there was no other representation of underlying blood pressure level that 
seemed to improve the prediction of CV-related mortality over that of the 
arithmetic mean, this became the focal point in the representation of blood 
pressure level for this section.  Blood pressure variability represented as the SD, 
COV, or VIM showed the strongest predictive ability.  Since VIM is the measure of 
variability independent of the mean, this was initially the focal point in the 
representation of blood pressure variability for this section.  
  




Both blood pressure mean and VIM were split into quartiles of the data, and their 
interaction with each other was investigated in an adjusted Cox PH model (adjusted 
for other pre-specified risk factors) for CV-related mortality.  With an interaction 
between the two quartile blood pressure variables, 16 subgroups were hence 
created, and (15) HRs were estimated representing the relative change in hazard 
compared to the subgroup representing the lowest quartile of blood pressure mean 
and the lowest quartile of blood pressure VIM.   Three-dimensional bar plots were 
created to visualise the relative change in hazard between each subgroup compared 
to the reference group.  These analyses were performed with a focus on PP, but 
were repeated using SBP. 
The modification of effect between both blood pressure mean and VIM with age was 
explored by further allowing an interaction between the subgroups of blood 
pressure mean and VIM with age.  Age was split initially into four groups: those <65 
years, 65-<70 years, 70-<75 years, and those 75 years and older at the landmark 
time-point (i.e. 5.5-years post-baseline). This analysis was also repeated with only 
two age groups, those below 70 and those 70 years and older at the landmark time. 
Again, adjusted HRs were estimated and three-dimensional bar plots were 
presented to show the relative hazard in each blood pressure mean and VIM 
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subgroup compared to a reference group within each category of age.  These 
analyses were also performed using PP, but were repeated for SBP for comparison. 
Having seen that PP had been the component of blood pressure that most strongly 
predicted CV-related mortality in terms of blood pressure level, and that PP had a 
similar level of predictive ability to SBP in terms of blood pressure variability, PP 
became the ultimate focus in the final analyses presented in this chapter. 
The last part of this analysis involved the development of a clinically useful 
predictive model, consisting of blood pressure level and variability, along with key 
risk factors.  The focus for this final objective was on PP, and results were not 
presented for SBP.  Since the COV for PP was only very slightly different from the 
VIM (COV = 𝑉𝐼𝑀 × x̄0.046) and had very low correlation with mean PP level (r=0.025), 
for simplicity and ease of interpretation the COV of PP became the focal point in the 
representation of blood pressure variability in the development of the predictive 
model.  
A series of models containing PP mean, PP COV, and age as continuous variables 
were produced which built upon each other to allow a higher degree of complexity, 
before being simplified in order to arrive at a final, more parsimonious model 
containing only the most important factors. The first model included PP mean, PP 
COV, and age, with no interactions, adjusted for other pre-specified risk factors (as 
previously described).  Linearity of each variable in the model was assessed, which 
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led to the second model containing any variable which showed evidence against 
linearity modelled in a more suitable way.  The next model added an interaction 
between PP mean and PP COV.  Then an interaction between PP mean and age was 
added, followed by an interaction between PP COV and age.  This became the fullest 
model from which backward stepwise elimination of parameters was undertaken.   
Finally, the full model was then simplified, by removing any interactions for which 
there was a lack of evidence, and removing any other pre-specified risk factors that 
had so far been automatically adjusted for but did not show strong evidence of an 
association with the outcome in the final model.  In order to demonstrate a 
convincing level of evidence, a threshold of p<0.01 was used as the level of 
evidence required for a risk factor, interaction, or non-linear relationship to be 
retained in the final model.  The model was simplified where possible in order to 
produce an appropriate but simple risk model for CV-related mortality.   
The C-statistic was calculated for the final clinically useful risk prediction model, as 
described by Harrell et al., in the context of Cox proportional hazards survival 
models 187.  The model was then validated internally using bootstrap resampling 
with 1000 resamples, in order to estimate the bias or “optimism” in the C-statistic 
calculated on the whole dataset, and hence estimate an unbiased C-statistic, as an 
estimate of external concordance (external discrimination) of the model. 
  




4.5.6.3.1 Exploring CV-related mortality across subgroups of blood pressure mean 
and VIM over age groups  
The analysis of quartile groups of both blood pressure mean and VIM showed a 
clear pattern of similarly increasing risk with increasing level of mean and VIM, for 
both PP and SBP.  The largest HR (as compared to the lowest quartile of blood 
pressure mean and VIM) was in the subgroup of those in the highest quartile of 
blood pressure mean and VIM for both PP and SBP, with a HR of 3.94 (95% CI: 2.51-
6.17) for PP and 2.38 (95% CI: 1.64-3.46) for SBP.  Table 34 presents the adjusted 
HRs, and Figure 49 visualises the relative differences in hazards between groups.  
Overall there was a similar increase in magnitude of relative hazard when moving 
up the quartile groups of one characteristic while keeping the other constant, for 
both SBP and PP, indicating that both blood pressure level and variability were of 
similar importance.  Those in the lowest quartile of blood pressure mean level but 
the highest quartile of blood pressure VIM had a similar magnitude of increased 
hazard as those in the highest quartile group of blood pressure mean level but 
lowest quartile of blood pressure VIM (compared to the reference groups).   
When further split into age groups, there was quite a striking difference in the 
magnitude of effect of blood pressure mean and VIM on CV-related mortality across 
ages.  A similar pattern of increasing risk with increasing blood pressure mean and 
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also with increasing blood pressure VIM was evident in each age group, but to quite 
a severely attenuated degree in older subjects.  For PP, there was not so much 
difference between those in the two youngest age groups (<70 years), and between 
those in the two eldest age groups (70+ years, see Figure 50).  For SBP the largest 
difference in magnitude of effect was seen in those under 65, and a less striking 
difference between ages 65 years and above.   
Splitting age into only two age-groups, for those <70 years, the HR comparing the 
group in the top quartiles of blood pressure mean and VIM to those in the bottom 
was 9.57 (95% CI: 5.39-16.99) for PP and 4.83 (95% CI: 2.86-8.13) for SBP (see 
Table 36 & Figure 51).  The effects were attenuated in older subjects with HRs 
comparing the same groups of 3.26 (95% CI: 1.98-5.36) for PP and 2.16 (95% CI: 
1.44-3.25) for SBP.    
While the relative differences in hazard were different between age groups, the 
absolute differences were very similar.  The absolute increase in rate of CV-related 
mortality from the lowest quartile groups of both mean and VIM to the highest was 
22.09 events per 1000 person-years (95% CI: 14.54-29.63) in those under 70 
years, and 25.32 events per 1000 person-years (95% CI: 16.04-34.59) in those 70+ 
years, for PP, from a Poisson survival model adjusted for other pre-specified risk 
factors.  For SBP the absolute increase in rate was also similar between age-groups, 
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13.76 events per 1000 person-years (95% CI: 8.31-19.20) in those under 70 years, 
and 16.96 events per 1000 person-years (95% CI: 8.00-25.92) in those 70+ years.   
In all of these analyses, on average the effect sizes were quite markedly larger when 
using PP compared to SBP, across the ages. 
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Figure 49: 3-D bar plot of adjusted HRs for sub-groups of blood pressure mean and VIM (each split into quartiles), from a 
Cox PH model 
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Table 35: Adjusted HRs for sub-groups of mean and VIM blood pressure (each 









VIM quartile group 
Q1 Q2 Q3 Q4 
      
  Pulse pressure 
<65 
Q4 3.56 (1.87-6.81) 6.37 (2.90-13.98) 5.97 (2.65-13.42) 9.81 (4.54-21.21) 
Q3 1.76 (0.91-3.89) 3.77 (1.71-8.28) 4.06 (1.88-8.75) 5.00 (2.31-10.82) 
Q2 1.05 (0.53-2.05) 2.68 (1.27-5.67) 2.81 (1.32-5.98) 4.23 (2.03-8.83) 
Q1 Reference group 1.87 (0.95-3.68) 2.19 (1.13-4.25) 2.91 (1.52-5.57) 
65-<70 
Q4 3.64 (1.94-6.84) 4.71 (2.21-10.04) 4.45 (2.03-9.74) 6.88 (3.26-14.54) 
Q3 1.45 (0.75-2.83) 2.25 (1.03-4.91) 2.44 (1.10-5.42) 2.83 (1.30-6.17) 
Q2 0.92 (0.46-1.86) 1.71 (0.77-3.77) 1.81 (0.80-4.08) 2.56 (1.17-5.59) 
Q1 Reference group 1.35 (0.67-2.72) 1.60 (0.81-3.15) 2.00 (1.04-3.82) 
70-<75 
Q4 1.79 (1.01-3.17) 1.91 (1.00-3.65) 1.52 (0.78-2.95) 3.20 (1.70-6.03) 
Q3 0.98 (0.53-1.78) 1.24 (0.65-2.40) 1.14 (0.58-2.24) 1.80 (0.94-3.45) 
Q2 0.79 (0.42-1.50) 1.20 (0.61-2.37) 1.07 (0.53-2.16) 2.08 (1.08-4.01) 
Q1 Reference group 1.11 (0.59-2.11) 1.11 (0.60-2.06) 1.89 (1.06-3.38) 
75+ 
Q4 1.94 (1.11-3.38) 1.86 (1.02-3.40) 1.88 (1.03-3.43) 2.55 (1.42-4.57) 
Q3 1.19 (0.66-2.15) 1.37 (0.74-2.56) 1.59 (0.86-2.94) 1.62 (0.87-3.01) 
Q2 0.98 (0.52-1.85) 1.35 (0.68-2.66) 1.52 (0.79-2.92) 1.89 (1.01-3.55) 
Q1 Reference group 1.00 (0.54-1.86) 1.27 (0.70-2.30) 1.39 (0.78-2.46) 
      
  Systolic blood pressure 
<65 
Q4 2.55 (1.36-4.78) 3.64 (1.64-8.05) 5.05 (2.35-10.84) 7.70 (3.60-16.51) 
Q3 1.90 (1.01-3.56) 3.69 (1.71-7.98) 3.53 (1.62-7.72) 6.90 (3.23-14.71) 
Q2 1.78 (0.94-3.35) 3.23 (1.49-7.01) 3.25 (1.48-7.10) 6.53 (3.04-14.00) 
Q1 Reference group 1.69 (0.88-3.23) 1.82 (0.96-3.46) 3.14 (1.72-5.74) 
65-<70 
Q4 1.74 (0.99-3.03) 1.41 (0.71-2.78) 2.26 (1.18-4.30) 2.76 (1.47-5.18) 
Q3 1.09 (0.62-1.92) 1.21 (0.60-2.42) 1.33 (0.67-2.66) 2.09 (1.07-4.05) 
Q2 0.80 (0.44-1.46) 0.83 (0.40-1.71) 0.95 (0.47-1.94) 1.54 (0.77-3.09) 
Q1 Reference group 0.96 (0.53-1.75) 1.20 (0.67-2.13) 1.66 (0.97-2.84) 
70-<75 
Q4 1.48 (0.89-2.45) 1.35 (0.75-2.41) 2.02 (1.15-3.54) 2.55 (1.47-4.42) 
Q3 0.95 (0.57-1.60) 1.19 (0.65-2.17) 1.22 (0.68-2.22) 1.97 (1.12-3.49) 
Q2 0.66 (0.38-1.15) 0.77 (0.41-1.45) 0.83 (0.44-1.58) 1.39 (0.75-2.56) 
Q1 Reference group 1.08 (0.63-1.86) 1.26 (0.75-1.11) 1.79 (1.10-2.93) 
75+ 
Q4 1.38 (0.86-2.22) 1.31 (0.79-2.18) 1.62 (0.99-2.64) 1.66 (1.03-2.67) 
Q3 1.08 (0.67-1.74) 1.39 (0.84-2.31) 1.18 (0.71-1.97) 1.55 (0.94-2.57) 
Q2 0.94 (0.57-1.53) 1.13 (0.68-1.90) 1.01 (0.59-1.72) 1.37 (0.81-2.31) 
Q1 Reference group 1.12 (0.68-1.85) 1.08 (0.66-1.75) 1.25 (0.80-1.96) 
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Figure 50: 3-D bar plots of adjusted HRs for sub-groups of mean and VIM BP (each split 
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Table 36: Adjusted HRs for sub-groups of mean and VIM blood pressure (each 









VIM quartile group 
Q1 Q2 Q3 Q4 
   
  Pulse pressure 
<70 
Q4 4.30 (2.52-7.35) 6.42 (3.58-11.53) 6.01 (3.28-11.01) 9.57 (5.39-16.99) 
Q3 1.77 (1.00-3.12) 3.28 (1.80-5.98) 3.61 (1.99-6.53) 4.20 (2.32-7.60) 
Q2 1.08 (0.59-1.96) 2.27 (1.25-4.13) 2.47 (1.35-4.52) 3.72 (2.08-6.65) 
Q1 Ref group 1.67 (0.94-2.98) 1.90 (1.09-3.33) 2.60 (1.52-4.46) 
70+ 
Q4 2.24 (1.37-3.67) 2.17 (1.30-3.62) 2.05 (1.22-3.43) 3.26 (1.98-5.36) 
Q3 1.20 (0.71-2.03) 1.44 (0.85-2.44) 1.60 (0.94-2.71) 1.86 (1.10-3.14) 
Q2 0.95 (0.54-1.66) 1.29 (0.73-2.27) 1.42 (0.81-2.48) 2.13 (0.25-4.63) 
Q1 Ref group 1.08 (0.61-1.93) 1.24 (0.71-2.17) 1.69 (1.00-2.89) 
   
  Systolic blood pressure 
<70 
Q4 2.05 (1.25-3.37) 2.28 (1.30-3.99) 3.43 (2.02-5.82) 4.83 (2.86-8.13) 
Q3 1.43 (0.87-2.35) 2.16 (1.24-3.75) 2.20 (1.26-3.85) 3.81 (2.23-6.52) 
Q2 1.18 (0.71-1.96) 1.66 (0.94-2.93) 1.77 (1.00-3.12) 3.15 (1.81-5.46) 
Q1 Ref group 1.25 (0.75-2.10) 1.45 (0.88-2.39) 2.39 (1.50-3.80) 
70+ 
Q4 1.45 (0.93-2.25) 1.41 (0.91-2.18) 1.90 (1.25-2.89) 2.16 (1.44-3.25) 
Q3 1.06 (0.68-1.66) 1.41 (0.91-2.19) 1.29 (0.83-2.01) 1.81 (1.18-2.77) 
Q2 0.87 (0.55-1.37) 1.08 (0.69-1.69) 1.03 (0.65-1.64) 1.48 (0.94-2.33) 
Q1 Ref group 1.10 (0.70-1.74) 1.14 (0.73-1.77) 1.52 (1.01-2.29) 
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Figure 51: 3-D bar plots of adjusted HRs for sub-groups of mean and VIM blood 
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4.5.6.3.2 Developing a clinical useful CV-related mortality risk prediction model 
containing PP mean and COV 
From a series of stages of model development focusing on the pulsatile component 
of blood pressure only, a clinically useful risk prediction model was developed 
including mean level and COV, along with age and other available risk factors (as 
previously identified as pre-specified risk factors for adjustment).  Table 37 
presents five models each increasing in complexity in some way from the previous.    
The simplest model presented in Table 37, Model 1, contained PP mean level, PP 
COV, and age modelled linearly, adjusted for other pre-specified risk factors.  The 
characteristic of variability had a slightly weaker association with CV-related 
mortality than mean level, with HRs of 1.26 and 1.33 per z-score increase, 
respectively.  There was no evidence against linearity for mean or COV, but 
evidence against linearity for age.  Investigations revealed that the effect of age on 
CV-related mortality was larger when over around 70 years of age.  A RCS 
transformation was considered for the modelling of age, however, a linear spline 
transformation with a single knot at 70 years of age, allowing the HRs to differ 
between ages <70 and 70+ years, was considered sufficient while still easily 
interpretable (see Figure 52 below for plots of adjusted relative hazard over age, 
with age modelled both with a RCS transformation and a linear spline 
transformation).  
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Figure 52: Plot of adjusted relative hazard (95% CIs) of age, modelled with 
spline transformations, with reference 70 years of age 
Restricted cubic spline transformation with 3 knots at 10th, 50th, and 90th percentile 
 
Linear spline transformation with a single knot at 70 years (as in final model) 
 
Estimates from the final derived model, when PP mean is at mean level (i.e. z-score is 
zero), and adjusted for PP COV, sex, and diabetic status.  
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In Model 2, with the addition of the linear spline transformation with knot at 70 
years for age, the estimated increase in hazard per 10-year increase in age was 
over double in those 70 years of age and over compared to those under 70 years.  
There was an estimated increase in hazard of 75% per 10-year increase in age (95% 
CI: 42%-117%) when under 70 years and 169% per 10-year increase in age (95% CI: 
130%-214%) in those 70 years and older. 
Model 3 introduced an interaction term between PP mean and PP COV.  The 
interaction term was estimated at 0.93 (p=0.002), meaning that for every z-score 
increase in one of the variables (either PP mean or PP COV), the HR for the other 
variable was modified, estimated to decrease by 7%, and vice versa. 
Model 4 introduced an interaction between PP mean and age, which produced 2 
interaction terms, one for ages less than 70 years, and the other for ages 70 years 
and older.  The overall p-value from a joint test of these two interaction 
components was 0.023.  There was much stronger evidence for an interaction in 
those 70 years and older (HR=0.85, p=0.030) compared to those under 70 years 
(HR=0.98, p=0.852).   
Finally, in Model 5, an interaction between PP COV and age was introduced, 
involving two interactions terms again.  While there was fairly weak evidence overall 
from a joint test of the two interaction terms (0.068), as with PP mean, the evidence 
for an interaction was stronger between PP COV and age in those 70 years and older 
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(HR=0.85, p=0.021).  All of these progressive models in Table 37 were adjusted for 
the additional aforementioned pre-specified risk factors.   
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Adjusted HR (95% 
CI)* 
p-value p-value for improvement 
of model vs. the last (LR 
test) 
Model 1: 
• All modelled linearly 
• No interactions 
 PP arithmetic mean (per z-score)  - 1.33 (1.25-1.42) <0.001 
- PP COV (per z-score) - 1.26 (1.19-1.33) <0.001 
Age (per 10 years) - 2.29 (2.06-2.55) <0.001 
Model 2: 
• Mean & COV modelled linearly 
• Age modelled with linear spline 
transformation with 1 knot at 70 years 
• No interactions 
 PP arithmetic mean (per z-score)  - 1.33 (1.25-1.42) <0.001 
0.007 
PP COV (per z-score) - 1.26 (1.19-1.33) <0.001 
Age (per 10 years) <70 1.75 (1.42-2.17) <0.001 
Age (per 10 years) 70+ 2.69 (2.30-3.14) <0.001 
Model 3: 
• Mean & COV modelled linearly 
• Age modelled with linear spline 
transformation with 1 knot at 70 years 
• Interaction between mean and COV  
PP arithmetic mean (per z-score)  - 1.35 (1.27-1.44) <0.001 
0.004 
PP COV (per z-score) - 1.29 (1.22-1.37) <0.001 
Interaction term (mean with COV) - 0.93 (0.89-0.98) 0.002 
Age (per 10 years) <70 1.75 (1.41-2.17) <0.001 
Age (per 10 years) 70+ 2.69 (2.30-3.14) <0.001 
Model 4: 
• Mean & COV modelled linearly 
• Age modelled with linear spline 
transformation with 1 knot at 70 years 
• Interaction between mean & COV  
• Interaction between age & mean 
PP arithmetic mean (per z-score)  - 1.48 (1.32-1.66) <0.001 
0.023 
PP COV (per z-score) - 1.29 (1.22-1.37) <0.001 
Interaction term (mean with COV) - 0.94 (0.90-0.98) 0.006 
Age (per 10 years) <70 1.63 (1.31-2.03) <0.001 
Age (per 10 years) 70+ 2.97 (2.51-3.53) <0.001 
Interaction terms (age with mean) <70 0.98 (0.80-1.20) 0.852  
Interaction terms (age with mean) 70+ 0.85 (0.74-0.98)  0.030 
Model 5: 
• Mean & COV modelled linearly 
• Age modelled with linear spline 
transformation with 1 knot at 70 years 
• Interaction between mean & COV  
• Interaction between age & mean 
• Interaction between age & COV 
PP arithmetic mean (per z-score)  - 1.49 (1.33-1.67) <0.001 
0.068 
PP COV (per z-score) - 1.44 (1.29-1.60) <0.001 
Interaction term (mean with COV) - 0.94 (0.90-0.99) 0.012 
Age (per 10 years) <70 1.59 (1.28-1.99) <0.001 
Age (per 10 years) 70+ 3.11 (2.61-3.81) <0.001 
Interaction terms (age with mean) <70 0.99 (0.81-1.22) 0.951  
Interaction terms (age with mean) 70+ 0.84 (0.73-0.96)  0.013 
Interaction terms (age with COV) <70 1.15 (0.94-1.41) 0.173 
Interaction terms (age with COV) 70+ 0.85 (0.74-0.98) 0.021 
* Adjusted for other pre-defined baseline risk factors 
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After refining Model 5 to create the final simplified model, leaving only risk factors 
and interaction terms that had a convincing level of evidence (p<0.01), a total of 
five risk factors remained.  The final model is presented in Table 38, containing PP 
mean (p<0.001), PP COV (p<0.001), an interaction between PP mean and PP COV 
(p=0.004), age (p<0.001), an interaction between age and PP mean when age is 70 
years and above (p=0.005), sex (p=0.004), and diabetes diagnosis at the landmark 
time (p<0.001).   
Both PP mean and PP COV were centred around their mean values (58.34 mmHg and 
0.138, respectively), and age was centred around 70 years (which was very close to 
the mean age of 69.29 years).  Therefore, the HRs in the model can be interpreted 
in that context.   
An increase in z-score of PP mean (representing a 10.86 mmHg increase) was 
associated with a 50% increase in hazard for those with mean PP COV (0.138) and of 
age 70 years or younger, adjusted for sex and diabetes status.  An increase in z-
score of PP COV (representing a 0.047 increase) was associated with a 29% increase 
in hazard for those with mean PP mean (58.34 mmHg), adjusted for age, sex, and 
diabetes status.  The interaction between PP mean and PP COV can be interpreted as 
the effect of a z-score increase in one risk factor decreases with the increase per z-
score of another risk factor by an estimated factor of 0.94, and vice versa.   
Chapter 4: Impact of blood pressure level and variability on cardiovascular-related mortality 
300 
 
An increase in age of 10 years was associated with a 74% increase in hazard for 
those under 70 years of age adjusted for the other risk factors in the model.  An 
increase in age of 10 years was associated with a 269% increase in hazard for those 
70 years and older who had mean PP mean, adjusted for the other risk factors in the 
model.  The interaction between age (for values of age 70 and older only) and PP 
mean can be interpreted as, for every additional 10-year increase in age, the 
estimated effect per z-score increase in PP mean decreases by an estimated factor 
of 0.83, and vice versa.   
To help illustrate the changes in relative hazard in the context of the interactions 
present in the final model, Figure 53 presents two plots.  The first (A) presents 
relative hazard across age, at different levels of PP mean (with the reference at 70 
years of age and mean PP mean).  The plot shows how, in general, the gradients get 
steeper after from 70 years of age and older (HRs get larger in magnitude) but to a 
lesser degree the larger the PP mean level was.  The second plot (B) presents 
relative hazard across PP mean, at different levels of PP COV (with the reference at 
mean PP mean and mean PP COV).  The gradient of the slope gets gentler (HR is 
smaller in magnitude) with increasing PP COV level.  The plots allow us to compare 
relative hazard levels, for example: with all other variables in the model held 
constant, someone of 70 years of age and mean PP mean of 58.34 mmHg (z=0) had 
a similar hazard to someone aged 55 years but with a higher PP mean of 80.06 
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mmHg (z=2); and someone with mean PP of 58.34 mmHg (z=0) and mean PP COV 
of 0.138 (z=0) had a similar hazard as someone with low PP at around 40 mmHg 
but high PP COV of 0.231 (z=2).   
Upon removal of each risk factor from the final model individually (with everything 
else remaining), the change in C-statistic was highest for age (0.058), and was the 
same for PP mean and PP COV (both 0.011).   
Being diabetic at the landmark time was associated with a 47% increase in hazard 
compared to non-diabetics (95% CI: 1.30-1.66).  Males had a 25% increased hazard 
compared to females (95% CI: 1.07-1.46).
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Table 38: Final clinically useful risk prediction model containing PP mean, PP COV, and other important risk factors 
 Age (years) 
<70 or 70+ 
Adjusted HR  
(95% CI)* 
p-value C-statistic decrease when 
excluded from full model  
PP arithmetic mean (per z-
score)  
 - 1.50 (1.37-1.63) <0.001 0.011 
PP COV (per z-score)  - 1.29 (1.22-1.36) <0.001 0.011 
Interaction term (mean with COV) - 0.94 (0.90-0.98) 0.004 - 
Age (per 10 years)  <70 1.74 (1.42-2.13) <0.001 
0.058  
 70+ 3.12 (2.63-3.69) <0.001 
Interaction term (age with mean) 70+ 0.83 (0.73-0.95)  0.005 - 
Sex Female  - -   
Male - 1.25 (1.07-1.46) 0.004 0.002 
Diabetes Mellitus  No - -   
Yes - 1.47 (1.30-1.66) <0.001 0.006 
* adjusted for all other variables in the table. 
Note: the model C-statistic is 0.740 
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Figure 53: Plots of risk factors in final clinically useful risk prediction model 
against adjusted relative hazard, by levels of other risk factors where 
interactions are present 
(A) Plot of age against adjusted relative hazard at different levels of PP mean 
(reference point is 70 years of age, and when PP mean is mean level of 58.34 mmHg) 
 
(B) Plot of PP mean against adjusted relative hazard at different levels of PP COV 
(reference point is when PP mean is at mean level of 58.34 mmHg, and PP COV is at mean level of 
0.138) 
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A risk score for 10-year CV-related mortality risk was calculated for each subject 
from the risk coefficients of the linear predictor from the final model, and 10-year 
CV-related mortality risk for each subject was calculated as 1 − 𝑏𝑎𝑠𝑒𝑟𝑖𝑠𝑘exp (𝑠𝑐𝑜𝑟𝑒) =
1 − 0.9350876exp (𝑠𝑐𝑜𝑟𝑒).  The distribution of risk scores is presented in Figure 54, 
along with the relationship between risk score and predicted probability of CV-
related mortality within 10-years.  47.3% of subjects had a predicted probability of 
death from CV-related causes within 10 years of over 10%, 14.9% of subjects had a 
risk over 25%, and 1.0% had higher than 50% risk of mortality within 10 years.   
Figure 54: Risk score distribution and predicted CV-related mortality risk 
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Subjects were stratified into groups based on their risk scores.  Six groups were 
formed consisting of five quintiles of risk score, with the highest quintile further 
split (i.e. into two top deciles).  Figure 55 presents a Kaplan Meier cumulative 
incidence plot of CV-related mortality, stratified by the 6 risk score groups.  There 
appears to be good discrimination between the risk groups, with a clear separation 
between cumulative incidence curves, even between the lower risk groups.  10-year 
CV-related mortality risk varied from 2.7% (95% CI: 2.0%-3.8%) in the lowest quintile 
group to 38.0% (95% CI: 33.7%-42.7%) in the highest decile group.   
Overall, the discrimination of the final model was good, with a C-statistic of 0.740 
(95% CI: 0.726-0.754).  Internal validation was conducted using a bootstrap 
resampling method to estimate the bias due to model overfitting, and hence 
estimate the magnitude of discrimination of the model if used on external data.  
Using 1000 bootstrap samples, the estimated bias in C-statistic was 0.005 (95% CI: 
0.001-0.015).  This implies that if this model was used on external data, the C-
statistic would be 0.734 (95% CI: 0.725-0.740).   
The model also showed good calibration (goodness-of-fit), with model-predicted 
CV-related mortality risk showing strong similarities within each risk group to the 
observed.  This can be seen visually in Figure 56, a bar-chart of predicted and 
observed CV-related mortality risk in each risk score group where there appears to 
be good agreement across the groups, and formally from a Nam-D’Agostino test 
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assessing the difference between predicted and observed risk there was no 
evidence for a difference (p=0.543).  
Figure 55: Cumulative CV-related mortality, by risk subgroups 
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Figure 56: Risk discrimination and model goodness-of-fit 
 
Note: Q1-Q4 represent the first four quintiles, and D9 and D10 represent the top two deciles of 
estimated risk from the final model.  
 
Model risk factors were distributed over the six risk groups as shown in Table 39. 
Although SD was not the measure of PP variability in the model, it is also presented 
in the table (greyed out) to show a more easily interpretable distribution of 
variability across the risk groups.  In the lowest risk group, mean age was 54 years 
and 15.5% were diabetic, compared to the highest decile risk group where mean 
age was 75 years and over 50% were diabetic.  There was not a large difference in 
the distribution of sex across risk groups. 
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There was a striking difference in mean PP mean and mean PP COV across risk 
groups.  Mean PP mean was 48 mmHg in the lowest risk group and nearly 72 mmHg 
in the highest.  Mean PP COV was 0.115 in the lowest risk group and 0.167 in the 
highest.  There was a very striking trend of increasing PP SD across risk groups, 
mean PP SD varying from 5.49 mmHg to 11.74 mmHg from lowest to highest risk 
groups, respectively, but of course the SD is not independent of the mean.   
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5.49 (1.57) 6.98 (1.88) 8.03 (2.49) 9.02 (2.90) 9.81 (3.36) 
11.74 
(4.14) 
Note, PP SD does not feature in the final clinically useful risk prediction model. 
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4.5.7 Conclusions and Discussion 
This long-term follow-up data of UK patients from the ASCOT trial provided solid 
evidence of the importance of visit-to-visit variability of blood pressure as a strong 
predictor of CV-related mortality, independent of mean level, in subjects with 
hypertension and at high risk of CVD.  This supports and builds upon existing 
evidence of the prognostic importance of blood pressure variability 188–191.  In 
addition, this research provides evidence that the PP component of blood pressure 
is at least as strong a predictor as SBP, and in these data perhaps even stronger.  
There have now been several studies that have provided evidence of the prognostic 
importance of blood pressure variability 132,192.  Despite growing evidence of the 
importance of blood pressure variability, it has been controversial as to how to use 
measures of variability in blood pressure in clinical practice.  Clinical guidance has 
remained almost entirely on measures of blood pressure level as the focus for 
assessing CV risk and managing hypertension 193.  This is understandable since 
blood pressure level remains the most relevant risk factor and one that is known to 
be susceptible to change through lifestyle/behavioural modifications and anti-
hypertensive pharmacological interventions.   
While there have been many substantial developments in anti-hypertensive drug 
research, including many large-scale Phase III trials, there have been no trials to 
date that have focused on the reduction of blood pressure variability.  This study 
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provides evidence that blood pressure variability may of similar importance as 
blood pressure level at identifying CV risk, and supports the concept that variability 
can be used to assess patient risk, and should be incorporated within the 
management of blood pressure.  
Some treatments have been identified as having beneficial effects on reducing 
variability.  It has been argued that some of the beneficent effects seen in the 
ASCOT trial from the CCB-based treatment regimen might be more through the 
mechanism which resulted in a reduction in blood pressure variability, as seen 
compared to the BB-based regimen, rather than due to differences in achieved 
blood pressure level 15,188.  The differences seen in achieved SBP were considered 
small from a clinically meaningful point of view 14,138.  Further, there was no 
difference in achieved PP level between BPLA groups of the ASCOT trial, while the 
differences seen in the variability of both SBP and PP between anti-hypertensive 
treatment arms were substantial.  Blood pressure variability was considerably lower 
in those allocated to amlodipine-based compared to atenolol-based treatment.  
The use of increasing numbers of blood pressure measures in the calculation of 
both blood pressure mean level and variability (SD), vastly increased their 
association with CV-related mortality.  For mean level, this increase in association 
had not reached an obvious peak with inclusion of all available blood pressure 
measures, both for SBP and PP.  It makes intuitive sense that the more measures 
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used, the more accurate the estimate of “usual level” can be.  Given how naturally 
variable blood pressure is, and how prone to measurement error, more blood 
pressure measurements will increase the accuracy of estimating the underlying level 
and reduce regression dilution bias as measurement error decreases when more 
blood pressure measurements are used.  For the variability in blood pressure, as 
measured by the SD, there seemed a threshold number of blood pressure measures 
used in its calculation of about six, after which there was little or no increase in the 
association between the SD and CV-related mortality with the addition of more 
blood pressure readings.   
The mean of earlier blood pressure measures (post treatment initiation) were more 
strongly associated with CV-mortality compared to later (more recent) measures.  
This result might be surprising since it might seem more intuitive that more recent 
blood pressure would correlate more with future risk.  It might be that in this 
context the blood pressure level soon after initiation of anti-hypertensive treatment 
could be an indication of how well subjects initially respond to treatment.  The 
higher the blood pressure early on following treatment initiation could be an 
indication of resistant hypertension or worse underlying condition, possibly 
highlighting those for whom it was more difficult to blood pressure control.  Later 
blood pressure measures were less informative, possibly because towards the of the 
trial there was less difference in blood pressure between patients, after sicker 
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patients had gone through more aggressive antihypertensive treatment and with 
longer treatment had slightly caught up those less ill who had had a more rapid 
decline in blood pressure earlier on.  The opposite was seen with the SD, and later 
measures seemed more informative than earlier.  It could be that earlier on a lot of 
the variability was coming from the decline in blood pressure level, while later on 
when blood pressure levels were more stable, the variability became more 
informative of underlying risk.    
In addition to blood pressure variability being shown to be important, the maximum 
blood pressure from a single clinical visit over the period of observation was shown 
to have a very strong relationship with CV-related mortality.  In fact, the association 
was stronger than for mean level, both for SBP and PP.  While maximum blood 
pressure is the measure of blood pressure from only a single clinical visit, it is 
selected in the context of all other measurements that fall beneath it, so is not 
independent of the other blood pressure measures.  Therefore, it doesn’t fall under 
the same limitations as other single measurements that show weaker associations 
with risk compared to the use of multiple measurements.  A potential reason for the 
strong prognostic value of maximum blood pressure could be that, in part, it may 
be capturing information about both underlying blood pressure level as well as 
some information about the magnitude of variability.  It could be that peaks in 
blood pressure are simply more important than blood pressure level itself, if peaks 
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in blood pressure are the cause the severe CV damage or an indirect indication of 
other factors responsive for increasing risk.  Also, the strong prognostic value of 
blood pressure variability could be, if only in part, because it will be capturing some 
information about damaging peaks in blood pressure.  Although some studies have 
recently identified the prognostic value of maximum blood pressure as a predictor 
of CV events, research in this area is still limited and would benefit from further 
investigation in order to better understand the relationship and how maximum 
blood pressure might be used in risk prediction and clinical management of risk 
188,194,195. 
Calculating both blood pressure gradient and blood pressure level by fitting a linear 
regression line using OLS on a subject-by-subject basis was problematic, leading to 
very wide, extreme, and unrealistic distributions.  Assuming these characteristics of 
blood pressure were normally distributed, using mixed effects models produced 
BLUP estimates of blood pressure gradient and blood pressure level that were more 
realistic.  There was a hint of an overall association between blood pressure 
gradient and risk of CV-related mortality.  Lower value gradients were associated 
with higher risk, both for SBP and PP, after adjustment for blood pressure level and 
other pre-specified risk factors, although evidence was weak in the case of PP.  
However, the relationships appeared more complex, with strong evidence against 
linearity for blood pressure gradient, and some evidence for interactions between 
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blood pressure gradient and blood pressure level, for both SBP and PP.  In summary, 
it appeared that lower value blood pressure gradients were associated with 
increased risk, but this was only the case for negative gradients, and the association 
become stronger at lower overall blood pressure levels.  These findings are hard to 
interpret and difficult to account for, and require further investigation.  In general, 
one might expect the opposite, that the lower the blood pressure gradient, the 
lower the risk.  However, in this context it is hard to know what is underlying in 
such patients who have more rapidly decreasing blood pressure levels. 
Building upon evidence in Chapter 3 of this thesis, comparing the predictive power 
of different components of blood pressure as measured at baseline, this research 
has highlighted the importance of PP level, and has suggested it may be superior to 
SBP in the prediction of CV-related mortality.  This further builds on the increasing 
evidence for the importance of PP, found to be more important in many studies 
than other components of blood pressure in predicting CVD-related events 196.  PP 
was quite strikingly the stronger predictor compared to SBP when looking at a 
number of different characteristics of blood pressure level, including the arithmetic 
mean, maximum, linear gradient and level at the mid-point over the period of 
observation.    The differences seen between the two components of blood pressure 
appeared more striking than seen in the previous chapter when comparing these 
components using baseline blood pressure measures.  A possible reason for a less 
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marked difference in association when using baseline measures could be because 
PP might suffer more from regression dilution bias than SBP.  As a consequence of 
being calculated based on both SBP and DBP, PP combines measurement error from 
both.  Hence, when this potential regression dilution bias is reduced when using a 
higher number of measurements to calculate blood pressure level, this could be 
causing the effect of PP to emerge stronger in comparison to SBP.   
The final clinically useful risk prediction model presented both PP mean and PP 
COV, both carrying a similar level of importance in the model, as well as age, sex 
and diabetes status at the landmark time.  The relative effect of PP variability was 
dependent on mean level, and vice versa, each seeming to have reduced relative 
association with CV-related mortality at higher levels of the other.   These two 
attributes of PP might share in informing about some of the biological mechanisms 
linked to increased risk, and if so the interaction could be plausible, since, if one is 
already high and giving information about a particular biological risk factor, then 
the increase in the other attribute of blood pressure might no longer be as 
informative.    
PP mean level increased with age (as did PP COV) but the relative effect of mean 
level reduced in magnitude with increasing age, with evidence for an interaction 
between those below 70 years and 70 years of age and older. A possible reason for 
this interaction with age could be because of fewer competing causes of mortality in 
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younger subjects.  However, the absolute differences in rates of CV-related 
mortality were very similar for PP mean across the ages, so this interaction on the 
relative scale may simply be a result of the increased underlying risk that older 
subjects were at that reduced the relative risk while the absolute difference was 
maintained across the ages.  
The final clinical useful model showed good discrimination and calibration.  
Appropriate external validation of the model is needed, however, internal validation 
using bootstrap resampling estimated only a slight reduction in discrimination, 
suggesting only a small amount of bias from model overfitting in this dataset.  
Internal validation using the bootstrap method as described by Harrell et. al. has 
been shown to be comparable to external validation 187,197.  In addition, this method 
of internal validation allows development of the model using all valid data-points, 
avoiding the need to develop the model on a reduced dataset in order to reserve 
some data for validation thereafter.  This good level of discrimination was 
demonstrated by the model despite the fact that the model contained relatively few 
risk factors.  Were it to be developed to include other known important risk factors 
for CV-related mortality, it could show greater discriminatory power 198.  
While this research cannot explain the root biological causes of increased risk, and 
cannot prove a causal link between blood pressure variability and CV-related 
mortality, the strong association between blood pressure variability and CV-related 
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mortality make it a highly important characteristic of blood pressure for the 
monitoring of patient health.  Possible mechanisms through which blood pressure 
variability may have a plausible causal impact on CV health are not entirely clear.  
Estimates of blood pressure variability will represent many things all contributing to 
its size.  Some aspects, such as seasonal variability which differ depending on frailty 
of the subject and variability linked to lifestyle factors such as the consumption of 
alcohol or smoking will be caught up in the measure of variability of blood pressure 
to a degree.  In addition, adherence to medication will also contribute to visit-to-
visit variability in blood pressure.  Beyond these external factors contributing to 
blood pressure variability, while there is still uncertainty, there have been 
suggestions of causal mechanisms through which the variability in blood pressure 
might have a direct causal impact on vascular health 130. Higher variability in blood 
pressure has been found to be associated with vascular function such as arterial 
stiffness and endothelial dysfunction of other kinds 199–201. 
While hypertension is diagnosed based on elevated levels of SBP and DBP, this 
evidence alongside existing suggests it might be as important to consider visit-to-
visit variability alongside blood pressure level when monitoring blood pressure and 
treating hypertension.  To focus solely on blood pressure level, as in current 
medical practice, may be missing important information that could aid patient 
management and treatment.   
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It would be beneficial to approach blood pressure monitoring, management and 
patient treatment with a more dynamic and broader approach, which could improve 
cardiovascular outcomes in high-risk patients.  Through new technologies such as 
digital blood pressure diaries that enable patients themselves to record their blood 
pressures at repeated occasions, it might be more possible in future to utilise 
repeated measurements of blood pressure in the calculation of subjects individual 
risks for CVD, and aid better, more personally tailored therapy.  
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 Overall conclusions and discussion 
Long-term follow-up data from the ASCOT trial legacy cohort has enabled 
investigation of important scientific questions relating to the long-term effects of 
anti-hypertensive treatments and lipid-lowering statin therapy, and the prognostic 
value of different aspects of blood pressure in relation to mortality in subjects with 
hypertension and at high risk of CVD.  The opportunity to utilise rich data from this 
large cohort of patients across a long follow-up has provided evidence that 
strengthens existing research, and aids in generating hypotheses for future 
research.   
The focus of this research began with the assessment of the long-term impact of 
allocated ASCOT trial treatments on mortality over this long, 17.4-year median 
follow-up.  A sustained beneficial effect of allocation to statin-therapy as compared 
to placebo was observed with a reduction in CV-related mortality, which appeared 
to be largely driven by a reduction in deaths from CHD.  This finding supports 
existing evidence of the long-term benefits of statins, and begs the question as to 
whether limited periods of statin use could deliver sufficient sustained long-term 
CV-health benefits, implying a reduced need for a continued, life-long dependency 
and exposure to statins. 
The difference in lipid levels between placebo and statin groups during the LLA 
blinded trial period was substantial.  This difference disappeared completely as 
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soon as the blinded LLA trial was ceased early after a median 3.3 years.  This might 
suggest that even a relatively short period of prolonged elevated lipid levels, as 
seen in the placebo group, could lead to worse outcomes in the long-term, and that 
the benefits associated with statin use over a small number of years can lead to 
long-term benefits in CV health and a longer life-span.    
While evidence exists for the long-term benefits of CCB-led treatment over placebo, 
this study provides evidence that amlodipine-based blood pressure -lowering 
treatment delivers long-term benefits as compared to alternative active BB-led 
treatment.  A sustained reduction in CV-related mortality was observed associated 
with amlodipine-based treatment compared to atenolol-based treatment, and more 
specifically a larger effect seen in the reduction of stroke-related deaths.    
There was a different effect on CV-related mortality observed between anti-
hypertensive treatment regimens between those involved in the LLA factor of the 
trial and those at higher risk, with higher lipid levels at baseline, who were not part 
of the LLA factor of the trial.  The atenolol-based group appeared to have similar 
rates of CV-related mortality to the amlodipine-based group in the LLA subgroup of 
ASCOT participants, while atenolol-based treatment was less effective than 
amlodipine-based treatment in the higher risk non-LLA subgroup.   
It was noted in the original trial results that it was unlikely that blood pressure 
control alone would have been responsible for the benefits observed with the 
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amlodipine-based allocation, as average within-trial blood pressure levels were not 
considered significantly different between blood pressure-lowering groups of the 
trial, from a clinically important perspective 15,138.  There may have been a number 
of other biological changes resulting from amlodipine-based treatment that 
account more for these observed improved health outcomes.  The more clinically 
significant difference in blood pressure variability seen between treatment groups 
may explain some of the benefit.  The reasons why a larger variability in one’s 
blood pressure over time is associated with poorer prognosis is not entirely 
understood, but the observed reduction in blood pressure variability associated 
with amlodipine-based treatment compared to atenolol-based treatment suggests 
that amlodipine-based treatment may in some way be responsible for impacting the 
biological mechanisms that manifest in a larger variability.  It could be that such a 
beneficial biological impact from a period of amlodipine-based treatment explains 
the sustained long-term effect on CV-related mortality, as compared to atenolol-
based treatment.   
The next part of this research compared components of blood pressure collected at 
baseline in their ability to predict mortality.  While there is vast historical knowledge 
of the importance of diastolic and systolic blood pressure as risk factors for CVD, 
MAP and PP have more recently increasingly been identified as possessing 
important predictive value.  SBP has more recently become known as the stronger 
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predictor of CVD compared to DBP, but the prognostic value of PP in comparison is 
still contentious.  PP is not commonly used in clinical practice or common in risk 
prediction.  Clinical guidelines for the management of hypertension give goals for 
DBP and SBP, but not PP.  Although PP is being used more frequently in clinical 
research due to the increasing evidence as to its predictive ability for arterial 
stillness and blood vessel deterioration, it is most often not the component of blood 
pressure that is of primary focus in observational studies and interventional trials.    
From the analysis of blood pressure as collected at baseline, there was evidence 
that PP was as strong a predictor of mortality as SBP, and perhaps stronger, 
particularly in older subjects.  When using repeated clinical visit-to-visit 
measurements, the strength of association of PP with mortality from CV-related 
causes was strikingly higher than that of SBP, when looking at both blood pressure 
level, and PP seemed to have a similar strength of association to SBP when looking 
at blood pressure variability.  The observed differences in magnitude of the 
relationships between the level of these two components and risk was more striking 
when using repeated measures compared to baseline measures alone.  This could 
be a result of the regression dilution bias phenomenon being more present with PP 
compared to SBP when using baseline measurements alone.  Since PP is calculated 
from two sources of uncertainly both from SBP and DBP, PP has the potential to 
possess more random variability and measurement uncertainly compared to the 
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other blood pressure components, and hence PP may be more exposed to 
regression dilution bias when using single measures in risk prediction.   
This evidence that PP may be a stronger predictor for CV-related mortality risk 
suggests that perhaps there would be value in setting clinical guidelines and 
healthy targets for PP in the management of hypertension.  In addition, PP as a 
single component representative of blood pressure may improve risk prediction 
over SBP in predictive models.     
The final part of this research demonstrated the importance of blood pressure 
variability alongside and in addition to blood pressure level as a risk factor for CV-
related mortality.  This builds upon recent emerging evidence of the importance of 
blood pressure variability as a risk factor for CVD.  When independent of the mean, 
visit-to-visit variability in blood pressure appeared to have a similar strength of 
relationship with CV-related mortality risk and a similar predictive value as blood 
pressure level.  In the final clinically useful risk prediction model, both mean level 
and COV of PP appeared to be contributing equally to the discriminative ability of 
the model.   
Currently, variability in blood pressure is most often represented as the variability in 
SBP.  The QRISK3 predictive model for developing a heart attack or stroke over the 
next 10 years in those who do not already have a diagnosis of CHD, includes SBP 
mean and SBP SD.  This model is the 3rd edition of the QRISK model updated to 
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include variability in SBP, amongst some other additional risk factors, in 2018 137.  
However, perhaps there is added prognostic value in substituting SBP for PP.  In this 
study, models containing both PP level and variability in PP performed better than 
models containing SBP level and variability in SBP.   
The final product in this thesis was the development of a clinically useful 10-year 
CV-related mortality risk prediction model containing PP mean and PP COV, 
alongside age, sex, and diabetes status.  The model showed good discrimination, 
despite only containing a small number of risk factors.  
 Limitations 
The research presented in this thesis comes with both strengths and limitations and 
it is important to interpret findings in the context of these strengths and 
limitations.   Like any clinical study, certain assumptions were made when 
conducting analyses.  In this study some assumptions could be tested, but others 
could not be.  
Within the context of a randomised, controlled trial, it is easier to make causal 
statements about observed differences between treatment arms.  This is because a 
randomised controlled trial benefits from the randomisation process, which, if 
carried out well, should lead to subjects being similar between groups except by 
chance.  Therefore, if treatment differences emerge within the trial context, the 
assumption that the effect observed is due to the interventions and not due to other 
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unknown confounding factors is more plausible compared to a non-randomised 
study.  Following the end of the ASCOT trial, as time went on over follow-up, 
differences between randomised groups may have before systematically more 
dissimilar as a direct consequence of the interventions.  Hence, over time, the 
cohort may to some degree have become exposed to unknown confounding factors 
that made the originally balanced groups, more and more dissimilar.  One of the 
main limitations in this study was that post-trial treatments were unknown.  It was 
known that after the early cessation of the LLA factors of the trial, the balance in 
statin use recorded during the remainder of the trial until the BPLA factor ceased, 
was balanced between originally randomised statin and placebo groups.  It might be 
reasonable to assume that both lipid-lowering and blood pressure-lowering 
treatment use were balanced between originally randomised groups if trial 
interventions had no impact, either biologically or psychologically, but given that 
this study presents evidence of treatment effects it is likely that some differences in 
future treatments emerged over time.     
As could already have been occurring during the trial period, groups may also have 
differed biologically after the trial as a direct result of the treatments received 
during the trial.   If the trial interventions led to differing health states, then the 
requirement for and impact of future treatments could surely be different between 
groups as a result.  Also, knowledge of having been randomised to a particular 
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group could also have had an impact on subjects’ future choices and attitudes.  In 
addition to future treatment differences, it could be possible that originally 
randomised groups might differ over time in terms of behavioural habits and 
lifestyle choices as a consequence of the group to which they were originally 
randomised.  As a result of all of these unknown factors, groups may have become 
slightly different over long-term follow-up.   
It may be acceptable to assume that a lot of the balance in characteristics between 
groups would be partially maintained, but it is likely that over time this would 
become less and less true.  The more different the groups become over follow-up 
time, the more the comparison of outcomes between groups could be biased, 
subject to potential unknown confounding factors.  This makes the estimand that is 
being used to compare originally randomised trial groups more complex to define 
as time goes on, and in some respects slightly unknown.    
Evidence for the treatment effects that emerged over follow-up, both from statin 
intervention and between the BPLA treatments, carried with them somewhat 
borderline statistical evidence at the 5% level.  As a consequence of not having 
larger effect estimates which carried stronger statistical evidence, the study 
possibly lacked power to detect changes in effect over time, and possibly lacked 
power to identify if and how effects differ between some subgroups.  The lack of 
identifying evidence of non-proportional hazards over time could be due to true 
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sustained and consistent effects over time except for random fluctuation, or it 
simply could be due to a lack of statistical power, given the borderline evidence for 
overall effects.  It has been discussed already that the concept of the HR not 
changing at all is probably not entirely convincing as subjects go from within-trial 
conditions, to post-trial life.  It is likely that any sustained effect from treatment, 
any late emerging effect, or any diminishing effect over time will in some way be 
muddied by unknown influences and confounding factors.  Hence, the results need 
to be interpreted within the context of these unknowns.  
In some places within this thesis, the 5% [significance] level was referred to, in 
reference to the most commonly used statistical significance level in clinical 
research.  However, the intension throughout this thesis was to consider p-values 
on their continuous scale rather than constructing an arbitrary level at which to 
dichotomise evidence for estimates as being either statistically significant or non-
significant (unless it was helpful to do so for variable selection when model 
building).   No adjustments were made to account for multiple statistical testing in 
this study, hence p-values do not represent the true probability of a chance finding 
and interpretation of p-values should be made with that in mind.  Having said that, 
the approach in this study was not to blindly conduct multiple tests to see which 
showed a statistical significance, often termed data dredging, but analyses were 
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considered in the context of what is clinically understood in light of existing 
evidence.   
The comparison of prognostic ability between different components of blood 
pressure began with the use of baseline office measurements.  This time-point was 
important, as it represented the point at which a patient might present at a clinical 
visit with uncontrolled hypertension in need of clinical intervention.  Hence, 
understanding the importance of baseline blood pressure and which components 
can best help guide clinical discussions for patients from that time-point is highly 
valuable.  A weakness in this study was that baseline blood pressure was measured 
from a single clinical visit.  Pragmatically, this may mirror real life in that a clinician 
may only have access to blood pressure measurements from one occasion taken at 
a single clinical visit from which to make decisions.  However, from an analysis 
perspective, having access to a larger number of blood pressure measurements 
from multiple clinical visits could lead to more accurate estimates of subjects’ true 
underlying baseline blood pressure levels, and hence have stronger predictive 
ability.  More recently conducted clinical trials and studies have optimised repeat 
blood pressure measurement collection through the use of ambulatory blood 
pressure machines which capture blood pressure continuously over the period 
during which they are used, or through the use of repeated blood pressure 
measurements taken at home by the patients themselves over a number of days 
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leading up to a clinical consultation.  The utilisation of multiple clinical (office), 
home, or ambulatory measurements of blood pressure, would help to give a more 
accurate estimate of a patient’s underlying blood pressure level at that particular 
time, reducing measurement error leading to less uncertainty.       
This limitation was somewhat overcome when using repeated blood pressure 
measures taken at different trial visits, both scheduled and unscheduled in the 
analysis presented in Chapter 4.  But of course, the analysis of repeated within- 
trial, post antihypertension treatment initiation represents a very different patient 
stage to that of baseline.     
For the assessment of blood pressure variability, this study assessed the clinical 
visit-to-visit variation in blood pressure.  The addition of the availability of 
repeated patient-recorded home blood pressure measurements and ambulatory 
blood pressure monitoring data, would have been highly valuable as the blood 
pressure variability in both of these methods of blood pressure measurement have 
been shown to possess stronger predictive ability for CV events than variability in 
clinic blood pressure measurements 202.   
It is important to acknowledge limitations to the study and interpret results within 
the context of the study design, and in the context of the study population. These 
findings also need to be revaluated in different populations.  Despite these 
limitations, this study possesses many strengths, and findings from these analyses 
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are an important contribution to continuously emerging CV health and treatment 
research and serve to provide evidence to inform hypotheses for future research.   
 Strengths 
This study benefits from the wealth of data that it utilises to address these 
important CV health questions.  The cohort of subjects included in these analyses 
was large and the follow-up time for this high-risk cohort was long during which a 
large number of events occurred.   The study provided a considerable number of 
repeated blood pressure measurements that were collected routinely and frequently 
as part of the trial schedule, with the addition of extra unscheduled measurements.  
Finally, the context from which this study cohort came from was a large-scale, high 
quality, high profile randomised, controlled clinical trial.     
The ASCOT trial was a very influential trial that impacted clinical practice.  Although 
evidence for the benefits of statins existed at the time of the ASCOT trial, statins 
had a controversial and slightly uncertain clinical and public perception.  The 
ASCOT trial played an important role, alongside other major trials, in helping to 
provide the much-needed strong and robust evidence for the good safety and 
efficacy profile of statin-therapy.  Alongside other research, the ASCOT trial helped 
to increase clinical and public confidence in statins. Having said this, statins do 
remain a source of ongoing debate and controversy to some extent today.  These 
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debates are mainly over the issue of who should and who shouldn’t receive statins, 
with some claiming statins are overprescribed in people at low risk of CVD. 
The results from the ASCOT trial also helped shape antihypertensive treatment, with 
amlodipine now one of the most commonly prescribed antihypertensive drugs along 
with ACE inhibitors such as Lisinopril.  Atenolol therapy was once one of the most 
commonly prescribed treatments for hypertension.  While it remains a highly 
prescribed drug to aid with the treatment of hypertension, beta blockers are not 
usually prescribed as first-line treatment for hypertension, with ACEi, calcium 
channel blockers and thiazide-type diuretics being the most common first-line 
treatments.  In addition, while atenolol was once the beta blocker most used, it is 
no longer the most commonly prescribed in its class.   
Having the opportunity to follow-up the ASCOT legacy cohort for future post-trial 
outcomes was a great opportunity.  The quality of clinical data collection captured 
as part of the trial was able to be utilised in this long-term follow-up analysis, 
which despite its limitations as discussed, provided many strengths over an 
observational cohort study not born out of a trial context.  Indeed, observational 
studies looking at treatment effects out of a randomised study context are at high 
risk of bias due to potential unknown and unmeasured confounding factors.  There 
have been many great developments in statistical methods for analysing 
observational data which help to reduce biases as much as possible and there is 
Chapter 5: Overall discussion, conclusions, limitations, strengths, and beyond  
333 
 
great value and insight gained from such observational studies.  However, this 
study benefits from having a randomised comparison providing an unbiased 
foundation to this study.  Even in light of the limitation that group differences could 
have emerged over time, the context that this legacy cohort study was born out of, 
is one of its major strengths.    
This legacy cohort study richly benefits from data collected as part of a defined trial 
protocol, where patients would be treated more similarly to each other and their 
measurements recorded in a more equal and similarly frequent, routine fashion 
then would be the case in a non-trial observational setting.  Hence collection of 
repeated blood pressure measurements over the trial period would likely be more 
regular, abundant, and reliable across the cohort subjects than it would using 
health record data etc.   
The results from this study support, enrich and build upon previous research.  It 
has supported and strengthened the evidence for the long-term benefits of statin-
therapy in high risk patients, and provided evidence of the long-term superior 
benefits of an antihypertensive treatment strategy made up of a CCB and ACEi, as 
compared to BB and diuretic.  The study has provided strong evidence as to the 
important prognostic strength of blood pressure variability alongside blood 
pressure level.  Finally, the study has given rise to strong evidence as to the 
prognostic value of PP as the component of blood pressure that may be a superior 
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marker compared to SBP for the prediction of CV-related mortality in high risk 
patients.   The strength of the study is that the findings are consistent with previous 
research, build upon existing knowledge and strengthen existing evidence, 
particularly where some uncertainty exists.   
 Future research 
Since conducting this analysis, access to electronic health records through registry 
linkages for consenting ASCOT legacy cohort subjects has provided data on 
morbidity outcomes, to add to the mortality data.   The availability of this data will 
allow for further development of the work presented within this thesis, for further 
and comprehensive evaluation of long-term treatment effects on morbidity, as well 
as, further assessment as to the relationship between blood pressure and clinical 
events.  
While there has been a growing amount of research conducted looking at the 
prognostic role of blood pressure variability, there is still a lack of understanding as 
to the biological mechanisms behind the association with CVD risk.   Future work 
should focus on trying to better understand underlying causal mechanisms at play.  
Blood pressure will vary over time due to a number of different factors: fundamental 
biological changes over time; lifestyle & behavioural factors; as a result of changes 
in antihypertensive medications possibly a consequence of poor blood pressure 
control; adherence to medications, even the type of antihypertensive medication, 
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for example.  A better understanding of which specific factors are causing increased 
blood pressure variability and in which way they contribute to risk is needed.  
Developing a better understanding of why an increased variability in blood pressure 
is associated with poorer outcomes would help with the treatment of patients at 
high risk by being able to directly target and treat the source of elevated variability.  
Work should also focus on the clinical implications of blood pressure variability, and 
the practical aspects of how best to measure, assess and use the assessment of 
blood pressure variability as part of patient care.  For example, it would be good to 
assess how the use of patient electronic health records could be used to gain 
insight into patients’ blood pressure variability, to be used by clinicians alongside 
blood pressure level and other risk factors in the management of cardiovascular 
health and the assessment of CVD risk.   
Further investigation into the classes of antihypertensive drugs that help to reduce 
blood pressure variability is required.  While historically clinical trials have aimed at 
the reduction of blood pressure as their primary objective, robust clinical trials with 
the focus on identifying those classes of antihypertensive drug that best control 
blood pressure variability are needed.    
Isolated systolic hypertension is recognised to be the most common type of high 
blood pressure in older people.  There is extensive evidence as to the increased 
risks associated with isolated systolic hypertension, and studies have shown the 
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benefit and importance of treating elderly patients with isolated systolic 
hypertension 203–206.  Despite this, and this growing evidence that PP may be the 
stronger marker of CV risk in older people than any other single component of 
blood pressure, PP still does not form part of guidelines for the management of 
high blood pressure.  Further research should be conducted into identifying the 
best PP target, to be used alongside existing targets in the management and 
treatment of hypertension.   In addition, the identification of the best existing 
therapies, and the development of new therapies that directly target the 
mechanisms behind the decline in vascular function that leads to increased arterial 
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